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Antipsychotics are commonly prescribed to people with dementia, especially in 
nursing homes, despite limited benefits and significant harms. There have been calls 
to better understand the reasons why antipsychotics continue to be inappropriately 
prescribed to people with dementia, and to develop sustainable interventions.  
Hence the overarching aim of this thesis was to develop and assess the feasibility of 
a theoretically-informed, evidence-based and sustainable intervention to rationalise 
(or optimise) antipsychotic prescribing in nursing home residents with dementia. 
Methods 
The overarching Medical Research Council (MRC) framework for developing and 
evaluating complex interventions guided our approach to this mixed-methods 
research. Firstly, a systematic review was undertaken to determine the effectiveness 
of pharmacists’ intervention in improving the appropriateness of prescribing in 
hospitalised older adults, with a particular focus on people with dementia. Secondly, 
a retrospective cross-sectional study was conducted examining prescribing 
differences between older adults with and without dementia, on admission to 
hospital. Next, a systematic review of qualitative evidence was undertaken to explore 
the influences on decision-making regarding antipsychotic prescribing in nursing 
home residents with dementia, which subsequently informed a semi-structured 
interview study exploring antipsychotic prescribing behaviours. The Behaviour 
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Change Wheel (BCW) was then used to develop a complex intervention with Patient 
and Public Involvement (PPI) throughout. Finally, a feasibility study of the novel 
intervention was conducted in a nursing home setting. 
Results 
Despite the fact that our cross-sectional study showed that hospitalised adults with 
dementia were prescribed significantly more antipsychotics, our systematic review 
found no pharmacist intervention existed which aimed to improve the quality of 
prescribing in this population. Our qualitative synthesis highlighted the complexity of 
decision-making with regards antipsychotic prescribing to nursing home residents 
with dementia. The interview study identified determinants influencing prescribing 
behaviours. Based on these findings, we developed the ‘Rationalising Antipsychotic 
Prescribing in Dementia’ (RAPID) complex intervention which consisted of academic 
detailing with general practitioners, education and training with nursing home staff, 
and an assessment tool. This intervention was found to be both feasible and 
acceptable, however limited uptake of the assessment tool compromised 
intervention implementation. 
Conclusion 
This thesis has made a significant original contribution to knowledge, generating a 
much needed conceptual understanding of this complex issue and contributing 
towards intervention development. Further research is required to evaluate the 




Chapter 1. Introduction 
1.1 Chapter Description 
This chapter provides an overview of the literature and methodological approach 
which have informed my research. I begin by discussing Dementia: the various 
subtypes, the epidemiology, as well as the economic and societal impact. Secondly, I 
explain the prevalence, causes, impact and management of Behavioural and 
Psychological Symptoms of Dementia (BPSD). Following this, I discuss potentially 
inappropriate prescribing (PIP) in people with dementia, focusing specifically on 
antipsychotics. I define what is meant by ‘off-label’ prescribing of antipsychotics in 
dementia; examining the prevalence rates across different settings and countries; 
and discussing the evidence of harms and benefits. Next, I focus on the evolving 
dementia policy landscape, the Health Information and Quality Authority (HIQA) and 
the impact of national approaches on antipsychotic prescribing. Then I briefly 
describe existing interventions to improve the appropriateness of prescribing to 
people with dementia. Finally, I present the aim and objectives; overarching 
methodological framework; the underpinning research paradigm; the study design; 





1.2.1 What is Dementia? 
Dementia is defined as a clinical syndrome, of a chronic and progressive nature, 
caused by neurodegeneration, in which there are difficulties with memory, language, 
problem-solving and other cognitive skills affecting a person’s ability to perform 
everyday activities (11-13). Both cognitive (e.g. memory impairment) and non-
cognitive problems (e.g. agitation and aggression) are core features of dementia (11, 
14, 15). Dementia is generally considered to be an umbrella term to describe a group 
of diseases that cause these symptoms (16). Although age is the main risk factor for 
developing dementia with almost 95% of all those affected 65 years or older (13), it 
is important to acknowledge that it is not part of normal ageing (15). 
1.2.2 The Main Causes (Subtypes) of Dementia and Clinical 
Presentations 
There are many different causes, or subtypes, of dementia with Alzheimer’s Disease 
(AD), being the most common, accounting for approximately 60-80% of all cases of 
dementia (11). The characteristic features of AD are the progressive accumulation of 
twisted strands of the protein tau (tangles) inside neurons in the brain and the 
protein fragment beta-amyloid (plaques) outside neurons (11). AD manifests in the 
early stages of those affected as difficulty remembering recent events, apathy and 
depression. Later symptoms include impaired communication, disorientation, 
confusion, poor judgment, distressing behaviours (e.g. agitation) and symptoms (e.g. 
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hallucinations) and ultimately, difficulty speaking, swallowing and independently 
mobilising (11).  
Vascular dementia (VaD) in isolation accounts for approximately 10% of cases and is 
generally caused by cerebrovascular disease (11, 17). However VaD is more 
commonly found as a Mixed Dementia alongside AD, in up to approximately 50% of 
all cases of dementia with an Alzheimer’s pathology (11, 18). In the early stages, VaD 
is characterised by an impaired ability to make decisions, plan or organise as opposed 
to the memory loss often associated with AD. Additionally, people with VaD can have 
significant difficulty with motor function (11). 
Lewy Body Dementia (LBD) is another cause of dementia, and is usually classified as 
either Dementia with Lewy Bodies (DLB) or Parkinson’s Disease Dementia (PDD) (19). 
LBD is associated with abnormal deposits of a protein called alpha-synuclein in the 
brain (11, 20). In DLB, parkinsonism (i.e. movement problems such as tremors, slow 
movement and stiffness) arises concurrently with or after the onset of dementia. 
Whereas, PDD is diagnosed when dementia occurs at least one year after the onset 
of Parkinson’s disease (19). People with LBD commonly experience issues with 
attention, visuospatial activity and executive function.  Visual hallucinations, gait 
imbalance, sleep disturbances and fluctuations in cognition are also particularly 
common in this cohort (19). DLB accounts for approximately 15% of cases of 
dementia, whereas PDD accounts for 3-5% of cases (14, 19). 
Frontotemporal Dementia (FTD) tends to occur in younger people with dementia and 
has a stronger genetic component than other dementias (21). Early symptoms of FTD 
include impulsive or inappropriate behaviours (e.g. sexual disinhibition) and 
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difficulties with communication (aphasia), which can progress to more severe 
behaviours and ultimately an inability to communicate (21). These clinical 
manifestations occur as a result of disease in the frontal and/or temporal lobes of 
the brain which are responsible for executive decision-making, impulse control and 
language comprehension (21). FTD accounts for approximately 3% of all dementia 
cases, but is the most common type of dementia in men under the age of 55 (12, 22). 
Other types of dementia which are less common include Creutzfeldt - Jakob Disease, 
Normal Pressure Hydrocephalus, Korsakoff’s Disease, Huntington’s Disease and HIV-
Associated Dementia. Collectively, these rarer types of dementia account for about 
8% of all dementia cases (23, 24). 
For the remainder of this thesis, unless there is a need to specify the subtype of 
dementia, the term ‘person with dementia’ shall be used to refer to a person with 
any subtype of dementia. 
1.2.3 Epidemiology of Dementia 
It is estimated that there are currently 50 million people living with dementia 
worldwide (25, 26). The global prevalence of dementia (50 million) is expected to 
increase to 82 million by 2030 and to 152 million by 2050 (26).  To illustrate this 
dramatic increase in the prevalence of dementia globally, it is currently estimated 
that every three seconds, one new case of dementia is diagnosed (25). This rapid 
projected increase in the global prevalence of dementia is largely attributed to rising 
life expectancies worldwide and hence an ageing population (25). 
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In Ireland, an estimated 55,000 people are currently living with dementia, and this 
figure is projected to reach 132,000 by 2041 and 152,000 by 2046 (27). 
Approximately 63% of all those with dementia in Ireland are living in the community, 
while 34% reside in nursing home settings. The remaining 3% of people with 
dementia are located in acute or psychiatric settings (28). 
1.2.4 The Economic and Societal Impact of Dementia 
The long duration of illness before death, and the substantial level of comorbidity, 
contributes significantly to the economic and societal impact of dementia (11). 
Globally, dementia is now estimated to cost US$1 trillion, and this is projected to 
double to US$2 trillion by 2030 (25). In the United Kingdom (UK), dementia currently 
has higher health and social care costs (£11.9 billion) than heart disease (£2.5 billion) 
and cancer (£5.0 billion) combined (29). In Ireland, the total annual cost of dementia 
was estimated to be €1.69 billion in 2010 (28). 
The economic cost of dementia is not evenly distributed between healthcare  (costs 
to the health service due to hospitalisation and medication), social care (costs due to 
nursing home care, respite care and home care) and informal care (costs to family 
and friends providing unpaid care),  with informal care providers bearing the greatest 
cost burden (28, 30). In Ireland, it was estimated that in 2010, €0.8 billion of the total 
economic cost of dementia was attributable to informal care (47%), whereas €0.73 
billion was attributable to social (residential)  care (43%) (28). Furthermore, the cost 
of dementia differs based on the severity of the disease and the care setting. Figure 
1 which is based on UK data, illustrates the breakdown of the estimated costs by 
residence and dementia severity per person. This graph shows us that the burden of 
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costs shifts from informal care to social care as a person with dementia moves into a 
nursing home setting (30). However as the prevalence of dementia is projected to 
increase dramatically over the next few decades (25), informal carers and social care 
systems in particular are both expected to face significant pressure to provide 
appropriate levels of care (Figure 2) (28, 30). 
 
Figure 1: Breakdown of the estimated costs by residence and dementia severity 






Figure 2: UK cost projections for dementia: the total annual cost for different 
sectors (30) (Reproduced with Permission) 
 
1.3 Behavioural and Psychological Symptoms of 
Dementia (BPSD) 
1.3.1 What is BPSD? 
Behavioural and Psychological Symptoms of Dementia (BPSD) are defined as “signs 
and symptoms of disturbed perception, thought content, mood or behaviour” in 
people with dementia (31). BPSD includes psychological symptoms such as 
depression, psychosis, anxiety as well as behaviours such as agitation, aggression, 
repetitive questioning, wandering and a variety of inappropriate or disinhibited 
behaviours (32). BPSD is known by other terms such as Neuropsychiatric Symptoms 
(NPS), challenging behaviours, behaviours that challenge, responsive behaviours, 
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behavioural symptoms and non-cognitive symptoms (33, 34), however for the 
purpose of this thesis, the term BPSD shall be used.  
1.3.2 How Prevalent is BPSD? 
BPSD is highly prevalent in dementia, with the majority of people with dementia 
experiencing at least one symptom or behaviour throughout their disease 
progression (35). For example, the Cache County study conducted in the United 
States (US), found that the 5-year prevalence of BPSD in a cohort of 408 people with 
dementia was 97% (36). The most commonly observed symptoms in this study were 
apathy, depression and anxiety (36). In another UK-based study of 231 people with 
dementia, the prevalence of clinically significant BPSD was found to be 79% (37). In 
this study, depression was most common in mild dementia, while delusions arose 
most frequently in moderate dementia and aberrant motor behaviour was the most 











1.3.3 What Causes BPSD? 
 
Figure 3: Conceptual model describing how interactions between the person with 
dementia, care giver, and environmental factors cause BPSD (32) (Reproduced 
with Permission) 
 
The causes of BPSD are complex and often poorly understood (32). However a 
recently developed conceptual model by Kales et al. in 2015, based on a 
comprehensive review of the literature and expert opinion, may help us to better 
understand the factors associated with BPSD, and hence enable more tailored 
approaches to management (Figure 3) (32). The authors of this study argue that 
neurodegeneration associated with dementia changes a person’s ability to interact 
with others and the environment, and it may also disrupt the brain circuitry involved 
in emotion and behaviours.  Hence the person has an increased vulnerability to 
stressors (i.e. patient factors, caregiver factors and environmental factors), which all 
increases the person’s risk of developing BPSD. This model describes how these 
12 
 
factors can interact with one another or act independently to cause these symptoms 
in people with dementia (Figure 3).  
Some of the patient factors may include premorbid personality or psychiatric illness 
(e.g. schizophrenia), acute medical problems (e.g. urinary tract infections) or unmet 
needs (e.g. pain, fear, and boredom). In particular the ‘Need-driven Dementia-
compromised Behaviour’ (NDB) model has been developed to explain how BPSD can 
be viewed as an “expression of unmet needs or goals” in people with dementia (38). 
In essence, this model describes how a person with dementia’s inability to 
communicate their needs or goals can manifest as various behaviours and symptoms 
(e.g. agitation and aggression) (38). 
In relation to caregiver (or carer) factors, these are related to the interaction between 
the carer and the person with dementia, which can often be suboptimal for various 
reasons (32). Carers of people with dementia experience higher levels of depression 
and anxiety and generally have poorer levels of wellbeing than non-carers, and this 
can impact on the quality of the relationship between the carer and the person with 
dementia (39, 40). Furthermore, a lack of education about dementia, negative 
communication styles (e.g. shouting) and a mismatch between carer expectations 
and the severity of dementia illness can all trigger or worsen symptoms in people 
with dementia (32). 
Finally environmental factors may contribute towards the development of BPSD in a 
person with dementia (32). The ‘Progressively Lowered Stress Threshold’ model 
describes how as the disease progresses and a person with dementia’s ability to 
process environmental stimuli decreases, the stress threshold becomes lower and so 
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the potential for higher levels of frustration increases (41). Hence over- or under-
stimulation, lack of activity and lack of routine can all trigger BPSD in people with 
dementia (32). 
1.3.4 What is the Impact of BPSD? 
BPSD can have a profound effect on people with dementia, causing emotional 
distress in the person and an increased risk of harm to self and/or others (15, 42, 43). 
The presence of BPSD is also associated with lower quality of life in people with 
dementia (44). BPSD can also have a significant negative impact on carers (11, 15, 
30). Twice as many carers of those with dementia compared with carers of people 
without dementia experience substantial emotional, physical and financial 
challenges (45). Approximately one-third of carers of people with dementia suffer 
from depression compared with 5-17% of non-carers of a similar age (40, 46, 47). 
Furthermore, carers of people with dementia have lower health-related quality of 
life than non-carers (48).  
A mixed-methods systematic review conducted by Feast et al. in 2016 explored the 
reasons why family carers struggle to deal with BPSD. The authors concluded that the 
primary reason why family carers were challenged by BPSD was the underlying belief 
that their loved one had lost, or would inevitably lose, their identity to dementia and 
thus would become “dehumanised” (49). Another systematic review by the same 
authors found that depressive behaviours in people with dementia were the most 
distressing for carers, followed by agitation/aggression and apathy (50). Therefore, it 
is not surprising that high levels of behavioural disturbance in people with dementia, 
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and in particular carers’ emotional reactions to these behaviours, is a strong 
predictor of institutionalisation (51, 52). 
However it is important to acknowledge that paid carers in formal settings such as 
nursing homes can also be adversely affected by BPSD (53). Nursing home staff in 
these setting experience high levels of stress and burn-out as a result of dealing with 
BPSD (54-56). Inadequate education and training to deal with BPSD, along with 
limited resources have all contributed to high turnover rates among nursing home 
staff, ultimately compromising the quality of care delivered to residents (11, 57, 58). 
1.3.5 How is BPSD treated? 
Due to the complex and multifactorial nature of BPSD, the management of BPSD can 
be quite challenging (32). However there is strong consensus from international 
guidelines that first line management of BPSD should involve non-pharmacological 
approaches (e.g. music therapy, reminiscence therapy and carer education/training) 
(14, 15, 32, 59). There is good evidence to support the use of music therapy for 
reducing depressive symptoms, behavioural issues and anxiety, as well as carer-
based interventions/staff training in communication skills for reducing agitation (60, 
61). Only in cases where there is severe distress, aggression, agitation or psychosis 
or an identifiable risk of harm to the individual with dementia and/or others, should 
pharmacological approaches be attempted (14, 59), and this will be discussed in 
detail below.  Reversible causes of BPSD (e.g. environmental stressor, urinary tract 
infection, pain or delirium) should always be ruled out and treated initially (14, 32, 
59). A person-centred approach is advocated when caring for people with dementia 
as each person’s needs are very individual, and a ‘one size fits all’ solution to BPSD 
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does not exist (14, 32, 62). In a similar fashion, although there may be stronger 
evidence to support the use of some non-pharmacological approaches over others 
(e.g. music therapy versus aromatherapy) (60, 61), there is a need to tailor the 
approach to meet the unique needs and preferences of the person with dementia 
(14, 59). Unfortunately these approaches can be resource-intensive and sometimes 
costly (63).  Furthermore, selection of an evidence-based non-pharmacological 
intervention is made more difficult by the fact that the overall evidence supporting 
the efficacy of these interventions is somewhat hampered by poor methodological 
quality and inadequate sample sizes (60). This lack of resources and scepticism 
regarding the efficacy surrounding non-pharmacological approaches has been found 
to be a significant barrier to utilising these approaches in practice (64). 
 
1.4 Potentially Inappropriate Prescribing (PIP) in 
Dementia 
1.4.1 What is PIP and how Common is it in People with Dementia? 
Medications are considered to be appropriately prescribed when they have a clear 
evidence-based indication, are cost effective and are well tolerated (65). Potentially 
inappropriate prescribing (PIP) is defined as “the practice of administering 
medications in a manner that poses more risk than benefit, particularly where safer 
alternatives exist” (66). A large number of implicit (judgement-based) and explicit 
(criterion-based) tools been developed and validated to measure PIP in older adults 
e.g. Beers (67) and Screening Tool of Older People's Prescriptions (STOPP) / Screening 
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Tool to Alert to Right Treatment (START) criteria (68). Although these tools have been 
developed for the general older population, they do include some criteria specifically 
for people with dementia e.g. psychotropics and anticholinergics (67, 68). Coupled 
with age-related changes in pharmacokinetics and pharmacodynamics, people with 
dementia are particularly susceptible to the cognitive and cardiac adverse effects of 
these medications (69, 70). 
Although there is limited literature examining the prevalence and consequences of 
PIP specifically in people with dementia, recent studies have shown that PIP is highly 
prevalent in this population and is associated with adverse health outcomes, 
especially hospitalisations (69-73). Furthermore, despite the plethora of PIP tools 
available for the general older population, there are only a few tools specific to 
people with dementia, and most of these focus on the advanced stages of dementia 
(74, 75).  
In terms of PIP in dementia, of particular concern is the inappropriate prescribing of 
psychotropic medications (i.e. antipsychotics, antidepressants, hypnotics, anxiolytics 
and anti-convulsants/mood-stabilisers). There have recently been tools developed 
specifically to measure the appropriateness of psychotropic prescribing in people 
with dementia (76, 77). An implicit tool called the Appropriate Psychotropic drug use 
in Dementia (APID) index, was developed to address the realisation that the high 
frequency of psychotropic utilisation in people with dementia, does not necessarily 
imply that it is inappropriate (76). In a cross-sectional study of 559 nursing home 
residents with dementia across the Netherlands, only 10% of psychotropic drug use 
for BPSD was found to be fully appropriate according to the APID index (78). Of the 
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seven domains of appropriateness measured in the APID index, it was found that 
indication, evaluation and therapy duration contributed most to PIP (78). Upon 
further analysis, the authors determined that older age and more pronounced BPSD 
were associated with more appropriate psychotropic prescriptions, however the 
authors concluded that more research was required to determine the influence of 
patient and healthcare professional factors on appropriate prescribing (79). An 
explicit tool known as the Quality Use of Medications in Dementia (QUM-D) has also 
been developed and focuses on ten factors specifically relating to the quality of 
psychotropic prescribing in people with dementia (77). When tested on a subgroup 
of people with dementia, this tool showed high inter-rater reliability (intra-class 
correlation coefficient = 1.0) and was also found to improve the appropriateness of 
prescribing from baseline to follow up (77). 
1.4.2 Antipsychotic Prescribing in People with Dementia 
Of all psychotropic medications, antipsychotics in particular are commonly 
prescribed for the management of BPSD (80-82). As discussed above, antipsychotics 
are considered to be second line for the management of BPSD, except in cases of 
severe distress, aggression, agitation or psychosis or when there is an identifiable risk 
of harm to the person with dementia and/or others (14, 59, 83).  
However the prescribing of antipsychotics to people with dementia remains a 
controversial topic with some arguing the case for judicious prescribing (84), citing 
significant flaws in the evidence-base (85), and the important role they play in 
treatment (86) as justification for their continued usage. Whereas others contest that 
these agents should rarely be used (87), some even argue that their use may 
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constitute a human rights infringement (88) and others have called for much tighter 
regulatory restrictions (89). A multitude of qualitative studies have been conducted 
to explore these wide range of views (64, 90, 91), however a better understanding of 
decision-making in this complex healthcare area is clearly required.  
1.4.3 ‘Off-label’ Prescribing 
The vast majority of antipsychotic prescribing in people with dementia is ‘off-label’ 
(92) – meaning that the medication is prescribed in a manner different from that 
approved by national regulatory bodies e.g. Food and Drug Administration (FDA) in 
the US (93). ‘Off-label’ prescribing is legal and common practice, particularly for rare 
conditions (e.g. amyotrophic lateral sclerosis) or for populations that may lack clinical 
trials (e.g. paediatrics and older people) (93). However there are ethical and legal 
difficulties surrounding ‘off-label’ prescribing, mainly the fact that the prescriber (as 
opposed to the manufacturer) is liable should harm occur (94). Furthermore when 
prescribing ‘off-label’, prescribers should always seek informed consent from 
patients, which may not always be feasible (94). 
The only antipsychotic that is currently licensed for BPSD in Ireland is risperidone 
(95). Furthermore the license stipulates that risperidone is only “indicated for the 
short-term treatment (up to six weeks) of persistent aggression in patients with 
moderate to severe Alzheimer's dementia unresponsive to non-pharmacological 
approaches and when there is a risk of harm to self or others” (95). In the US however, 
there are currently no antipsychotics licensed for the management of BPSD, and 
instead they all carry a ‘black-box’ warning regarding the risk of harm when used in 
people with dementia (96).  
19 
 
1.4.4 Prevalence of Antipsychotic Prescribing in People with Dementia 
There have been a plethora of cross-sectional studies conducted across various 
settings and countries, all showing the prevalent prescribing of antipsychotics in 
people with dementia. A systematic review and meta-analysis conducted by Kirkham 
et al. in 2017 found antipsychotic prescribing to be widespread across many 
countries, and calculated the pooled estimates of antipsychotic prescribing to be 
significantly lower in community settings compared to nursing home settings (12.3% 
versus 37.5%; Q = 61.77, p < 0.0001) (Figure 4) (97). There was also great variability 
between studies, with the prevalence of antipsychotic prescribing ranging from 
3.74% to 32.47% in community settings and from 23.64% to 64.0% in nursing home 
settings. The authors of this review found that increasing dementia severity was 




Figure 4: Forest plot of the prevalence of antipsychotic prescribing in community 
and long-term care (nursing home) settings (97) (Reproduced with Permission) 
 
Another systematic review by Janus et al. in 2016 examined the prevalence of 
antipsychotic prescribing in nursing homes across Western Europe (80). The authors 
calculated the pooled estimate of antipsychotic prescribing to be 27% (95% 
Confidence Interval [CI] = 27-28) across all 38 studies. The highest rate of 
antipsychotic prescribing was found in Austrian studies (pooled estimate = 45%) and 
the lowest rates were found in French and Norwegian studies (pooled estimates = 
25% for both). Once again, there was substantial variation between studies with the 
prevalence ranging from 11.9% to 54.0%. The pooled average of 27% is lower than 
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that calculated by Kirkham et al. (37.35%), but this may be explained by the fact that 
Janus et al. also included studies of nursing home residents without distinction as to 
their level of cognitive impairment, whereas Kirkham et al. only included residents 
with a confirmed diagnosis of dementia (97). As nursing home residents without 
dementia tend to be prescribed less antipsychotics than residents with dementia, 
this may explain the lower pooled average reported by Janus et al (98). 
By comparison, there is limited published data on the prevalence of antipsychotic 
prescribing in Irish nursing home or community settings. A retrospective study 
conducted by our research group found that of 375 residents with dementia residing 
in 14 publicly funded nursing homes across Cork, 159 (42.4%) were prescribed an 
antipsychotic (99). However it is important to note that this study had several 
limitations. Firstly the researchers were reliant on a documented diagnosis of 
dementia in the medical notes, however these diagnoses are commonly under 
reported (100). Furthermore, the data were collected in 2009/2010 in 14 publicly 
funded nursing homes in one county in Ireland, hence there is uncertainty regarding 
the generalisability of these findings today across all 577 nursing homes in Ireland 
(101). 
Furthermore, there have been relatively few cross-sectional studies conducted in 
acute care settings globally. White et al. report that in a cohort of 230 people with 
dementia admitted to two acute hospitals in the UK, 12.2% of these patients were 
prescribed an antipsychotic at any time during admission (102). In another UK based 
study, which retrospectively analysed prescribing to people with dementia in 34 
acute English hospitals, 16.6% of inpatients with dementia were found to be 
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prescribed an antipsychotic during their admission (103). The Irish National Audit of 
Dementia Care (INAD) study conducted in all 35 public acute hospitals across Ireland 
in 2013, determined that 41% of inpatients with dementia were prescribed 
antipsychotics (104, 105). It is important to note however, that the population 
selected for this audit may not have been representative of all hospitalised dementia 
patients due to the specific audit requirements (i.e. explicit dementia diagnosis and 
a minimum length of stay of five days).  
1.4.5 Evidence of the Harms and Benefits of Antipsychotic Usage in 
Dementia 
Concerns about the use of antipsychotics in people with dementia began in the early 
2000s when the European Medicines Agency (EMA) and the US FDA issued drug 
safety warnings about atypical (newer generation) antipsychotics in 2004/2005 
(106), which expanded to include all antipsychotics in 2008/2009 (107, 108). 
Substantial evidence points to an increased risk of harm and limited benefit as a 
result of antipsychotic usage for the management of BPSD (109-112). In a review of 
16 meta-analyses that evaluated the use of antipsychotics in people with dementia, 
Tampi et al. found that antipsychotics demonstrated only modest efficacy in treating 
BPSD (113). The use of these agents in people with dementia is often limited by their 
adverse effect profile, particularly the increased risk of stroke (3-fold increase) and 
death (2-fold increase) compared to placebo (112-115). Other adverse effects of 
antipsychotics include sedation, pneumonia, hip fractures, abnormal gait and 
extrapyramidal side effects (e.g. movement disorders) (113, 116, 117). 
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Of all psychotropics used for the management of dementia, atypical antipsychotics 
have the strongest evidence of efficacy, albeit the benefits are modest (standardised 
effect size 0.13 to 0.16) (118). The best available evidence from clinical trials would 
suggest that risperidone is the most effective - and quetiapine the least effective - 
antipsychotic for treating BPSD, especially aggression or psychosis (15, 113, 119). 
Even when treatment with antipsychotics is effective, guidelines strongly advocate 
that treatment is tapered and withdrawn after a period of about 12 weeks (14, 59), 
as the evidence suggests that these drugs can be safely withdrawn in most people 
without the return of BPSD  (120). However the evidence does point to an increased 
risk of behaviour recurrence in those with severe BPSD at baseline, or in those who 
have responded well to long-term antipsychotic use (120). 
To illustrate the risk-benefit ratio of antipsychotic usage in dementia, the Centre for 
Effective Practice in Canada have developed an info-graphic (Figure 5) (121). 
Essentially the evidence suggests that for every 100 people with dementia treated 
with an antipsychotic for BPSD, 20 will gain benefit, and 80 will gain no benefit - one 
of whom is likely to die or have a stroke. The risk of death appears to be drug- and 
dose-dependent with haloperidol conferring the greatest risk. Compared with non-
users, people with dementia receiving haloperidol were found to have an increased 
mortality risk of 3.8% (95% CI [confidence intervals] = 1.0% - 6.6%) with a number 
needed to harm (NNH) of 26 (95% CI = 15 - 99). Of all antipsychotics, quetiapine 
conferred the lowest risk of mortality of 2.0% (95% CI = 0.7%-3.3%) with an NNH of 
50 (95% CI = 30-150) (109). Furthermore, the use of haloperidol as the first choice 
antipsychotic in dementia is not recommended due to the significantly higher risks 
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of extrapyramidal side effects caused by this drug, compared to atypical 
antipsychotics (14, 59). 
 
Figure 5: The Risk-Benefit Ratio for Antipsychotic Usage in Dementia (121) 
(Reproduced with Permission) 
 
1.4.6 Evidence of the Harms and Benefits of the use of Other 
Psychotropic Medicines in Dementia 
There is very limited evidence of efficacy to support the use of any other psychotropic 
agent (antidepressants, anti-dementia drugs, anticonvulsants, hypnotics and 
anxiolytics) for the management of BPSD; furthermore they all cause various side 
effects, particularly sedation (14, 15, 59). However, the CitAD trial found that 
citalopram at a dose of 30mg daily significantly reduced agitation in people with 
dementia compared to placebo (122). Yet at this high dose of citalopram (20mg is the 
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maximum dose licensed for older adults), cognitive and cardiac adverse effects were 
significantly more common in the treatment group, and hence this may limit its usage 
in practice. Trials are currently being conducted with other psychotropics such as 
carbamazepine and mirtazapine (NCT03031184), however until there is sufficient 
evidence of efficacy and safety to support the use of any of these drugs for these 
indications, they should be avoided (unless for co-morbid conditions e.g. depression 
or epilepsy) (15). 
1.5 The Evolving Dementia Policy Landscape 
1.5.1 Policy Approaches in Different Countries 
There has been an evolving policy approach to dealing with the issue of inappropriate 
antipsychotic prescribing for people with dementia, with a particular emphasis on 
nursing home settings (123). Across different countries, there have been various 
approaches adopted, some being more successful than others (123)   
In the US, the Omnibus Reconciliation Act (OBRA) of 1987 was introduced to regulate 
antipsychotic prescribing in nursing home residents. In essence, prescribing an 
antipsychotic in a nursing home required a specific diagnosis and behavioural 
indication as a result of OBRA (124). The FDA issued a ‘black-box’ warning about 
atypical antipsychotics in 2005 (106), which expanded to include all antipsychotics in 
2008 (107). More recently in 2012, the Centres for Medicare and Medicaid Services 
(CMS) launched a national partnership programme to improve the quality of care for 
nursing home residents with dementia (125). This programme entailed 
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comprehensive training for nursing home staff, public reporting of antipsychotic use 
and a ‘five-star’ quality rating system for nursing homes (126). 
Drug safety warnings regarding the use of antipsychotics in dementia were also 
released across the UK (and all European Union [EU] countries) in 2004 and 2009, 
similar to the FDA warnings (108, 127). Subsequently, the seminal Banerjee report 
released in 2009, discussed the limited evidence base to support the widespread 
usage of antipsychotics and estimated that 180,000 people with dementia in the UK 
were prescribed an antipsychotic annually, with 1,800 of those dying every year as a 
consequence of taking this medication (128). This report called for urgent action and 
suggested a goal of reducing antipsychotic prescribing levels by two thirds within 
three years (128). Various dementia strategies and other policy documents in the UK 
have re-emphasised the importance of reducing these levels, with governance 
changes, as well as audit and feedback loops being implemented to encourage 
ongoing monitoring of antipsychotic prescribing (129-132). 
In Ireland, the National Dementia Strategy was launched in 2014 with the 
overarching aim of “improving dementia care so that people with dementia can live 
well for as long as possible, can ultimately die with comfort and dignity, and can have 
services and supports delivered in the best way possible” (133). The strategy explicitly 
pointed to the risks associated with the use of antipsychotics in people with 
dementia, and a priority action plan of the strategy was to develop guidance material 
on the appropriate use of psychotropic medication in people with dementia. These 




1.5.2 Health Information and Quality Authority (HIQA)  
HIQA established in 2007, is the independent national regulator of health and social 
care including nursing homes, in Ireland. The aim of HIQA is to drive continuous 
improvement in Ireland’s health and social care services. HIQA's role includes 
developing standards and guidance, as well as inspecting and reviewing health and 
social care services (134). 
Of particular relevance to the prescribing of antipsychotics to people with dementia 
is the HIQA Guidance on Restraint Procedures (135). In this document, chemical 
restraint is defined as “the use of medication to control or modify a person’s 
behaviour when no medically identified conditions is being treated, or where the 
treatment is not necessary for the condition or the intended effect of the drug is to 
sedate the person for convenience or disciplinary purposes” (135). Giving a resident 
who wanders a sedative is outlined as an example of chemical restraint. Further 
guidance is specified in HIQA’s National Standards for Residential Care Settings for 
Older People in Ireland, with a particular importance placed on promoting bodily 
integrity, personal liberty and a restraint-free environment (136). 
Reporting of chemical restraint incidents in nursing homes have recently become 
mandatory in Ireland. The regulations governing the reporting of restraint incidents 
are contained in the Health Act 2007 (Care and Welfare of Residents in Designated 
Centres for Older People) Regulations 2013 (137).  
 Regulation 7 (3) states:  The registered provider shall ensure that, where 
restraint is used in a designated centre, it is only used in accordance with 
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national policy as published on the website of the Department of Health from 
time to time.  
 Schedule 3.4 (g) of the regulations requires that the nursing home keep “a 
record of any occasion on which restraint is used, the resident to whom it is 
applied, the reason for its use, the interventions tried to manage the 
behaviour, the nature of the restraint and its duration”. 
 Schedule 4.2 (k) requires that the nursing home shall notify the Chief 
Inspector (in HIQA) on a quarterly basis of “any occasion when restraint was 
used”.  
In this way, the nursing home’s registered provider is obliged by law keep a record of 
any form of restraint and report this to the Chief Inspector on a quarterly basis. 
1.5.3 The Impact of National Approaches on Antipsychotic Prescribing 
Various drug safety warnings (106, 107), national policy programmes (128) and 
regulatory initiatives (125) have been put into effect across many countries, in an 
attempt to curb the excessive usage of antipsychotics. Significant reductions over 
time have been observed in Canada (97, 138), the US (126, 139, 140), France (141) 
and the UK (108, 127, 142-144). However not all studies have consistently shown 
reductions in antipsychotic prescribing, with some conducted in Germany (145), 
Norway (146) and the UK (147) showing no significant changes, while others 
conducted in Italy (127), France (148) and Japan (149) have actually shown an 
increase in prescribing over time. Conflicting results within countries may be due to 
different populations of interest (e.g. community-dwelling versus residential) or 
different methods of data collection (142, 147).  Nonetheless, concerns have been 
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raised regarding the substitution of antipsychotics with other less evidence-based 
psychotropics such as anticonvulsants or antidepressants (126, 142), and also the 
increased level of schizophrenia diagnoses in US nursing home settings observed in 
recent times, possibly to avoid mandatory reporting of antipsychotic usage (150). 
Although there seems to be an overall reduction in antipsychotic usage for the main 
part, it is still unclear how such programmes, regulations and policies impact on 
individual healthcare professionals’ decision-making process. Moreover there is a 
lack of research conducted on the negative unintended consequences of such 
national approaches. Similarly in Ireland while there has been a move towards 
greater regulation of antipsychotic prescribing in nursing homes in line with other 
jurisdictions, the impact of these changes is yet to be evaluated. 
1.6 Interventions to Improve the Appropriateness of 
Prescribing in People with Dementia 
1.6.1 Nursing Home Setting 
Interventions aimed at improving the appropriateness of prescribing in people with 
dementia have predominantly focused on antipsychotics (or psychotropics more 
broadly), and have been conducted primarily in the nursing home setting (151, 152). 
A systematic review published in 2014 by Thompson-Coon et al. found 22 studies 
evaluating the effectiveness of interventions to reduce inappropriate prescribing of 
antipsychotics to nursing home residents with dementia (151). These interventions 
were categorised as educational programmes (n = 11), in-reach services (involving 
interdisciplinary teams providing outreach services to nursing homes) (n= 2), 
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medication reviews (n = 4) and multicomponent interventions (n = 5) (151). 
Irrespective of the nature of the intervention, the majority were found to result in 
relative reductions in antipsychotic prescribing levels of between 12% and 20%. 
However, the authors added that there was “little information in the included studies 
to aid understanding of the sustainability of the effects of interventions,” and 
recommended further qualitative work be conducted to explore the barriers and 
facilitators to appropriate antipsychotic prescribing, as well as a more in-depth 
exploration of nursing home culture (151). Additionally the authors remarked on the 
lack of detail provided for many of the interventions, preventing future replication 
by other researchers. Similar to the findings of a Cochrane review on the more 
general topic of interventions to optimise prescribing in nursing homes (153), the 
authors of the systematic review were unable to make definitive recommendations 
for practice due to the diversity of interventions and the often poor quality of 
included studies (151). However both reviews commented on the potential benefits 
of interdisciplinary interventions, particularly those involving pharmacists (151, 153). 
A more recent systematic review examined the effects of psychosocial interventions 
on psychotropic prescribing for nursing home residents with dementia (152). The 
authors found that compared to usual care, the interventions that focused on 
changing the culture of nursing homes were more effective at reducing antipsychotic 
prescribing (relative risk [RR] = 0.71; 95% CI = 0.57 – 0.73), than those which simply 
provided education and training (RR = 1.50; 95% CI = 0.49 – 4.64) (152). The authors 
explained this finding by stating that dementia education on its own is of limited 
benefit because of its short-term effects (154). Furthermore the authors found that 
involving the prescribers in such interventions resulted in a significantly greater 
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reduction in antipsychotic prescribing (RR = 0.66; 95% CI = 0.54 – 0.80). The authors 
concluded that involving the prescriber in these psychosocial interventions is 
potentially key to changing prescribing behaviour within the context of a nursing 
home. 
1.6.2 Acute and Community Settings 
Meanwhile interventions to improve the appropriateness of prescribing in people 
with dementia in either acute or community settings are relatively limited. 
Considering that almost two-thirds of all people with dementia live in the community 
(28), and a quarter of all hospitalised older adults have dementia (100), the limited 
number of interventions in these settings is surprising. A systematic review of 
interventions to manage BPSD in community-dwelling adults with dementia was 
recently  published by Trivedi  et al. (155). Of 48 randomised controlled trials (RCTs) 
included in this systematic review, only one discussed medication usage in people 
with dementia as an outcome, specifically antipsychotics, and this study is discussed 
below (156). Furthermore, to the best of our knowledge, the few interventions 
conducted in acute settings have not yet been collated into a systematic review.  
One RCT conducted in the US, randomised 153 community-dwelling adults with 
dementia to the intervention (interdisciplinary collaborative care management 
focused on guideline recommendations, led by an advanced nurse practitioner) or 
usual care (156). Intervention patients experienced significant fewer behavioural 
symptoms and a reduction in carer stress compared with patients who received usual 
care after 12 months of this programme. However there was no significant 
differences in the utilisation of antipsychotics between groups (156). A non-
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randomised evaluation conducted within primary care in the UK (which was not 
included in the systematic review), evaluated the effect of a pharmacy-led program 
to review low-dose antipsychotics in people with dementia (157). From a total of 
1,051 people with dementia screened, 70 were receiving low-dose antipsychotics 
which were initiated by primary care, and in 43 people (61% of 70) their 
antipsychotics were withdrawn or dose reduced (157). However this was a one-
armed study with no follow up, therefore caution is advised when interpreting these 
results. Additionally, this study was not exclusively for community-dwelling people 
with dementia as it also included people with dementia residing in nursing homes. 
A before-after study conducted in Switzerland, examined the effect of collaborative 
interdisciplinary geriatric and psychiatric care on PIP in 150 consecutively 
hospitalised older adults with dementia (158). The intervention was found to 
significantly reduce the incidence of PIP according to the STOPP/START criteria (p < 
0.0001). Of note, the prevalence of patients prescribed at least one long-term (>1 
month) antipsychotic reduced from 14.7% to 1.4% (p < 0.0001) (158). However, there 
were several limitation with this study such as the uncontrolled nature of this 
intervention and the non-random selection of participants. These limitations should 
be considered when interpreting these findings. 
1.7 Summary and Gaps in Knowledge 
In summary, dementia is highly prevalent and is projected to increase dramatically 
over the next few decades. BPSD affects almost all people with dementia at some 
stage throughout their disease progression, and these behavioural symptoms can 
have a significantly negative impact on the person with dementia and others. The 
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causes of BPSD are complex and often poorly understood, and its management is 
frequently suboptimal. Antipsychotics in particular, continue to be frequently 
prescribed inappropriately to people with dementia for the management of BPSD, 
especially in nursing home settings. This is in spite of substantial evidence of the 
harms caused by antipsychotics, and various national approaches to curb excessive 
usage. The reasons for the persistent inappropriate prescribing of these medicines 
are still unclear. Furthermore, despite the large number of interventions conducted 
in this setting, there are still some uncertainties regarding the precise components 
of an intervention required in order to successfully change behaviour, the impact 
context has on implementation of the intervention, as well as the sustainability of 
effects.  
Hence, there is a need for a theoretically-informed, evidence-based intervention to 
sustainably rationalise (or improve the appropriateness of) antipsychotic prescribing 
in people with dementia. In order to successfully achieve this aim, there are several 
important gaps in our knowledge which firstly need to be addressed.  
 We need to learn about the effectiveness of pharmacists’ interventions in 
improving the quality of prescribing in people with dementia, as this may 
prove to be an effective approach to undertake going forward. We know that 
pharmacists’ interventions are effective in nursing home settings (151, 153), 
however the evidence surrounding their effectiveness in acute settings is 
unclear. 
 We also need to better understand the Irish context by examining 
psychotropic prescribing patterns in people with dementia. We have some 
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Irish data to show that antipsychotic and psychotropic prescribing is highly 
prevalent in nursing home settings (99), however there are limited Irish data 
in other settings. 
 We need to determine what setting would be the best in which to develop 
and undertake an intervention to rationalise antipsychotic prescribing in 
people with dementia. Although Chapter 2 focuses on the acute setting and 
Chapter 3 focuses on a hospitalised population that is predominantly 
community-dwelling based, we will be mindful of the fact that the burden of 
antipsychotic prescribing occurs in the nursing home setting (97). The 
remainder of the thesis will then focus on the chosen sector in order to 
remain focused. 
 We need to draw on existing international qualitative evidence to understand 
why antipsychotics continue to be inappropriately prescribed to people with 
dementia. Understanding this behaviour will be an important step in the 
development of our intervention. 
 We need to explore Irish-specific barriers and facilitators to appropriate 
antipsychotic prescribing in people with dementia. Having collated the 
international perspective, it will be important to understand the local 
prescribing context and to explore recent phenomena which may impact on 
prescribers’ decision-making. 
 We need to determine what an evidence-based and theory-informed 
intervention to rationalise antipsychotic prescribing in people with dementia 
looks like. Drawing on our previous work, international literature (151, 159) 
and theory (160-162) we need to establish the optimal composition of this 
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intervention, and define a potential mechanism of behaviour change. In 
particular we need to be careful in deciding who will be delivering the 
intervention and the way in which it is delivered. Although the temptation 
may be to conduct a pharmacist-led medication review, due to our focus on 
these types of interventions in Chapter 2, there may be important cultural 
factors arising from our qualitative work in Chapter 5, potentially affecting 
acceptability and/or feasibility, which may change our thinking on this matter. 
 Finally, we need to assess whether this novel intervention is feasible to 
conduct and is acceptable to stakeholders within an Irish setting, so that the 
intervention may be up-scaled and potentially sustainably implemented. 
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1.8 Methodological Approach 
1.8.1 Thesis Aim and Objectives 
In light of the gaps in knowledge described above, the overarching aim of this thesis 
was as follows: 
 To develop and assess the feasibility of a theoretically-informed, evidence-
based and sustainable intervention to rationalise antipsychotic prescribing in 
nursing home residents with dementia. 
To achieve this overarching aim, the objectives of this thesis were: 
1. To systematically review and synthesise the quantitative evidence 
surrounding the effectiveness of pharmacists’ interventions to improve the 
appropriateness of prescribing in hospitalised older patients, with a particular 
focus on patients with dementia. 
2. To examine prescribing patterns in older patients with and without dementia 
on admission to hospital, within the Cork Region, with a particular focus on 
psychotropic drug use and polypharmacy. 
3. To systematically review and synthesise the qualitative evidence surrounding 
the influences on decision-making regarding antipsychotic prescribing in 
nursing home residents with dementia. 
4. To explore the barriers and facilitators to appropriate antipsychotic 
prescribing in nursing home residents with dementia. 
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5. To develop a theoretically-informed, evidence-based intervention to 
sustainably improve the appropriateness of antipsychotic prescribing to 
nursing home residents with dementia. 
6. To assess the acceptability and feasibility of the novel intervention in an Irish 
nursing home setting. 
1.8.2 Methodological Framework 
The Medical Research Council (MRC) framework for developing and evaluating 
complex interventions was used as the overarching framework for my thesis (Figure 
6) (163). This framework provided guidance on the ‘development’ and 
‘feasibility/piloting’ phases, in order to meet the aim and objectives of this thesis. In 
particular, it helped with making appropriate methodological and practical choices 
throughout the thesis, and contributed towards making the findings more 
generalisable.  Importantly, this framework emphasises that these phases are not 
necessarily linear and are often iterative. 
 
Figure 6: The Medical Research Council (MRC) framework for developing and 




To help design the intervention, I used the Behaviour Change Wheel (BCW) approach 
(164) and also incorporated Patient and Public Involvement (PPI) (165). The BCW is 
an approach to designing behaviour change interventions based on theory and 
evidence (Figure 7). Essentially the BCW provides the intervention designer with 
theory-informed tools and techniques to help understand and change behaviour in a 
step-by-step and transparent manner (164).  
 
Figure 7: The Behaviour Change Wheel (150) (Reproduced with Permission) 
 
 
PPI is defined as research that is carried out ‘with’ or ‘by’ members of the public 
rather than ‘to’, ‘about’, or ‘for’ them (165). The goal of PPI is to achieve a partnership 
between the patients/public and researchers, resulting in improved research 
relevance, quality and outcomes (166). Involving people with dementia in research 
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in a meaningful way is feasible despite challenges such as verbal communication 
impairment, memory loss and diminished decision-making capacity (167, 168). 
Furthermore, involving people with dementia in research through PPI is strongly 
advocated by Alzheimer Europe and other groups who work to promote the rights, 
dignity and autonomy of people with dementia (169). In terms of this PhD, I 
incorporated PPI into the primary qualitative research study (Chapter 5) and 
intervention design process (Chapter 6). Advisory group members were consulted on 
a range of topics including the issue of antipsychotic prescribing in people with 
dementia itself, semi-structured interview topic guides and recruitment, intervention 
selection and dissemination activities. Members were not reimbursed, however a 
voucher was provided to all members at the end of their involvement as a small token 
of appreciation. The strengths and limitations of the PPI component in my research 
is discussed in Chapter 8. 
As discussed, a core component of the thesis was to incorporate evidence and theory 
into the intervention design. The existing evidence base was identified through 
evaluating previously conducted high quality systematic reviews such as the one 
conducted by Thompson-Coon et al. (151). If there was a need for a more up-to-date 
synthesis in order to help answer research questions pertinent to the overarching 
aim of my thesis, this was also conducted. Identifying and developing theory is 
recommended by the MRC guidance when developing and evaluating complex 
interventions in order to “develop a theoretical understanding of the likely process of 
change” (163). The explicit use of theory in intervention development has been 
argued as a means of reducing the time needed to develop complex interventions, 
optimise their design, identify the necessary successful contextual conditions and 
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enhance understanding and generalisability (170, 171). For this thesis, I primarily 
used the BCW to inform the choice of theoretical approach, however a paper by Per 
Nilsen also provided a helpful overview of implementation theories, models and 
frameworks to consider (172). An in-depth description of how I used the BCW and 
PPI within the overarching MRC framework, for the development of the complex 
intervention, is provided in Chapter 6.   
1.8.3 Research Paradigm 
I approached this research from a pragmatism paradigm, meaning that the most 
suitable methods to answer the research questions were employed (173).  The two 
opposing traditional paradigms are that of positivism (the notion of a singular reality, 
requiring an objective and value-free inquiry i.e. quantitative research methods), and 
constructivism (the concept that there is no such thing as a single objective reality, 
and these multiple realities can only truly be explored through subjective inquiry i.e. 
qualitative research methods) (174, 175). Pragmatism offers an alternative to the 
debate between positivism and constructivism and focuses on the problem to be 
researched, and the utility of the findings, rather than arguing which worldview is 
more important (175). Pragmatism values both quantitative and qualitative methods 
as a means of conducting practical, relevant and high quality research (174, 175), and 
hence a mixed-methods investigation was undertaken for this thesis. In essence, 
pragmatism as a research paradigm appealed to me as a pharmacist, because of its 
focus on practicality rather than its broader philosophical basis (173). Taking this 
approach allowed me to make use of the most appropriate methods for my research, 
which ended up being mixed-methods. To maintain reflexivity throughout my PhD, I 
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kept a reflective diary to document my thoughts and decision-making. Reflexivity in 
mixed-methods research has been found to be an effective, ongoing means of 
critically reviewing work, processes and researcher development (176). 
1.8.4 Study Design  
As depicted in Figure 8, a sequential explanatory (quantitative followed by 
qualitative) mixed-methods design was employed for Chapters 2-6, followed by 
concurrent triangulation (simultaneous qualitative and quantitative)  for Chapter 7 
(174). The purpose of combining methods for this thesis were twofold; firstly for 
development (one method used to inform the development of another) and secondly 
for complementarity (qualitative and quantitative methods used to address different 
aspects of the same research question) (177). Throughout my thesis, equal weighting 








1.8.5 Thesis Outline 
Each of the six objectives outlined above, are aligned to a specific study chapter 
(Chapters 2 - 7), and each of these chapters is either published in a peer-reviewed 
journal or drafted for submission (Figure 9). The six study chapters are then followed 
by an overall discussion chapter (Chapter 8). The methods used in this thesis, and the 
resultant findings are discussed separately in each of the six study chapters. In brief, 
the outline for the remainder of this thesis is as follows: 
Chapter 2: A systematic review and meta-analysis of the effectiveness of 
pharmacists’ interventions in improving the appropriateness of prescribing in older 
hospitalised patients, with a particular focus on patients with dementia. 
Chapter 3: A retrospective cross-sectional analysis of medication data collected for 
older patients with and without dementia, on admission to six acute hospitals across 
Cork city and county. 
Chapter 4: A systematic review and synthesis of qualitative evidence surrounding the 
influences on decision-making regarding antipsychotic prescribing in nursing home 
residents with dementia, using a meta-ethnographic approach. 
Chapter 5: A primary qualitative research study exploring the barriers and facilitators 
to appropriate antipsychotic prescribing in nursing home residents with dementia, 
using semi-structured interviews. 
Chapter 6: A methodological study describing the development of a complex 
intervention using the BCW approach and informed by PPI. 
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Chapter 7: A mixed-methods feasibility study of the newly developed complex 
intervention in an Irish nursing home setting. 
Chapter 8: An overall discussion of the research, including strengths and limitations 




Figure 9: Thesis outline (Objectives and Outputs) 
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Chapter 2. Improving the Appropriateness of 
Prescribing in Older Patients: A Systematic 
Review and Meta-Analysis of Pharmacists’ 
Interventions in Secondary Care 
2.1 Chapter Description 
In Chapter 1, I explained how people with dementia are particularly vulnerable to the 
adverse effects of certain medications, and how pharmacists as part of 
interdisciplinary teams have been found to be effective in reducing inappropriate 
prescribing to this cohort, in certain settings. In this chapter, I examine the 
effectiveness of pharmacists’ interventions in improving the appropriateness of 
prescribing in older hospitalised adults, with a particular focus on those with 
dementia. An addendum is provided at the end of this chapter with a discussion of 
up-to-date search results. 
 
 
The work of this chapter has been published as:  Walsh KA, O'Riordan D, Kearney PM, 
Timmons S, Byrne S. Improving the appropriateness of prescribing in older patients: a 
systematic review and meta-analysis of pharmacists’ interventions in secondary care. 





PIP in older hospitalised patients, and in particular those with dementia, is associated 
with poorer health outcomes. PIP reduction is therefore essential in this population. 
2.2.2 Methods 
We conducted a comprehensive electronic literature search using twelve databases 
from inception up to and including September 2014. Inclusion criteria were 
controlled trials (randomised or non-randomised) of interventions involving 
pharmacists conducted in hospitals, with an objective of the study being PIP 
reduction in patients 65 years or older, or patients with dementia of any age, using 
any validated PIP tool as an outcome measure. We conducted risk of bias 
assessments utilising the Cochrane Risk of Bias Tool. 
2.2.3 Results 
A total of 1,752 records were found after duplicates were removed. Four trials (n = 
1,164 patients; two randomised, two non-randomised) from three countries were 
included in the quantitative analysis. All studies were at moderate risk of bias. No 
study focused specifically on dementia patients. Three trials reported statistically 
significant reductions in the Medication Appropriateness Index (MAI) score in the 
intervention group (mean difference from admission to discharge = -7.45, 95% CI: -
11.14, -3.76) and other PIP tools such as Beers Criteria. One trial reported reduced 




Multi-disciplinary teams involving pharmacists may improve prescribing 
appropriateness in older inpatients, though the clinical significance of observed 
reductions is unclear. More research is required into the effectiveness of 
pharmacists’ interventions in reducing PIP in dementia patients. Additionally, easily 





PIP is a universal term to describe various suboptimal prescribing practices, in 
particular the use of medicines where the risk associated with its use outweighs the 
potential benefits, especially when there are more effective alternatives available 
(178). PIP in older people is highly prevalent across a variety of healthcare settings 
and is associated with an increased risk of adverse drug events, morbidity, mortality 
and healthcare utilisation (179-183). 
People with dementia are particularly vulnerable to the adverse effects of certain 
classes of medications (184). Of particular concern are anticholinergics (185, 186), 
antipsychotics (112, 187) and benzodiazepines (188, 189) which are known to cause 
considerable harm to this population if prescribed inappropriately e.g. increased risk 
of falls, stroke and mortality. Reduction of PIP is therefore of critical importance in 
this population (190). 
Clinical pharmacists are suitably trained to carry out medication reviews in older 
patients and have been found to improve the appropriateness of prescribing in 
different settings (191-194). However, a European-wide survey of hospital 
pharmacists reported that only 6% of hospital pharmacies perform decentralised 
clinical services (whereby pharmacists work at least 50% of the time on the ward) 
(195). This suggests that clinical services provided by hospital pharmacists are still 
quite limited in Europe. This is in contrast to the United States where this model of 
care is widely implemented (196).  
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Our primary objective for this review was to collate all the available evidence on the 
effectiveness of pharmacist interventions on the quality of prescribing among older 
hospitalised patients. A secondary objective of our review was to undertake a parallel 
meta-analysis specifically among hospitalised patients of any age with dementia.  
2.4 Methods 
2.4.1 Search Strategy and Selection Criteria 
2.4.1.1 Search Strategy 
We conducted this systematic review and meta-analysis in compliance with 
‘Preferred Reporting Items for Systematic Reviews and Meta-Analyses’ (PRISMA) 
guidelines (197). We conducted an electronic search of the literature using the 
following twelve electronic databases from inception up to and including June 2014; 
Medline (through OVID), PubMed, EMBASE, Centre for reviews and dissemination 
databases, Cochrane database of systematic reviews, CINAHL, Web of Science, 
Science Direct, ClinicalTrials.gov, metaRegister of Controlled Trials, ProQuest 
Dissertations and Theses, and Index to Theses in Great Britain and Ireland. We 
updated the search in September 2014. 
We designed the search strategy in Medline (through OVID) using a combination of 
important key words and Medical Subject Headings (Appendix 1). Using one key 
paper that was known a priori as being eligible for inclusion (198), we adapted the 
search strategy to suit the specific search capabilities of each of the remaining 
databases to ensure that it was sensitive enough to at least detect this paper. This 
approach was utilised in order to be as sensitive as possible due to the anticipated 
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limited number of potentially relevant studies. For example in PubMed, the search 
terms included synonyms and various combinations of the following key words; 
“pharmacist” AND “inappropriate prescribing” AND (“older people” OR “dementia”) 
AND “hospital” AND “pharmaceutical care”. However this differed for Medline 
(OVID) where the search terms included synonyms and combinations of the following 
key words (“older people” OR “dementia”) AND “inappropriate prescribing” AND 
“hospital”. Although the search strategy was adapted for each database, we 
attempted to utilise the PICO framework where possible for each database (i.e. 
population, intervention, comparator and outcome). However there have been some 
limitations reported in the literature with using the PICO framework (199), hence we 
decided upon advice from the medical librarian to use variations of this framework 
(200), with the aim of being sensitive enough to detect one particular study at the 
very least from each database (198).   
Additionally, we utilised other methods including hand-searching key journals and 
conference proceedings, citation searching of highly cited key papers, scanning 
reference lists of key papers and by contacting experts in the field. 
2.4.1.2 Eligibility criteria 
Inclusion criteria were controlled trials of interventions (randomised controlled trials, 
non-randomised controlled trials or controlled before-after studies) involving 
pharmacists conducted in hospitals, in which an objective of the study (either primary 
or secondary) was the reduction of PIP in patients 65 years or older, or patients of 
any age with dementia, using any validated PIP tool as an outcome measure.  
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As determined a priori, we included studies involving patients younger than 65 years 
old if the effectiveness in older and younger people could be clearly separated, or if 
the studies looked specifically at people with dementia due to the fact that a certain 
proportion may have young-onset dementia (201). Trials which were conducted 
across transitions of care were only included if there was a clear delineation between 
the inpatient and outpatient settings in terms of the population, intervention, 
comparator and outcomes. Additionally the inpatient intervention must have 
occurred first. Only the data in relation to the inpatient setting were extracted.  
Examples of validated PIP tools include STOPP/START  (202), Beers Criteria (203) and 
MAI (204). Explicit criteria (e.g. STOPP/START and Beers Criteria) contain specific 
clinical and drug recommendations that can reduce PIP in older patients. Implicit 
criteria (e.g. MAI) refer to quality indicators of prescribing that can be applied to 
prescriptions and require professional judgement (205).  
There was no language exclusion initially. Potentially relevant foreign language 
articles were only excluded once the authors confirmed there were no English 
versions available. We contacted authors of potentially relevant studies published in 
conference abstracts, Masters Theses and on-going clinical trials to determine 
whether the study had been published in full in a peer-reviewed journal or a PhD 
thesis. Hence Masters Theses and ongoing clinical trials were excluded. 
2.4.1.3 Study selection 
For the first stage of study selection, two reviewers independently screened titles 
and abstracts to identify potentially relevant papers. In the second stage, two 
reviewers independently reviewed the full texts of papers. Consensus on inclusion in 
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both stages was reached by discussion between reviewers, with arbitration by a 
senior supervisor if necessary. 
2.4.2 Data Extraction 
Data extraction were performed by one reviewer and verified by another. Authors of 
the primary studies were contacted at this stage if vital data were missing. 
2.4.3 Risk of Bias Assessments 
Risk of bias assessments were conducted by two independent reviewers utilising the 
Cochrane Collaboration’s tool (206). We piloted the tool on two of the five papers 
initially and as a result it was modified by consensus as follows: objective and 
subjective outcomes were separated, as the main outcome of interest (MAI) is a 
subjective outcome. The ‘other bias’ domain dealt with issues that did not fit into 
other domains e.g. contamination bias. Using this tool, the nine domains were 
deemed to have a low, high or unclear risk of bias. Consensus on the assessments 
was reached by discussion, with arbitration by a senior supervisor if necessary. 
2.4.4 Data Synthesis 
We performed quantitative analysis where there was a common comparable 
outcome in at least three included studies and combining results in this manner was 
considered appropriate. For the two continuous outcomes of interest, (a) the 
summated MAI scores per patient at discharge and (b) the change in summated MAI 
scores per patient from admission to discharge, we performed fixed or random 
effects meta-analyses depending on the degree of statistical heterogeneity as 
estimated by the I2 statistic. The summated MAI score is reported as a continuous 
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variable (0 to 18 per medication) with higher scores inferring more inappropriate 
prescribing (204).  
Following previous convention in a Cochrane review of a related topic, if clinical 
heterogeneity was apparent or if substantial/considerable statistical heterogeneity 
was observed (I2 > 50% or if Chi2 < 0.1), we analysed the data using the random-
effects model (207). The random-effects model assumes that the varying effect sizes 
underlying different studies are drawn from a normal distribution. Studies in health 
services research are likely to have numerous differences in terms of population, 
intervention and outcome, such that a common effect size is not seen and thus 
heterogeneity is assumed. In trials where the effects are assumed to be different, but 
similar, a random-effects model can be utilised to reflect this similarity (208). 
We utilised Review Manager 5.3 to create overall summary estimates of effects 
(209). The continuous data were presented as the mean differences with their 95% 
CI. Clinical outcomes such as mortality, Emergency Department (ED) visits, hospital 
re-admissions and adverse drug reactions (ADRs), and all other PIP criteria outcomes 
were interpreted as a narrative synthesis. 
2.5 Results 
2.5.1 Search Results 
We found a total of 1,752 unique records after duplicates were removed from 
electronic database searching (n = 1,940) and other sources (n = 185) (Figure 10). 
After the exclusion of records based on their title and abstracts (n = 1,731) there were 
21 papers suitable for full text review. No foreign language article was found to be 
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eligible. Five papers were eligible for inclusion in the final review (198, 210-213). Only 
four of these papers were included in the meta-analysis, as we considered one paper 
to have an unacceptably high risk of bias as we agreed that addition of this biased 
study could falsely skew the overall results  (210). However we conducted sensitivity 
analyses to assess the impact of including and excluding this study (Figure 14 and 
Figure 15 below). 
 





2.5.2 Characteristics of Included Trials 
The characteristics and outcomes of the five included trials are summarised in Table 
1. No trial specifically studied patients with dementia; therefore the secondary 
objective of this review could not be undertaken. 
One included trial was conducted between primary and secondary care settings. 
Additionally, the appropriateness of prescribing was a secondary outcome in this 
trial, and the primary authors only assessed a random sample of 400 patients for this 
outcome out of 834 total patients (Table 1). 
In three trials, the intervention comprised of the addition of a clinical pharmacist to 
the already existing ward-level healthcare team (198, 210, 211). The other two trials 
involved interventions conducted by a newly formed multi-disciplinary team, which 
included a clinical pharmacist (212, 213). The various components of the multi-
disciplinary teams, the speciality of the physicians involved and the activities 
undertaken by the pharmacists are detailed in Table 2. 
Several prescribing criteria to evaluate appropriateness of prescribing in older 
patients were utilised in these trials, MAI (198, 210-213), STOPP/START (211), Beers 
criteria (198, 213), Assessment Of Underutilisation of medication (AOU) (213) and 
Assessing Care Of Vulnerable Elders (ACOVE) (198). Data from the MAI criteria are 






2.5.3 Results of the Risk of Bias Assessments  




Table 1: Study design, characteristics and outcomes of the included studies. 
Author 
and Year 





































































wards in a 
university 
hospital 











I: 82 ± 6 




I: 7.9 ± 3.4 
C: 8.3 ± 4.4 
Yes NR I: 11.5 ± 12.4 
C: 18.8 ± 
12.9* 
I: 6.36 ± 10.3 
C: 17.5 ± 
15.0* 
 








wards in a 
university 
hospital 









I: 86.4 ± 
4.2 






I: 8.7 ± 4.5 
C: 7.3 ± 4.4 
Yes I: 11.0% 
C: 14.5% 
I: 8.5 ± 6.8 
C: 8.7 ± 7.3 
I: 5.0 ± 4.2 
C: 10.0 ± 7.3 



















wards in a 
university 
hospital 






admission and of a 
medication review 









I: 83.0 ± 
7.0 





I: 8.1 ± 4.2 
C: 8.0 ± 4.0 
Yes NR I: 12.5 ± 
13.05 
C: 10.8 ± 
10.88 
 
I: 4.5 ± 7.99 
C: 4.9 ± 7.25° 



























I: 7.7 ± 3.6 






NR I: 10.0 ± 7.8 
C: 7.7 ± 7.2 
I: 5.3 ± 4.9 
C: 9.6 ± 8.2 
I: 20.5 
C: 11.2* 







drug reactions and 
suboptimal 
prescribing in frail 
elderly patients. 




























RCT To evaluate the 
effect of 
pharmaceutical 
care provided in 









I: 82.4 ± 
6.9 






I: 7.9 ± 3.5 





I: 24.1 ± 17 
C: 21.2 ± 14.3 
I: 7.1 ± 7.5 
C: 19.3 ± 12.5 




 I: 22.5 
C: 30.1° 
No., numbers; S.D, standard deviation; Rx, prescription; I, intervention group; C, control group; RCT, randomised controlled trial; NRCT, Non-randomised controlled trial; 
^value included patients with a diagnosis of dementia or the identification of cognitive problems without dementia; MAI, medication appropriateness index; ADRs, adverse 
drug reactions; ED, emergency department; * Statistically significant difference between intervention and control group where P < 0.05; ° No statistically significant 
difference found between intervention and control groups where P ≥ 0.05; ** Statistically significant difference between intervention and control group using quotient as a 
comparison where 95% CI does not cross 1.0.  NR, reviewers asked primary authors for this information however it was Not Recorded.  










































































































































Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes No 
Med Rec, medicines reconciliation; MAI, medication appropriateness index; STOPP, screening tool of older persons’ prescriptions; START, screening tool to alert doctors to 








No., number; I, S.D, standard deviation; intervention group; C, control group; STOPP, screening tool of older persons’ prescriptions; START, screening tool to alert doctors to 
right treatment; Beers, beers criteria; AOU, assessment of underutilisation of medication; ACOVE, assessing care of vulnerable elders; *Statistically significant difference 
between intervention and control groups where p <0.05. Note that blank fields indicate that this information was not reported by the authors. Authors were not contacted 
for this additional information as they were considered unlikely to have used all of the other PIP criteria.
Study No. of inappropriate 
drugs per patient 
according to Beers 
criteria at admission 
(mean ± S.D) 
No. of inappropriate 
drugs per patient 
according to Beers 
criteria at discharge 
(mean ± S.D) 
No. of 
inappropriate 
drugs per patient 
according to STOPP 
criteria at 
admission 
(mean ± S.D) 
No. of 
inappropriate 
drugs per patient 
according to STOPP 
criteria at 
discharge 
(mean ± S.D) 






(mean ± S.D) 





at discharge  
(mean ± S.D) 




AOU criteria at 
admission  
(mean ± S.D) 




AOU criteria at 
discharge 




















          
Gillespie 
(2013) (211) 
  I: 1.4 ± 1.5 
C: 1.5 ± 1.5 
I: 0.9 ± 1.0 
C: 1.7 ± 1.5* 
I: 0.4 ± 0.7 
C: 0.4 ± 0.7 
I: 0.1 ± 0.3 
C: 0.5 ± 0.7* 








I: 0.5 ± 0.7 
C: 0.5 ± 0.7 
I: 0.2 ± 0.5 
C: 0.4 ± 0.6 * 
    I: 1.4 ± 1.3 
C: 1.0 ± 1.1 
I: 1.0 ± 1.1 





I: 0.29 ± 0.56 
C: 0.44 ± 0.69 
I: 0.03 ± 0.17 
C: 0.04 ± 0.21* 
      I: 0.75 ± 0.89 
C: 0.92 ± 0.95 
I: 0.17 ± 0.43 




Figure 11: Risk of bias assessments.   
 
 
Figure 12: Review authors' judgements about each risk of bias item presented as 




Overall, we assessed the five included studies to have a moderate to high risk of bias 
(206). We determined one study in particular to be at a high risk of bias (210). As such 
the confidence in the results of this trial is seriously weakened and in order to 
preserve the quality of evidence in the meta-analysis, we decided by consensus to 
exclude this trial from the quantitative analysis. We performed a sensitivity analysis 
and we determined that removal of this study did not impact on the findings (Figure 
14 and Figure 15). 
 
Figure 13(a).  Forest plots of comparison: Summated MAI scores at discharge. 






Figure 14: Sensitivity Analysis: Summated MAI score at discharge including study 
at high risk of bias. 
 
 
Figure 15: Sensitivity Analysis: Summated MAI score at discharge excluding study 
at high risk of bias. 
 
We found the blinding of subjective outcome assessments to have an unclear or high 
risk of bias in three of the studies (198, 210, 211) (Figure 12). As MAI is a subjective 
outcome, it is important to consider the potential impact that bias in this domain 
may have on the overall result.  
2.5.4 Quantitative Analysis 
In the four trials included, there were a total of 1,164 patients (589 and 575 in the 
intervention and control arms respectively). The mean number of prescribed 
medications and the standard deviations were 8.1 ± 4.0 and 7.5 ± 3.9 in the 
intervention and control arms respectively. Summated MAI scores per person were 
reported as an outcome in all four trials and so were amenable to quantitative 
analysis (Table 1). MAI scores at baseline ranged greatly both within and between 
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trials (0-35 in one trial (211) and 0-64 in another (212)). This information was not 
reported by the other trials, however it is evident from the variation in the mean and 
standard deviations of the MAI scores at baseline that the range differed greatly 
between trials (Table 1). 
The intervention resulted in a reduction in MAI score at discharge (n=4, mean 
difference in MAI score = -5.27, 95% CI: -8.44, -2.11). Similarly, the intervention 
resulted in a reduction in MAI score, when the changes from baseline data were 
analysed (n=4, mean difference in MAI score = -7.45, 95% CI: -11.14, -3.76) (Figure 
13). 
We identified considerable statistical heterogeneity among these trials with I2 values 
of 93% and 95% determined for Figure 13(a) and Figure 13(b) respectively. We 
performed a random-effects model to address heterogeneity among studies.  
2.5.5 Clinical Outcomes 
Overall the interventions had varying effects on other outcomes (Table 1). Two trials 
failed to show any statistically significant difference in mortality and hospital re-
admission, however neither were powered to look at these outcomes (198, 211). One 
of these trials did show significant reductions in both ED visits and drug-related 
readmissions (211). In one trial, ADRs were detected significantly more frequently in 
the intervention group (Table 1) (213). The authors of this study hypothesised that 






Our systematic review and meta-analysis shows that multi-disciplinary patient care 
teams involving pharmacists may improve the appropriateness of prescribing in older 
hospitalised patients. We calculated an overall reduction in the mean MAI score per 
patient of 7.45 in the intervention group. However, the clinical significance of such 
an MAI score reduction is unclear. In a study set in a primary care setting in the US 
higher MAI scores were associated with an increased number of ED visits (although 
the relationship was found to be non-significant) (214). Additionally, in a study 
conducted in a hospital setting in Belgium, higher MAI scores were significantly 
associated with drug-related hospital admissions (215) (216). However an association 
between MAI scores and mortality or total hospital admissions has not yet been 
proven. It must be noted that the two included studies reporting mortality and 
admission outcomes were not adequately powered to detect any differences. Given 
its unclear clinical significance and subjective assessment, MAI score improvements 
should be viewed with caution.  
Furthermore, one of the studies found that ADRs were detected significantly more 
frequently in the intervention compared to the control group (213). The authors of 
this study speculated that this was due to the increased knowledge and awareness 
of the intervention team as a result of the training. However it is also possible that 
ADRs occurred more frequently as a result of the intervention pharmacists’ 
recommendations to withdraw or initiate medication. 
This positive association between pharmaceutical care of older patients and 
appropriate prescribing has been determined previously in several reviews (207, 217-
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222). The mechanism of this improvement may be due to a combination of aspects 
such as medicines reconciliations, medication reviews and in particular, working as 
part of a multi-disciplinary team (196, 207, 217-220, 222-225).  
A secondary objective of this review was to collate all the available evidence on the 
effectiveness of pharmacists’ interventions on the appropriateness of prescribing in 
hospitalised dementia patients. From the exhaustive search of the literature we 
concluded that no such trial had been carried out by pharmacists, as of yet. Two 
interventional studies involving interdisciplinary geriatric and psychiatric care teams 
were found which reported significant reductions in PIP in this population, but they 
did not involve a pharmacist (158, 226). As hospitalised dementia patients are 
particularly vulnerable to the adverse effects of PIP, it is crucial that more research is 
conducted in this area in order to help guide hospital policy and practice. 
Pharmaceutical care might improve the appropriateness of prescribing in dementia 
patients to a greater extent than the general older population, but even more likely 
it would improve clinical outcomes to a greater extent, given the particular risks of 
PIP in this group. Such information would thus guide healthcare management to 
target scarce pharmacy support to this vulnerable group. 
The main strength of our systematic review was the comprehensive search strategy 
applied by us without language or date limitations. By complementing the electronic 
search with other manual search methods this ensured an exhaustive search. 
Furthermore, study selection and risk of bias assessments were performed by two 
independent reviewers with arbitration by a third party if necessary. This reduced 
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the risk of studies being omitted and also reduced the risk of selection bias entering 
the review process (227).  
A limitation is that we found considerable statistical heterogeneity between included 
studies. Consequently the pooled estimates of effects should be viewed with caution. 
This heterogeneity may be a consequence of both clinical (variability of the 
interventions and patient characteristics) and methodological diversity (variability in 
the blinding of subjective outcomes and allocation concealment).  There were too 
few studies included to adequately perform subgroup analyses to explore the 
heterogeneity. Some researchers argue that meta-analyses should only be 
undertaken when a group of studies is sufficiently homogenous; as conclusions are 
less clear when included studies have differing results (228, 229). In order to 
incorporate heterogeneity among the studies we decided that a random-effects 
model would be appropriate, as it allows the true effect size to vary from study to 
study (230).  
Another limitation was that we found the trials to be at a moderate risk of bias and 
this may have impacted on the overall findings. Furthermore, as is common within 
complex interventions, it was difficult to ascertain the precise components that 
contributed to the intervention success. Future studies should be designed to 
mitigate this risk of bias by conducting adequate randomisation procedures and 
paying particular attention to blinding outcome assessors. They should also provide 
better reporting of the precise specifications of trial processes, including who exactly 
delivers the intervention and to whom (231). 
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It is important to note that the published literature is surprisingly limited in this area. 
Furthermore, we found that measuring PIP in a robust and clinically meaningful way 
is challenging, and we suggest that user-friendly PIP tools should be further 
developed to allow the effectiveness of interventions to be compared. 
Despite these limitations, this study is useful for clinicians as it provides evidence that 
involvement of a pharmacist in the patient care team may reduce PIP, which is 
definitively linked to poorer outcomes, even if the included studies didn’t prove 
better outcomes. More high quality research may be required to definitively prove 
better patient outcomes. Policy-makers have a key role to play in increasing the 
number of pharmacists in multi-disciplinary patient care teams (232). Creation of 
more clinical-specialist pharmacist roles as opposed to drug-distribution roles, by 
greater use of automation in the dispensary, is one strategy which may permit 
pharmacists to have adequate time to perform clinical duties and to take on more 
multi-disciplinary patient care roles (233, 234). 
2.7 Conclusion 
Pharmacists may improve the appropriateness of prescribing in older hospitalised 
patients when they work as part of a team. However in light of the moderate risk of 
bias, subjective nature of MAI assessments and high heterogeneity, these results 
should be viewed with caution. Moreover, PIP tools should be further developed to 
permit better assessment of the effectiveness of interventions. More research is 
required to determine the effectiveness of pharmacists’ interventions in hospitalised 
dementia patients. In order to develop such interventions a greater understanding 
of the unique pharmaceutical care needs of dementia patients is required. This can 
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be achieved through additional quantitative (e.g. examining prescribing patterns) 
and qualitative research (e.g. exploring barriers and facilitators to changing 




2.8.1 Updated Search Results 
An updated search of the electronic databases was conducted on July 2nd 2018, to 
search for all potentially relevant articles published since September 2014 (date of 
latest search prior to publication). A total of 1,473 records were identified. After 
duplicate removal 1,024 records were screened by title and abstract and 25 full-text 
articles were subsequently assessed for eligibility. This resulted in five articles 
meeting our inclusion criteria and hence were included in our updated search (235-
239) (Figure 16).  
2.8.2 Analysis Methods 
Due to the heterogeneity of outcome measures reported, only one of the five new 
articles could be included in the updated meta-analysis (235) (Figure 17). Therefore 
a narrative synthesis of all five new studies, and an updated quantitative synthesis 















2.8.3 Updated Narrative Synthesis and Meta-Analysis 
Chiu et al. conducted a non-randomised, controlled trial (NRCT) in a geriatric unit of 
a regional hospital in Hong Kong (235). Two hundred and twelve patients ≥ 65 years 
old, were allocated to either routine care (n=104) if they were admitted on Friday 
through Sunday, or to the pharmacist intervention (n=108) if they were admitted on 
Monday through Thursday. The pharmacist intervention involved medicines 
reconciliation, medication review, and medication counselling. The control group did 
not receive pharmaceutical care. Recommendations made by the pharmacist were 
communicated to physicians in written and oral formats. The intervention improved 
medication appropriateness as determined by the MAI tool (applied by the 
intervention pharmacist), as the summated MAI score was significantly lower in the 
intervention group compared to control group at discharge (0.95 ± 2.02 vs. 2.02 ± 
2.53, p <0.001) (Figure 17). Furthermore, unplanned hospital readmissions were 
significantly lower in the intervention group compared to control, one month after 
discharge (13.2% vs. 29.1%, p = 0.005). However, the difference in unplanned 
hospital readmissions became non-significant at three months (36.8% v 48.5%, p 
=0.086). Moreover there were no differences in the length of stay (p = 0.888), 
number of ED visits (p=0.079), or mortality rates (p = 1.000) between the two groups. 
In an RCT conducted in Canada by Cossette et al., 247 patients ≥ 65 years old, with at 
least one potentially inappropriate medicine (PIM) according to either Beers (203) or 
STOPP (68) criteria, were randomly allocated to receive either usual care or the 
intervention, upon admission to one of the participating university hospitals (237). 
As randomisation was conducted by hospitalisation episode, a patient could be 
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included in both control and intervention groups during different admissions. 
Furthermore, the same patient could be captured multiple times within the same 
group if there was multiple admissions during the study period. Hence for these 247 
patients, 139 hospitalisations were randomised to the intervention group and 133 
hospitalisations were randomised to the control group. The intervention consisted of 
computerised alerts of PIMs, along with assessment of these alerts for clinical 
relevance by pharmacists, and subsequent development of a therapeutic plan to 
reduce PIM use with the attending physician. Control group hospitalisations did not 
receive computerised alerts or the collaborative pharmacist-physician follow up. At 
discharge, there were significantly more PIM cessations or reduced dosages in the 
intervention group compared to control (48.1% vs. 27.3%; absolute difference 20.8%; 
95% CI 4.6 – 37.0%). However there were no significant differences between the two 
groups in terms of length of stay (p = 0.9), in-hospital mortality (p = 0.3), ED visits (p 
= 1.0) or re-admissions (p = 0.3). 
In Belgium, a NRCT was conducted by Van der Linden et al. investigating the 
effectiveness of a pharmacist intervention in improving the quality of prescribing and 
clinical outcomes, in 214 patients ≥ 65 years old admitted to acute geriatric wards 
(239). Allocation to the intervention (n=117) or control group (n=97) was based on 
whether the patient was admitted to the control ward or one of the two intervention 
wards. The intervention consisted of medicines reconciliation along with medication 
review based on the RASP (Rationalisation of home medication by an Adjusted STOPP 
in older Patients) list of PIMs (240). This intervention was conducted by the study 
pharmacists. The control group did not receive pharmaceutical care. At discharge, 
more PIMs were discontinued in the intervention group compared to control 
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[median (Interquartile range [IQR]) = 2 (1-3) vs. 0.5 (0-1); p <0.001]. Furthermore, the 
intervention was associated with a statistically (but not clinically) significant 
improved in quality of life measured using the EQ-5D-3L (+0.064 points, p = 0.008). 
However no differences were found between the two groups with regards any other 
clinical outcomes (e.g. mortality [p = 1.000], delirium [p = 1.000], inpatient falls [p = 
0.520], outpatient falls [p=1.000], readmissions [p = 0.629], ED visits [p = 0.189]), 
except for the number of ED visits without hospital admission, which favoured the 
intervention group (8.9% in control vs. 1.1% in intervention, p = 0.021).  
An Australian NRCT conducted by Mulvogue et al., examined the effect of the 
addition of a clinical pharmacist to a physician-led geriatric ward round, on the 
quality of prescribing for inpatients ≥ 65 years old (238). In the comparator group, 
which occurred pre-intervention, there was a total of 96 patients. In the intervention 
group, there was a total of 100 patients. During the comparator study period, there 
was no pharmacist on the ward round and during the intervention study period, 
there was a pharmacist involved in twice-weekly physician-led ward rounds. 
Inappropriate prescribing as measured by the mean number of STOPP/START criteria 
per patient (202), was lower in the intervention group compared to comparator 
group at discharge, but not significantly so (1.18 ± 1.37 vs. 1.50 ±1.41; p=0.07). The 
impact on clinical outcomes was not measured in this study. 
Finally, Najjar et al.  conducted a NRCT in Saudi Arabia assessing the effectiveness of 
an educational and clinical pharmacist intervention in reducing the incidence of PIMs 
(as measured by Beers (203) and STOPP criteria (68)) among hospitalised patients ≥ 
65 years old (236). Four hundred patients were enrolled in this study, 200 in the 
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comparator group (pre-intervention period) and 200 in the intervention group. The 
education component, which consisted of four 1-hour long sessions and the provision 
of written material, which was developed and delivered by a geriatrician and clinical 
pharmacists aimed to improved physicians’ knowledge of updated evidence-based 
guidelines for prescribing in older people. The clinical pharmacist intervention 
component involved increased collaboration (e.g. audit and feedback, ward round 
participation) between the pharmacists and prescribers with the aim of utilising 
STOPP and Beers criteria to optimise prescribing. It is not clear what level of 
pharmaceutical care was delivered during the comparator period. As a result of the 
intervention, the incidence rate of PIMs was significantly lower in the intervention 
group compared to the comparator group (29.5% vs. 61%; p<0.001). However the 
prevalence of PIMs on admission and discharge for both groups was not reported. 
The impact on clinical outcomes was not assessed in this study. 
2.8.4 Discussion 
In total, five additional studies were found which all reported an improvement in the 
appropriateness of prescribing for older hospitalised patients as a result of 
pharmacists’ interventions. Four out of five reported that these improvements were 
statistically significant in favour of the intervention group. We can see that the 
addition of Chiu et al. to the forest plot in Figure 17, did not significantly change the 
direction or magnitude of the effect size compared to the original forest plot (Figure 
13(a)) (-4.37; 95% CI: -7.14, -1.59 vs. -5.27; 95% CI: -8.44, -2.11). Hence, the findings 
from these newer studies are in line with our originally included studies. 
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However, the interventions did not appear to have impacted on any of the clinical 
outcomes reported, except quality of life and the number of ED visits without 
hospital admission in one study (239), and unplanned hospital readmissions at one-
month in another study (235). This apparent limited effect on clinical outcomes is in 
line with our initial findings, as well as another seminal systematic review (241). The 
possible reason behind these consistently non-significant impacts on clinical 
outcomes, particularly with regards mortality, is that the influences on these 
outcomes are often multifactorial and are not necessarily directly related to PIP 
(242), although associations have been reported (183). The recently published 
OPTIMIST RCT conducted in Denmark, which recruited over 1,400 hospitalised 
patients with polypharmacy (over the age of 18), found that the multifaceted 
pharmacist intervention significantly reduced the number of hospital readmissions 
and ED visits compared to usual care (243). However this intervention, similar to our 
findings, did not have any significant impact on mortality. 
Once again, no study focused specifically on dementia patients, nor was any specific 
sub-group analysis conducted on this patient group. This is disappointing considering 
how vulnerable patients with dementia are to the adverse effects of certain 
medications (244), as well as the high prevalence of PIP and polypharmacy in 
hospitalised patients with dementia (245). Research is urgently required to 
determine the effectiveness of pharmacists’ intervention in this area. 
Due to time constraints, the searches and data extraction for this updated review, 
were conducted solely by the primary researcher. Furthermore, no grey literature 
searching and no risk of bias assessments were conducted, for this updated search. 
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Hence it is possible that important studies were unintentionally omitted from this 
updated search. Furthermore, there were some methodological concerns with the 
included studies, however these have not been quantified utilising any standardised 
risk of bias tool. Therefore I recommend that an updated systematic review be 




Chapter 3. Patterns of Psychotropic 
Prescribing and Polypharmacy in Older 
Hospitalised Patients in Ireland: A 
Retrospective Cross-Sectional Study 
3.1 Chapter Description 
In Chapter 2, I conducted a systematic review and meta-analysis, and the findings 
showed that pharmacists’ interventions in hospital settings were effective at 
reducing PIP in older hospitalised patients. However I found no intervention aimed 
at improving the quality of prescribing specifically in hospitalised patients with 
dementia. In this chapter, I investigate whether there are any differences between 
older patients with and without dementia on admission to hospital, in terms of 
patterns of prescribing. Evidence from this study will help to identify divergence in 
these prescribing patterns and hence will suggest areas for future targeted 
interventions. 
 
The work of this chapter has been published as: Walsh KA, O'Regan NA, Byrne S, 
Browne J, Meagher DJ, Timmons S. Patterns of psychotropic prescribing and 
polypharmacy in older hospitalized patients in Ireland: the influence of dementia on 





BPSD are ubiquitous in dementia and are often treated pharmacologically. The 
objectives of this study were to describe the use of psychotropic, anticholinergic and 
deliriogenic medications and to identify the prevalence of polypharmacy and 
psychotropic polypharmacy, among older hospitalised patients in Ireland, with and 
without dementia. 
3.2.2 Methods 
All older patients (≥ 70 years old) that had elective or emergency admissions to six 
Irish study hospitals were eligible for inclusion in a longitudinal observational study. 
Of 676 eligible patients, 598 patients (88% of total eligible patients) were recruited 
and diagnosed as having dementia, or not, by medical experts. These 598 patients 
were assessed for delirium, medication use, co-morbidity, functional ability and 
nutritional status. We conducted a retrospective cross-sectional analysis of 
medication data on admission for 583/598 patients with complete medication data 
(97.5% of those recruited), and controlled for age, sex and co-morbidity. 
3.2.3 Results 
Of 149 patients diagnosed with dementia, only 53 (35.5%) had a previous diagnosis. 
At hospital admission, 458 patients of the 583 included patients (78.6%) experienced 
polypharmacy (≥ 5 medications). The prevalence of polypharmacy (≥ 5 medications) 
was 84% (n=123) in people with dementia and 77% (n=335) in people without 
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dementia, however this difference was not significant (p=0.08). People with 
dementia were significantly more likely to be prescribed at least one psychotropic 
medication than patients without dementia [99/147 (67.4%) vs. 182/436 (41.7%); 
p<0.001]. People with dementia were also more likely to experience psychotropic 
polypharmacy (≥ two psychotropics) than those without dementia [54/147 (36.7%) 
vs. 61/436 (14%); p<0.001]. There were no significant differences in the prescribing 
patterns of anticholinergics [23/147 (15.7%) vs. 42/436 (9.6%); p=0.18] or 
deliriogenics [79/147 (53.7%) vs. 235/436 (53.9%); p=0.62]. Patients admitted from 
nursing homes were almost five times more likely to be prescribed an antipsychotic 
than those who were admitted from home controlling for dementia diagnosis, age, 
sex and co-morbidity (χ2 = 26.7; aOR = 4.8; 95% CI = 1.9 - 12.1; p-value = 0.001). 
3.2.4 Conclusion 
Polypharmacy and psychotropic drug use is highly prevalent in older Irish patients on 
admission to hospital, especially in people with dementia. Hospital admission 
presents an opportunity for medication reviews in people with dementia, however 
interventions aimed at improving the appropriateness of antipsychotic prescribing in 









The number of people with dementia is escalating worldwide; estimates project the 
prevalence at over 131.5 million by 2050 (25). The majority will experience BPSD, also 
referred to as NPS during their disease (246). BPSD refers to the spectrum of 
distressing, non-cognitive symptoms of dementia, ranging from wandering and 
agitation to delusional and aggressive behaviour (247). Psychotropic medications are 
commonly prescribed to manage BPSD and have some evidence to support their use 
(42, 248). For example, the CitAD trial showed that the addition of citalopram to a 
psychosocial intervention was more effective at reducing agitation and caregiver 
distress in people with dementia than the addition of placebo (122). Furthermore, 
treatment of BPSD with atypical antipsychotics has been found to cause a small yet 
significant reduction in caregiver burden (249). However, antipsychotics  are known 
to increase the risk of stroke and mortality in people with dementia (112), and a 
recent study has found that for every 26 people with dementia treated with 
haloperidol, there was one death  (109). Additionally, the DIADS-2 trial found that 
sertraline was not efficacious for the treatment of depression in people with 
dementia and was associated with an increased risk of adverse events (250, 251). 
Guidelines generally recommend that non-pharmacological treatments should be 
used as first line treatment of BPSD, and only when these fail should psychotropic 
agents be trialled for short-term use (83). Despite this, the usage of antipsychotics 





Polypharmacy, which is defined as the use of five or more medications (252), is 
common in older people and is associated with poorer health outcomes (253). 
Similarly, psychotropic polypharmacy (concurrent use of two or more psychotropic 
agents) increases the risk of adverse events (254). Delirium super-imposed on 
dementia is often drug-related and medications such as opioids and benzodiazepines 
can trigger a delirium episode in susceptible people (255). Also, anticholinergic 
medications can negatively affect cognitive and physical function in older people and  
their use should be minimised in people with dementia (256). 
Hospitalisation in people with dementia is associated with significantly poorer health 
outcomes (257). People with dementia are particularly vulnerable in this setting, due 
to the challenges of illness, new medications, and unfamiliar environments/carers 
(258). The INAD report of dementia care in acute hospitals found high levels of 
antipsychotic prescribing in hospitalised people with dementia, particularly when 
admitted from nursing homes (105). The authors highlighted a need for regular 
medication review on admission, echoed in the recently published Irish National 
Dementia Strategy (133). However, only 20 healthcare records from each hospital 
were reviewed for antipsychotic prescribing in this audit (105). Furthermore, only 
people with an explicit diagnosis of dementia who had a minimum length of stay of 
five days were included. Therefore it is unclear whether this data is representative of 
the majority of Irish people with dementia who are admitted to hospital. 
The objectives of this study were to describe the use of psychotropic, anticholinergic 
and deliriogenic medication among older hospitalised patients, with and without 
dementia, and to identify the prevalence of polypharmacy (≥5 medications) and 
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psychotropic polypharmacy (concurrent use of ≥2 psychotropic agents) in these 
patient groups. Furthermore another key objective of this study was to examine 
antipsychotic prescribing patterns in patients admitted from nursing homes 
compared to patients admitted from their own homes. Our first research question 
was “Are there any differences in the patterns of prescribing between older people 
(≥70 years) with and without dementia, upon admission to six acute hospitals in the 
south of Ireland, controlling for age, sex and co-morbidity?” Our primary hypothesis 
was that people with dementia are significantly more likely to be prescribed 
psychotropics and to be exposed to psychotropic polypharmacy than people without 
dementia, as previously reported (259, 260). Our secondary hypothesis was that 
people with dementia are more likely to be prescribed deliriogenic and 
anticholinergic medications and to be prescribed more medications than people 
without dementia, however the evidence for this is mixed or lacking (261, 262). Our 
second research question was “Are there any differences in the prevalence of 
antipsychotic prescribing between older people admitted to hospital from a nursing 
home setting compared to those admitted from their own home, controlling for age, 
sex, co-morbidity and dementia status?” Our hypothesis was that older people 








3.4.1 Study Design, Setting and Patients 
The Cork Dementia Study has been described in detail elsewhere (100). In brief, this 
longitudinal observational study explored the prevalence and associations of 
dementia in older patients admitted to all six acute hospitals in County Cork, Ireland. 
County Cork has a population of 519,032 which is comprised of 49.61% males, an 
older population (≥70 years) of 42,382 (8.17%) (263) and an estimated dementia 
population of 4,830 (0.93%) (247). This is relatively comparable to the proportions 
for the Republic of Ireland as a whole [total population = 4,588,252; males = 49.53%; 
older population ≥70 years = 361,755 (7.89%) and estimated dementia population = 
41,720 (0.91%)].  
Eligibility criteria for this study included age ≥70 years old and elective or emergency 
admission (non-day case). The cut-off age of 70 years as opposed to 65 years, was 
decided by the original study developers (of which I was not a part of) in order to 
increase the ‘yield’ of dementia patients as the prevalence increases with age - hence 
maximising study efficiency (100).  Recruitment occurred in each hospital for a period 
of two weeks and lasted from May 2012 to February 2013. Written informed consent 
was obtained for all patients. Exclusion criteria included patient refusal or being 
moribund on arrival to hospital. Patients were diagnosed with dementia by a three 
step approach, involving initial cognitive screening utilising the Standardised Mini-
Mental State Examination (SMMSE), followed by informant-derived data utilising the 
Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE). Finally, 
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dementia status was established by the senior author (ST), a consultant geriatrician, 
based on all available information (i.e. cognitive testing, informant-derived data, 
medical and demographic history). Patients were also assessed for delirium, 
depression, medication use, co-morbidity, functional ability and nutritional status. 
Data were prospectively collected by researchers with nursing or psychology 
backgrounds, after extensive training in all assessment tools. The primary researcher 
of this study (KW) was not involved in the initial data collection phase. 
This present study is a retrospective cross-sectional analysis of the original Cork 
Dementia Study medication data, collected on admission. Firstly, the original 
medication data were cleaned by the primary researcher, a pharmacist, using a 
three-step cycle of screening, diagnosing and editing suspected data irregularities, 
for the purpose of ensuring that incorrectly-spelled or partially-filled entries could be 
corrected and coded accurately (264). Secondly,  we coded the cleaned medication 
data by World Health Organisation (WHO) Anatomical Therapeutic Chemical (ATC) 
classifications (265), excluding emollients or nutritional supplements without any 
active ingredients. Information on strength, quantity, duration, or usage at follow-
up, were not recorded consistently so were not coded. Patients with missing 
medication data were excluded from the analysis. Finally, the coded medication data 
were cleaned again and linked at individual patient-level to the previously coded 
clinical data.  
The ‘Strengthening The Reporting of OBservational studies in Epidemiology’ (STROBE) 
guidelines have been followed in the conduct and reporting of this research (266). 
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Ethical approval was obtained from the local ethics committee (reference ECM 4 (t) 
06/12/11 & ECM 3 (yy) 07/07/15) (Appendix 12) 
3.4.2 Prescribing Patterns 
The primary outcome in this study was the difference in prescribing patterns 
between people with and without dementia, focusing on psychotropic agents in 
people with dementia, in particular antipsychotics. The definition of a psychotropic 
varies significantly throughout the literature; by consensus, we included 
antipsychotics (N05A), antidepressants (N06A), anxiolytics (N05B), hypnotics (N05C), 
anticonvulsants/mood-stabilisers (N03A) and anti-dementia drugs (N06D), as these 
medication classes are used to manage BPSD (42). It is important to acknowledge 
that anti-dementia drugs are inevitably utilised more in people with dementia than 
people without dementia, due to their cognitive enhancing properties. Additionally, 
some studies do not consider anticonvulsants/mood-stabilisers to be psychotropics 
(267, 268). Therefore we conducted sensitivity analyses to assess the impact of more 
conservative psychotropic definitions on our outcomes by excluding the following in 
a step-wise manner: 
(a) N06D (Anti-dementia drugs), 
(b) N06D and N03A (Anti-dementia drugs and anticonvulsants/mood-stabilisers). 
We utilised ATC codes, but reclassified Lithium (N05AN01) as a mood-stabiliser rather 
than an antipsychotic (269).  We were also interested in psychotropic polypharmacy, 
and patterns of antipsychotic prescribing in those admitted from nursing homes. 
Other prescribing patterns of interest included the 14 main ATC anatomical groups 
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(excluding ‘D - Dermatologicals’), levels of minor or major polypharmacy (5-9 
medications; or ≥10 medications respectively), deliriogenic medications and 
anticholinergics. Deliriogenic medication definition was based on published 
literature, decided upon by consensus between the study pharmacist (KAW) and two 
consultant geriatricians (ST, NOR) who are delirium experts. The included deliriogenic 
medications were predominantly in line with findings from a systematic review 
conducted by Clegg et al. which investigated the associations between medications 
and risk of delirium (255).  These definitions and the associated ATC codes are shown 
in Table 4. 
Table 4: Drug Class Definitions by WHO-ATC Code 
Drug Class WHO-ATC CODE 
Psychotropic  




Anticonvulsants/mood stabilisers  N03A (including N05AN01 - Lithium) 
Anti-dementia drugs N06D 
Potentially Deliriogenic Drugs as decided a 
priori by consensus  
 
Benzodiazepines N05BA, N05CD, N03AE01 
Opioids N02A, N01AH, N02BE51, R05DA, R05FA 
Dihydropyridines C08CA 
Tricyclic Antidepressants N06AA 
Anticholinergics (excluding 
inhaled/topical) 
A03AA, A03AB, A03B, A03CA, A03CB, 
A03DA, A03DB, A03E, A04AD01 
G04BD01-G04BD11, N02AG, N04A, 
N06AA,  
Steroids (excluding inhaled/topical) H02, A14A, G01B 
H2- receptor antagonists  A02BA 
Anti-Parkinson’s Drugs N04 
Benzodiazepine-related drugs N05CF 
 
Other drugs which may increase the risk of 
delirium but were not included in our a priori 
deliriogenic group 
 







Anti-dementia drug N06D 
Anticonvulsant/mood stabiliser  N03A (including N05AN01 - Lithium) 
Typical v Atypical Antipsychotics  
Typical Antipsychotics  N05AA, N05AB, N05AC, N05AD, N05AE, 
N05AF, N05AG (except N05AE04 - 
Zisprasidone) 
Atypical Antipsychotics  N05AH, N05AL, N05AX (including 
N05AE04 - Zisprasidone) 
WHO-ATC = World Health Organisation – Anatomical Therapeutic Chemical 
 
3.4.3 Statistical Analysis 
The original data were entered into a FileMaker Pro 11 database and subsequently 
exported into Excel 2011 for ATC coding and linking, before transferral into STATA 
software version 13 (StataCorp, College Station, TX, USA) for data analysis; statistical 
significance at p-value <0.05 was assumed. We utilised descriptive statistics to 
summarise the population. We assessed differences in prescribing patterns between 
those with and without dementia using the χ2 test (Fisher’s exact test if expected cell 
frequency was <5) for categorical variables, and Student’s t-test (normally 
distributed) or Mann-Whitney U test (non-normally distributed) for continuous 
variables. To control for age, sex and co-morbidity (Cumulative Illness Rating Scale in 
Geriatrics) effects, these were entered as independent variables into a model for 
each dependent variable, utilising multivariate linear or logistic regression, for 
continuous or binary dependent variables respectively. Results are reported in terms 






3.5.1 Study Population Characteristics 
Of 676 patients eligible for study enrolment, 598 were recruited and had a diagnosis 
of dementia or no dementia assigned (Figure 18). In total, a quarter of patients had 
dementia (n = 149); 53/149 (35.5%) had a known diagnosis prior to the study, and 
another 16/149 (11%) had known cognitive impairment. Eighty patients (53.5%) were 
newly (de-novo) diagnosed with dementia in the study, 29% (n = 23) of whom had 




Figure 18: Flow Diagram of Participants 
 
Fifteen patients had missing medication data, resulting in 583 patients (147 with 
dementia and 436 without dementia) with linked medication and clinical data. There 
was no significant difference in terms of the proportion of patients with missing 
medication data between those with and without dementia (χ2 = 1.1; p-value = 0.29). 
Just under half of the study population were male (49%; n = 285), the median age 
was 79 [IQR = 74 - 84)] and the vast majority were admitted from a home 
environment (own home, children’s home, or social/sheltered accommodation) 
(91%; n = 530) (Table 5). People with dementia were significantly older, more 
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dependent and had higher co-morbidities than those without dementia (all p-values 
< 0.001). People with dementia were also significantly more likely to be admitted 
from a nursing home, to be acutely admitted to hospital, or to have delirium on 
admission (all p-values ≤ 0.001). One fifth (n = 115) of all patients were diagnosed 
with delirium at admission and people with dementia constituted the majority of 



















Table 5: Demographics of study population 
 
 
1N=2 dementia patients without completed medication data 
2N=13 non-dementia patients without completed medication data 
*Statistically significant at p-level <0.05, utilising MWU test. 
**Statistically significant at p-level <0.05, utilising χ2 test 















Sex, N (%)      
Male 63 (42.3) 222 (50.9) 285 (48.9) 0.091 χ2=2.9 
Age      
Median 84 78 79 <0.001* MWU=-8.2 
IQR 79-89 74-82 74-84   
Home Type Admitted 
From, N (%) 
     
Home 113 (76.9) 417 (95.6) 530 (90.9) <0.001** χ2=56.1 
Nursing Home 27 (18.4) 8 (1.8) 35 (6.0)   
Sheltered 
Accommodation 
7 (4.8) 11 (2.5) 18 (3.1)   
CIRS-G score      
Median 11 9 10 <0.001* MWU=-4.1 
IQR 8-15 7-12 7-13   
Barthel Index      
Median 11 20 19 <0.001* MWU=12.7 
IQR 6-17 17-20 14-20   
Admission Type, N (%)      
Acute 120 (81.6) 300 (68.8) 420 (72.0) 0.003** χ2=9.0 
Elective 27 (18.4) 136 (31.2) 163 (28.0)   
















3.5.2 Prescribing Patterns 
Six patients were taking no medication on admission. People with dementia were 
prescribed almost one medication more per patient, on average, than those without 
dementia (mean ± SD = 7.9 ± 3.3 versus 7.1 ± 3.6; T = -2.1; p-value = 0.04) as shown 
in Table 6. However when corrected for age, sex and co-morbidity, this difference 
became non-significant (β = 0.3; 95% CI = -0.4 - 1.0; p-value = 0.43). The prevalence 
of polypharmacy was 84% in people with dementia and 77% in people without 
dementia, however this difference was not significant (p=0.08). Furthermore, there 
was no significant difference between the two groups in terms of the prevalence of 
major polypharmacy (27% in people with dementia and 23% in people without 











P-value 5  T-value, χ2 
or Fishers 
exact test 
Controlling for Age, Sex and co-
morbidity6  
Total number of medications prescribed 1154 3117 4271 - - - 
Number of patients prescribed ≥ 1 medication, N (%) 147 (100) 430 (98.6) 577 (99.0) 0.15 χ2 = 1.1 aOR = 0.9, 95% CI = 0.1-4.7 
Number of medications per patient       
Mean 7.9 7.1 7.3 0.04* T = -2.1 β = 0.3, 95% CI = -0.4-1.0 
SD 3.3 3.6 3.5    
Range 1-17 0-20 0-20    
Number of patients who experienced the following 
levels of polypharmacy, N (%): 
      
Minor Polypharmacy (5-9 medications) 83 (56.5) 233 (53.4) 316 (54.2) 0.53 χ2 = 0.4 aOR = 1.0, 95% CI = 0.7-1.6 
Major Polypharmacy (≥ 10 medications) 40 (27.2) 102 (23.4) 142 (24.4) 0.35 χ2 = 0.9 aOR = 1.0, 95% CI = 0.6-1.6 
Any Polypharmacy (≥ 5 medications) 123 (83.7) 335 (76.8) 458 (78.6) 0.08 χ2 = 3.1 aOR = 1.1, 95% CI = 0.6-1.9 
Number of patients prescribed ≥ 1 of the following 
Psychotropic medications, N (%) 
      
Antipsychotics 20 (13.6) 21 (4.8) 41 (7.0) <0.001** χ2 = 13.0 aOR = 3.7, 95% CI = 1.8-7.6ǂ 
Typical Antipsychotics 5  (3.4) 9 (2.1)  14 (2.4) 0.36 χ2 = 0.8 aOR = 1.6, 95% CI = 0.5-5.5 
Atypical Antipsychotics 16 (10.9) 13 (3.0) 29 (5.0) <0.001** χ2 = 14.5 aOR = 4.7, 95% CI = 2.0-10.9ǂ 
Antidepressants 47 (32.0) 84 (19.3) 131 (22.5) 0.001** χ2 = 10.1 aOR = 2.1, 95% CI = 1.3-3.3ǂ 
Anxiolytics 21 (14.3) 27 (6.2) 48 (8.2) 0.002** χ2 = 9.5 aOR = 2.3, 95% CI = 1.2-4.6ǂ 
Hypnotics 29 (19.7) 74 (17.0) 103 (17.7) 0.45 χ2 = 0.6 aOR = 0.9, 95% CI = 0.5-1.5 
Anti-Convulsants/mood-stabiliser 16 (10.9) 50 (11.5) 66 (11.4) 0.85 χ2 = 0.03 aOR = 0.9, 95% CI = 0.5-1.7 
Anti-Dementia drugs 35 (23.8) 3 (0.7) 38 (6.5) <0.001** F < 0.001 aOR = 47.9, 95% CI = 13.8-166.3ǂ 
Any Psychotropic Medication1 99 (67.4) 182 (41.7) 281 (48.2) <0.001** χ2 = 28.9 aOR = 2.6, 95% CI = 1.7-4.0ǂ 
Any Psychotropic Medication (excluding Anti-Dementia 
dugs) 
83 (56.5) 182 (41.7) 265 (45.5) 0.002** χ2 = 9.6 aOR = 1.6, 95% CI = 1.1-2.4ǂ 
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Any Psychotropic Medication (excluding Anti-Dementia 
drugs and Anti-Convulsants/mood-stabilisers) 
75 (51.0) 155 (35.6) 230 (39.5) 0.001** χ2 = 11.0 aOR = 1.7, 95% CI = 1.1-2.5ǂ 
Number of patients who experienced the following 
levels of psychotropic prescribing, N (%) 
      
No psychotropic medication prescribed1 48 (32.7) 254 (58.3) 302 (51.8) <0.001** χ2 = 28.9 aOR = 0.4, 95% CI = 0.2-0.6ǂ 
Only one psychotropic medication prescribed1 45 (30.6) 121 (27.8) 166 (28.5) 0.5 χ2 = 0.4 aOR = 1.0, 95% CI = 0.6-1.6 
Psychotropic Polypharmacy1 (≥ 2 psychotropics) 54 (36.7) 61 (14.0) 115 (19.7) <0.001** χ2 = 35.9 aOR = 3.5, 95% CI = 2.1-5.6ǂ 
Psychotropic Polypharmacy (≥ 2 psychotropics) 
(excluding Anti-Dementia dugs) 
43 (29.3) 60 (13.8) 103 (17.7) <0.001** χ2 = 18.1 aOR = 2.5, 95% CI = 1.5-4.1ǂ 
 
Psychotropic Polypharmacy (≥ 2 psychotropics) 
(excluding Anti-Dementia dugs and Anti-
Convulsants/mood stabilisers) 
35 (23.8) 44 (10.1) 79 (13.6) <0.001** χ2 = 17.7 aOR = 2.7, 95% CI = 1.5-4.6ǂ 
 
Number of patients prescribed ≥ 1 of the following 
Potentially Deliriogenic Medication2, N (%) 
      
Benzodiazepines 32 (21.8) 52 (11.3) 84 (14.4) 0.003** χ2 = 8.6 aOR = 1.7, 95% CI = 0.9-2.9 
Opioids 18 (12.2) 78 (17.9) 96 (16.5) 0.11 χ2 = 2.5 aOR = 0.7, 95% CI = 0.4-1.3 
Dihydropyridines 18 (12.2) 72 (16.5) 90 (15.4) 0.22 χ2 = 1.5 aOR = 0.8, 95% CI = 0.4-1.4 
Tricyclic Antidepressants 9 (6.1) 17 (3.9) 26 (4.5) 0.26 χ2 = 1.3 aOR = 1.5, 95% CI = 0.6-3.6 
Systemic Anticholinergics3 23 (15.7) 42 (9.6) 65 (11.2) 0.045** χ2 = 4.0 aOR = 1.5, 95% CI = 0.8-2.8 
Systemic steroids 7 (4.8) 40 (9.2) 47 (8.1) 0.09 χ2 = 2.9 aOR = 0.4, 95% CI = 0.1-0.9^ 
H2- Receptor Antagonists 2 (1.4) 2 (0.5) 4 (0.7) 0.27 F = 0.27 aOR = 2.5, 95% CI = 0.3-23.4 
Anti-Parkinson’s Drugs 6 (4.1) 9 (2.1) 15 (2.6) 0.18 χ2 = 1.8 aOR = 2.0, 95% CI = 0.6-6.4 
Benzodiazepine-related drugs 14 (9.5) 46 (10.6) 60 (10.3) 0.72 χ2 = 0.1 aOR = 0.7, 95% CI = 0.4-1.4 
Any Potentially Deliriogenic Drug 79 (53.7) 235 (53.9) 314 (53.9) 0.97 χ2 < 0.01 aOR = 0.9, 95% CI = 0.6-1.4 
Systemic NSAID4 5 (3.4) 29 (6.7) 34 (5.8) 0.15 χ2 = 2.1 aOR = 0.5, 95% CI = 0.2-1.5 
Number of patients prescribed ≥ 1 of the following 
medications according to the WHO-ATC anatomical 
groups7, N (%) 
      
Alimentary Tract and Metabolism (WHO-ATC A) 110 (74.8) 296 (67.9) 406 (69.6) 0.11 χ2 = 2.5 aOR = 0.9, 95% CI = 0.6-1.5 
Blood and Blood Forming Organs (WHO-ATC B) 105 (71.4) 302 (69.3) 407 (69.8) 0.62 χ2 = 0.2 aOR = 1.0, 95% CI = 0.6-1.6 
Cardiovascular System (WHO-ATC C) 126 (85.7) 381 (87.4) 507 (87.0) 0.60 χ2 = 0.3 aOR = 0.7, 95% CI = 0.4–1.3 
Genito-Urinary System and Sex Hormones (WHO-ATC G) 31 (21.1) 70 (16.1) 101 (17.3) 0.16 χ2 = 1.9 aOR = 1.2, 95% CI = 0.7-2.0 
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Systemic Hormonal Preparations (WHO-ATC H) 25 (17.0) 100 (22.9) 125 (21.4) 0.13 χ2 = 2.3 aOR = 0.6, 95% CI = 0.4-1.0 
Anti-infectives for Systemic Use (WHO-ATC J) 22 (15.0) 41 (9.4) 63 (10.8) 0.06 χ2 = 3.5 aOR = 1.6, 95% CI = 0.8-2.9 
Anti-neoplastic and Immunomodulating Agents (WHO-
ATC L) 
5 (3.4) 26 (6.0) 31 (5.3) 0.23 χ2 = 1.4 aOR = 0.7, 95% CI = 0.2-1.9 
Musculo-Skeletal System (WHO-ATC M) 38 (25.9) 100 (22.9) 138 (23.7) 0.47 χ2 = 0.5 aOR = 1.2, 95% CI = 0.8-2.0 
Nervous System (WHO-ATC N) 111 (75.5) 239 (54.8) 350 (60.0) <0.001* χ2 = 19.6 aOR = 2.0, 95% CI = 1.3-3.2ǂ 
Anti-parasitic Products, Insecticides and Repellents 
(WHO-ATC P) 
2 (1.4) 10 (2.3) 12 (2.1) 0.74 F = 0.74 aOR = 0.6, 95% CI = 0.1-3.3 
Respiratory System (WHO-ATC R) 37 (25.2) 125 (28.7) 162 (27.8) 0.41 χ2 = 0.7 aOR = 0.8, 95% CI = 0.5-1.2 
Sensory Organs (WHO-ATC S) 13 (8.8) 28 (6.4) 41 (7.0) 0.32 χ2 = 1.0 aOR = 1.0, 95% CI = 0.2-2.2 
Various (WHO-ATC V) 1 (0.7) 4 (0.9) 5 (0.9) 1.0 F = 1.0 aOR = 0.5, 95% CI = 0.1-5.2 
1Psychotropic defined as Antipsychotics, Antidepressants, Anxiolytic, Hypnotics, Anticonvulsants/mood-stabiliser and Anti-Dementia Drugs. 2Deliriogenic Medications 
defined by group consensus a priori. 3Systemic anticholinergics defined by group consensus a priori. 4Systemic Non-steroidal anti-inflammatory drugs not included in the 
potentially deliriogenic drug category, but shown here for illustration purposes. 5P-value for two-way table with measures of association 6Adjusted Odds Ratio for dependent 
variable utilising linear or logistic regression as appropriate, with age, sex and CIRS-G as the independent variables. 7WHO-ATC D (Dermatologicals) excluded as emollients 
without any active ingredients were not coded. *Statistically significant at p-level <0.05, utilising Student’s t-test. **Statistically significant at p-level <0.05, utilising χ2 test or 
Fishers exact test. ǂStatistically significant at p-level <0.05, utilising logistic regression. ^Although significant at p-level <0.05, this variable does not contain a minimum of 
10 cases of event and no event that are usually required for logistic regression analysis, therefore the findings should not be interpreted as statistically significant  
CIRS-G = Cumulative Illness Rating Scale in Geriatrics, aOR = Adjusted Odds Ratio, NSAID = Non-steroid anti-inflammatory drug, WHO-ATC = World Health Organisation 
Anatomical Therapeutic Chemical, β = beta- coefficient, 95% CI = 95% Confidence Interval 
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People with dementia were significantly more likely to be prescribed at least one 
psychotropic medication (χ2 = 28.9; aOR = 2.6, 95% CI = 1.7 - 4.0; p-value < 0.001). 
Atypical antipsychotics, antidepressants, anxiolytics and anti-dementia drugs were 
all significantly more likely to be prescribed to people with dementia, even 
controlling for age, sex and co-morbidity (all p-values < 0.05). However there was no 
significant difference in hypnotic, anticonvulsant/mood-stabiliser or typical 
antipsychotic prescription between the two groups (all p-values > 0.05). The 
prevalence of psychotropic polypharmacy was 37% in people with dementia and 14% 
in people without dementia and thus people with dementia were over three times 
more likely to experience psychotropic polypharmacy (χ2 = 35.9; aOR = 3.5; 95% CI = 
2.1 - 5.6; p-value < 0.001). Sensitivity analyses found that even when we excluded 
anti-dementia drugs and subsequently anti-convulsants/mood-stabilisers from our 
definition of psychotropics, people with dementia were still significantly more likely 
to be prescribed at least one psychotropic (p-values ≤ 0.002) and to be exposed to 
psychotropic polypharmacy (p-values < 0.001) than those without dementia (Table 
6). Removing these two classes of medications reduced the prevalence of 
psychotropic polypharmacy in patients with and without dementia to 29% versus 
14% (excluding N06D), and then to 24% versus 10% (excluding N06D and N03A) 
respectively. 
Looking at psychotropic medications in more detail, 32% of people with dementia 
were prescribed antidepressants, compared to 19% of people without dementia (χ2 
= 10.1; aOR = 2.1; 95% CI = 1.3 - 3.3; p-value = 0.002). Similarly, 14% of people with 
dementia (n = 20) were prescribed at least one antipsychotic, compared to 5% of 
their peers (n = 21) (χ 2 = 13.0; aOR = 3.7; 95% CI = 1.8 - 7.6; p-value < 0.001). In terms 
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of those who had a previous diagnosis of dementia, 28% (15/53) were prescribed an 
antipsychotic, compared to just 5% (5/94) of those who had no prior diagnosis or a 
diagnosis of cognitive impairment. Patients admitted from nursing homes were 
almost five times more likely to be prescribed an antipsychotic than those who were 
admitted from home controlling for dementia diagnosis, age, sex and co-morbidity 
(χ2 = 26.7; aOR = 4.8; 95% CI = 1.9 - 12.1; p-value = 0.001). Atypical antipsychotics 
(n=30) were more commonly prescribed than typical antipsychotics (n = 14), 
predominantly quetiapine (n = 17) and olanzapine (n = 11). 
Just over half of all patients were prescribed ≥ 1 potentially deliriogenic medication 
(54%), with no differences in the level of prescribing of these agents between the 
two groups (χ2 < 0.01; aOR = 0.9; 95% CI = 0.6 - 1.4; p-value = 0.6). Benzodiazepines 
and systemic anticholinergics were significantly more likely to be prescribed to 
people with dementia (both p-value < 0.05), but differences became non-significant 
after adjusting for age, sex and co-morbidity (both p-value > 0.05). 
The four most commonly prescribed WHO-ATC anatomical groups were (1) 
cardiovascular system, (2) blood and blood forming organs, (3) alimentary tract and 
metabolism, and (4) nervous system, prescribed to 87%, 70%, 70% and 60% of all 
patients respectively (Table 6). There were no differences in the level of prescribing 
of any of the 13 included WHO-ATC anatomical groups (all p-values > 0.05), except 
for nervous system drugs, which were more commonly prescribed to people with 






3.6.1 Main Findings 
This retrospective cross-sectional study aimed to explore the prescribing patterns of 
psychotropic, anticholinergic and deliriogenic medications, and polypharmacy, in a 
well-defined cohort of hospitalised older Irish patients; and to assess differences 
between people with and without dementia. Overall, we found that this population 
was prescribed high levels of medication, with over three-quarters experiencing 
polypharmacy and a quarter experiencing major polypharmacy. People with 
dementia were more likely to be prescribed psychotropic medications and to 
experience psychotropic polypharmacy. We found no differences in the prescribing 
patterns in terms of number of medications, anticholinergic medications, deliriogenic 
medications or any of the other main WHO-ATC anatomical groups, except for 
nervous system medications.  
Another important finding of the Cork Dementia Study was that only 35.5% of people 
with dementia had an explicit diagnosis of dementia prior to the study. Previous 
studies conducted in Australia (270) and the UK (271) reported similar levels of 
under-diagnosis in people with dementia requiring an admission to hospital. This low 
rate of diagnosis may result in inappropriate medications being prescribed to people 
with dementia and hospital physicians incorrectly assuming capacity to consent for 
complex treatments (100). 
Our results are in agreement with several pharmacoepidemiological studies, which 
found a high prevalence of psychotropic medicine use in older hospitalised patients 
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in general (272), and significantly higher levels of psychotropic medications being 
prescribed to people with dementia than to those without dementia (259, 273-275). 
These findings are not surprising due to the ubiquity of BPSD in dementia. One large 
scale study of the longitudinal course of BPSD in people with dementia reported a 
five-year period prevalence of BPSD symptoms of 97% (36). The most commonly 
reported symptoms were apathy, depression and delusions. Of note in this study, 
many people with dementia already had BPSD at the time of initial dementia 
diagnosis. Furthermore, many studies have reported the presence of BPSD in Mild 
Cognitive Impairment (MCI) (276). There are very recently published criteria for 
diagnosing Mild Behavioural Impairment (MBI) (277) that describe BPSD as a possible 
index manifestation of dementia, in advance of measurable cognitive impairment. 
This is an important conceptual advance in our understanding of dementia, and the 
prescription of psychotropic medications for changes in behaviour or personality may 
give an indication of an emergent dementia. Furthermore, benzodiazepines are often 
associated with cognitive decline and dementia (278); with the implication of 
causality between the two, although  a recent study has questioned this causal 
association (279). An alternative hypothesis is that anxiety can present as the index 
manifestation of dementia, with  benzodiazepines prescribed, and when  the 
underlying dementia ultimately declares itself,  the benzodiazepine is labelled as the 
culprit for cognitive decline (277). The bottom line is that BPSD are fundamental and 
core features of dementia, and result in greater illness burden, higher caregiver 
burden, poorer quality of life, higher rates of institutionalisation, faster cognitive 




Notwithstanding these  important contextual issues, the fact remains that people 
with dementia are often excessively and inappropriately prescribed psychotropic 
medications, and for prolonged periods of time (128). We know that in people with 
dementia, antipsychotics significantly increase the risk of stroke and mortality (109) 
and benzodiazepines significantly increase the risk of falls and hip fractures (282). 
Prescription of multiple psychotropic agents results in even greater risk of adverse 
events (254). It is imperative that prescribers and care providers adhere to guidelines, 
in so far as possible, by utilising non-pharmacological interventions in the first 
instance and prescribing antipsychotics as a last resort, with regular review and trials 
of withdrawal (83). There is evidence to support the use of non-pharmacological 
interventions in managing BPSD (283), however better quality trials are required in 
this area. 
The prevalence of antipsychotic usage in the pharmacoepidemiological studies 
mentioned above ranged from 5% to 43% in those with dementia, highest in studies 
looking at institutionalised patients. In comparison, the prevalence of antipsychotic 
usage in people with dementia in our study, where 91% of patients were admitted 
from a home environment (and hence predominantly reflecting primary care 
prescribing patterns) was 14%, lower than a previous study of home-dwelling older 
people (33%) (259). This probably reflects the high rate of undiagnosed cases in our 
study, with only 35.5% having a prior diagnosis. The rates of prescribing in our study 
population with known dementia was 28%, similar to that found in the study by 
Hartikainen et al. The INAD study conducted in 2013 found that 41% of people with 
dementia were prescribed antipsychotic medications during their admission in Irish 
hospitals, and also found poor levels of documentation of mental health assessment 
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and drug indication (104, 105). This figure is much higher than what we found in our 
study, and may reflect the purposeful selection of patients for the audit who had an 
explicit diagnosis of dementia and a longer length of stay, thereby potentially 
representing a much frailer sub-population of people with dementia. Additionally, as 
the data were collected on admission to hospital, the prescribing patterns captured 
in our study, better reflects primary care prescribing practices rather than in-patient 
prescribing practices. Nonetheless, the high figure reported in the INAD study is still 
alarming, considering the same audit conducted in England and Wales in 2012-2013 
(130) and Northern Ireland in 2014-2015 (284) found much lower levels of 
antipsychotic prescribing; 18% and 21% respectively. 
We found that patients admitted from a nursing home (n=35) were almost five times 
more likely to be prescribed an antipsychotic than those admitted from other home 
types. The INAD report also found that  people with dementia admitted from nursing 
homes were significantly more likely to be prescribed an antipsychotic compared to  
those admitted from their own home (46% v 19%; p < 0.001) (104, 105). Similarly, a 
cross-sectional Finnish nursing home population study found that 43% of residents 
were prescribed antipsychotics (275). These findings would indicate that in a busy 
hospital setting, pharmacists and other healthcare professionals should prioritise 
people with dementia, along with patients admitted from nursing homes, for review 
of their antipsychotic medications. However, as discussed in Chapter 2, there is a 
distinct lack of such studies conducted in hospitalised dementia patients. It is 
important that any antipsychotic medication review conducted in a hospital setting 
involves effective communication with the patient’s General Practitioner (GP), carers 
and nursing home staff, as it is necessary to know the indication for the antipsychotic 
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and whether any non-pharmacological intervention or dose reduction had been 
previously attempted (285). It is also crucial that these community-based care 
providers are informed of any plans for dose titrations or withdrawals at hospital 
discharge to prevent the unintended re-commencement of these patients on 
antipsychotics. Additionally, as the highest prevalence of antipsychotic prescribing 
occurred in those admitted from nursing homes, future interventions aimed at 
improving the appropriateness of antipsychotic prescribing in people with dementia 
may be more worthwhile if conducted in nursing home as opposed to acute settings. 
We did not find any significant differences in terms of anticholinergic, deliriogenic or 
total number of medications prescribed between the two patient groups. We were 
surprised by the former finding, as previous studies have reported higher levels of 
anticholinergic prescribing in people with dementia (286). One potential hypothesis 
is that a greater level of awareness surrounding the risk of cognitive decline with 
these agents has resulted in more careful prescribing in people with dementia. 
However a repeated cross-sectional study conducted in Scotland found that despite 
the increasing evidence surrounding the adverse effects of anticholinergics, exposure 
to these agents in older adults has actually increased in recent years (287). We were 
unable to find literature on the prevalence of deliriogenic medication usage in people 
with dementia, thus our a priori hypothesis on this topic was purely speculative, 
based on the knowledge that the people with dementia in the study had more co-
morbidities than their peers. Further research should be conducted to investigate the 
consequences of deliriogenic prescribing in people with dementia. The evidence on 
medication burden in people with dementia is mixed, with some studies finding 
people with dementia are prescribed more (261) and others finding they are 
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prescribed less medications (262) than people without dementia. The discrepancies 
may relate to population differences between the studies.  
3.6.2 Strengths and Limitations 
The main strength of this research was the large number of patients recruited into 
this multi-centred trial and the vast amount of rich data that were collected from 
each patient allowing us to tease apart effects of dementia from confounding factors 
such as age, sex and co-morbidity. However, when the sample size for the primary 
outcome (i.e. the difference in proportion of patients with and without dementia 
who were prescribed at least one psychotropic – based on the most conservative 
definition for a psychotropic) was retrospectively calculated, it was clear that this 
study was not powered to detect this difference. In terms of comparing two 
proportions using α=0.05 and power of 80%, it was calculated that 159 patients 
would be required in each group to detect a statistically significant difference 
between 51% and 35.6%. Although 436 patients without dementia were recruited 
into this study, only 147 patients with dementia were recruited. Hence caution 
should be used when interpreting these findings.  
The main limitation of this study is the retrospective nature of the medication 
analysis, so that it was not possible to resolve any ambiguous medication data 
entries. However the quality of data collection was quite high and this ambiguity 
rarely occurred. Secondly, as the study is observational, it is not possible to draw any 
conclusions on causality, as dementia or cognitive impairment may have been the 
cause of or potentially even the result of differences in medication usage between 
the two patient groups. Thirdly, the lack of information on strength, quantity and 
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duration of medication usage is a limitation to our study. It would have been 
interesting to investigate the differences in dosing within and between the two 
patient groups, as toxicity with antipsychotics, for example, is largely dose-
dependent (288). Finally, as the study was conducted in only one county in Ireland, 
the findings may not be representative of the entire older Irish population. However, 
as the demographic profile of Cork County is relatively similar to that of the rest of 
the country, we believe these results may possibly be representative of the entire 
older Irish population. 
 
3.7 Conclusion 
Psychotropic drug use and polypharmacy is highly prevalent, and dementia is under-
diagnosed among older Irish hospitalised patients. People with dementia are more 
likely to be prescribed antipsychotics, antidepressants, anxiolytics and anti-dementia 
drugs. People with dementia are also more likely to be exposed to psychotropic 
polypharmacy. These differences in prescribing patterns may be largely attributed to 
BPSD in dementia, and neuropsychiatric symptoms in pre-dementia clinical 
syndromes like MCI and MBI. Longitudinal research is required to assess the long-
term impact that medication usage or non-usage has on the development of 
dementia in older people and also to assess the impact that a diagnosis of dementia 
has on the physician’s prescribing patterns. Furthermore, as the highest prevalence 
of antipsychotic prescribing occurred in those admitted from nursing homes, future 
interventions aimed at improving the appropriateness of antipsychotic prescribing in 
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people with dementia may be more worthwhile if conducted in nursing home as 
opposed to acute settings.
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Chapter 4. Influences on Decision-Making 
Regarding Antipsychotic Prescribing in 
Nursing Home Residents with Dementia: a 
Systematic Review and Synthesis of 
Qualitative Evidence 
4.1 Chapter Description 
In Chapter 3, I established that psychotropic drug use is highly prevalent in older Irish 
adults on admission to hospital, especially in those with dementia. From examination 
of the patterns of prescribing in this study, it was evident that antipsychotic 
prescribing was most prevalent in those admitted from nursing homes. Hence, in 
order to effectively target inappropriate antipsychotic prescribing to people with 
dementia in a future intervention, I realised that the best option would be to focus 
on nursing home settings. In this chapter, I conduct a meta-ethnography, essentially 
exploring the reasons why antipsychotics continue to be inappropriately prescribed 
to nursing home residents with dementia. Collating and understanding what is 
known on this complex topic, are important first steps in the development of an 
evidence-based, theory-informed intervention. An addendum is provided at the end 
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Regarding Antipsychotic Prescribing in Nursing Home Residents With Dementia: A 
Systematic Review and Synthesis of Qualitative Evidence. Journal of the American 
















Antipsychotic prescribing is prevalent in nursing homes for the management of BPSD, 
despite the known risks and limited effectiveness. Many studies have attempted to 
understand this continuing phenomenon, utilising qualitative research methods, and 
have generated varied and sometimes conflicting findings. To date, the totality of this 
qualitative evidence has not been systematically collated and synthesised.  
4.2.2 Aims 
To synthesise the findings from individual qualitative studies on decision-making and 
prescribing behaviours for antipsychotics in nursing home residents with dementia, 
with a view to informing intervention development and quality improvement in this 
field. 
4.2.3 Methods 
A systematic review and synthesis of qualitative evidence was conducted (PROSPERO 
protocol registration CRD42015029141). Six electronic databases were searched 
systematically from inception through July 2016 and supplemented by citation, 
reference and grey literature searching. Studies were included if they utilised 
qualitative methods for both data collection and analysis, and explored antipsychotic 
prescribing in nursing homes for the purpose of managing BPSD. The Critical 
Appraisal Skills Programme (CASP) assessment tool was utilised for quality appraisal. 
A meta-ethnography was conducted to synthesise included studies. The Confidence 
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in the Evidence from Reviews of Qualitative research (CERQual) approach was used 
to assess the confidence in individual review findings. All stages were conducted by 
at least two independent reviewers. 
4.2.4 Results 
Of 1,534 unique records identified, 18 met the inclusion criteria.  Five key concepts 
emerged as influencing decision-making: Organisational Capacity; Individual 
Professional Capability; Communication and Collaboration; Attitudes; Regulations 
and Guidelines. A ‘line of argument’ was synthesised and a conceptual model 
constructed, comparing this decision-making process to a dysfunctional negative 
feedback loop. Our synthesis indicates that when all stakeholders come together to 
communicate and collaborate as equal and empowered partners, this can result in a 
successful reduction in inappropriate antipsychotic prescribing. 
4.2.5 Conclusion 
Antipsychotic prescribing in nursing home residents with dementia occurs in a 
complex environment involving the interplay of various stakeholders, the nursing 
home organisation and external influences. In order to improve the quality of 
antipsychotic prescribing in this cohort, a more holistic approach to BPSD 
management is required. While we have found the issue of antipsychotic prescribing 
has been extensively explored using qualitative methods, there remains a need for 




Antipsychotics are commonly prescribed to manage BPSD (128). These medications 
have a role to play in BPSD when there is a danger of harm to self or others, when 
there is a psychosis, or when non-pharmacological approaches have not been 
effective (289). However, these agents are often prescribed inappropriately, despite 
evidence of an increased risk of stroke and mortality, and a lack of effectiveness in 
these patients (109, 112, 128). As discussed in Chapter 3, people with dementia are 
prescribed significantly more of these agents than the general older population (2, 
290) and it is in the nursing home setting where the majority of this prescribing 
occurs (291). 
A 2014 systematic review found that many interventions are effective in the short-
term at reducing the inappropriate prescribing of antipsychotics in nursing homes to 
people with dementia (151). The authors highlighted the need for a greater 
understanding of the contextual drivers of inappropriate prescribing in order to 
improve the long-term sustainability of the reviewed interventions. 
Qualitative research allows for a rich understanding of complex social environments 
such as nursing homes and can be used to develop and improve interventions in this 
context (292). A number of original qualitative studies have been conducted on 
antipsychotic prescribing in people with dementia but to date these have not been 
the subject of a systematic review. 
The most commonly utilised method for synthesising qualitative evidence is  meta-
ethnography (293). This seven-step method of qualitative evidence synthesis 
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employs an inductive approach moving from specific observations to broader 
generalisations. It is a systematic interpretive approach that is particularly useful for 
generating new theories or concepts, which can influence policy and practice (294). 
For example, recently published clinical guidelines on multimorbidity (295) have 
been informed by a high-quality meta-ethnography in this similarly complex field 
(296).  
The aim of our study was to synthesise the findings from individual qualitative studies 
in order to develop novel interpretations of the influences on decision-making 
regarding the prescribing of antipsychotics in nursing home residents with dementia, 
with a view to informing intervention development and quality improvement in this 
field. 
4.4 Methods 
We conducted a systematic search of primary qualitative studies exploring 
antipsychotic prescribing in non-acute, long-term care institutions. We used a ‘meta-
ethnographic synthesis’ (293), as adapted by Atkins et al. (297) to guide our methods. 
The review protocol was registered with the PROSPERO international prospective 
register of systematic reviews (registration number: CRD42015029141) 
(https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=29141). 
Six electronic databases were searched from inception to July 2016; Medline, 
PubMed, EMBASE, CINAHL, PsycINFO and Academic Search Complete. Database-
specific search strategies were developed with assistance from a medical librarian. 
Search terms included a combination of Medical Subject Heading terms, keywords 
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and a comprehensive list of synonyms of the following: ‘dementia’ AND ‘prescription’ 
AND ‘antipsychotic agents’ with the aim of being as sensitive as possible. Qualitative-
specific search terms such as ‘interview’ and ‘qualitative’ were not used, as we 
believed this may have hindered discovery of poorly labelled, yet potentially 
relevant, mixed-methods studies. The search was not limited by dates of publication 
or country of origin. To supplement the database search, we conducted hand-
searches of key journals and conference proceedings; citation searches of highly 
cited key studies; reviews of reference lists of key studies; and contacted authors of 
relevant conference abstracts and studies. The grey literature search was further 
supplemented by checking the first 100 hits from Google Scholar and by consulting 
the websites and key personnel from various international Alzheimer’s Societies 
(Appendix 2). Google Scholar has been found to be a useful method for locating 
relevant qualitative studies with high yields, in a previous meta-ethnography (298). 
We included any English-language, peer-reviewed primary study, published in full, 
using recognised qualitative research methods of both data collection (e.g. focus 
groups, semi-structured interviews, ethnographic approaches and documents) and 
analysis (e.g. grounded theory, narrative analysis, thematic analysis, framework 
analysis, discourse analysis and interpretive phenomenological analysis). Mixed-
methods studies were only included if they utilised qualitative methods as a 
component of the study. Only the qualitative components of these studies were 
extracted for analysis. We only included questionnaire studies if the written 
comments had been analysed using qualitative methods. Studies which did not 
provide an account of the qualitative methods of data collection or data analysis 
were excluded, even if the study referred to itself as a qualitative study. 
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Through our initial scoping of the literature, it became clear that the terms 
‘antipsychotic’, ‘psychotropic’, ‘psychoactive’ and ‘pharmacological interventions’ 
are often used interchangeably, especially in terms of managing BPSD. Some studies 
included nursing homes and community settings, making it difficult to disentangle 
nursing home specific findings. Furthermore, not all studies explicitly stated that the 
nursing home residents had dementia, even though evidence shows the vast majority 
of nursing home residents have dementia. To avoid missing potentially relevant 
findings, we made a decision to include studies (otherwise meeting our inclusion 
criteria) that explored the prescription of ‘pharmacological agents’ (with at least 
implied inclusion of antipsychotics) for the purpose of managing BPSD in people with 
dementia (in any setting where there is at least some explicit mention of nursing 
homes). Studies exploring management of other mental health conditions (e.g. 
schizophrenia), other specific settings (e.g. acute hospital) where there is no explicit 
reference to nursing homes, or those explicitly referring to other specific 
psychotropic agents (e.g. antidepressants) were considered to be beyond the scope 
of this review and were excluded. 
For the first stage of study selection, one reviewer (KW) conducted preliminary 
screening of titles to exclude records that were clearly not relevant (e.g. pre-clinical 
studies). For the second stage, two reviewers (KW and RD) independently screened 
titles and abstracts, against inclusion criteria, to identify potentially relevant studies. 
In the third stage, two reviewers (KW and RD) independently reviewed full texts of 
studies. Consensus on inclusion in stages two and three was reached by discussion 
between both reviewers, with arbitration by a senior reviewer (ST) if required. The 
CASP assessment tool for qualitative research was used to assess the quality of 
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included studies (299), by two reviewers (KW and JB) independently, and consensus 
was reached by discussion. Studies were not excluded based on the assessed level of 
quality. Methodological limitations of included studies were accounted for in the 
CERQual assessments (discussed below) (300). 
Four reviewers (KW, RD, EC and CS) read and re-read the included studies, with a 
focus on the content and context. As a group, we identified what we believed to be 
the conceptually-richest ‘index paper’ (301), and used this as the starting point. Three 
reviewers (KW, RD and EC) read all 18 included studies starting with the ‘index paper’ 
and then chronologically. One reviewer (KW) open coded the study findings of all 
included studies (results and discussion sections), focusing specifically on first-order 
interpretations (views of the participants) and second-order interpretations (views 
of the authors). To ensure credibility and dependability of coding, another reviewer 
(CS) coded the ‘index paper’ and two other randomly selected studies (91, 302), and 
differences in interpretation were discussed and consensus reached (303). The four 
reviewers convened several times to discuss independently derived concepts and 
patterns from the studies. Reflexivity was preserved as one reviewer (KW) conducted 
memo writing (303).  As a multidisciplinary group, we were cognisant of our 
professional biases, therefore we ensured that there was a balance between clinical 
(KW and CS) and non-clinical (EC and RD) reviewers at this stage.  
Collectively, we developed five key concepts to reflect the main findings of all 
included studies. We developed a matrix of these concepts and assessed how each 
individual study related to each concept (Appendix 4) Two reviewers (KW and SB) 
independently extracted data regarding contextual information from each included 
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study. Discrepancies were resolved through discussion between both reviewers. QSR 
International’s NVivo version 11 was used to assist with data analysis and synthesis 
(304). 
In line with the constant comparative method of qualitative analysis (305), the first- 
and second-order interpretations were compared and contrasted across primary 
studies to identify similarities and disagreements. The importance of context to each 
interpretation was carefully observed. In this way, reciprocal (when concepts in one 
study can incorporate those of another) and refutational translations (when the 
concepts in different studies contradict one another) were conducted (294). All eight 
reviewers were involved in this and the following stages to ensure no important 
meanings were lost upon translating one study into the next. 
We collaboratively developed third-order interpretations by synthesising first- and 
second-order interpretations, from each study. The synthesis required refining the 
key concepts and building on the analysis iteratively. This process was repeated until 
we were satisfied that the third order interpretations added to, but were still 
representative of, the findings of the total dataset. These interpretations act as 
testable, novel hypotheses, which are still grounded in the data (297). We then linked 
these using a ‘line of argument’ in order to develop an overarching conceptual model 
explaining the phenomenon (296). Noblit and Hare describe this ‘line of argument’ 
synthesis as a means of uncovering novel understandings that were hidden in the 
individual studies (discovering a ‘whole’ among a set of parts) (293). 
We reported our results in line with the ‘ENhancing Transparency in REporting the 
synthesis of Qualitative research’ (ENTREQ) statement (306) (Appendix 3) and 
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expressed our search strategy results as a PRISMA flow diagram (197) (Figure 19). To 
present the findings of the review in a manner useful for policy-makers, we used 
CERQual (300). This tool allows assessment of the confidence in synthesised 
qualitative findings. We assessed the extent to which the review findings (i.e. third-
order interpretations) were reasonable representations of the phenomenon of 
interest, by independent application of CERQual, by two reviewers (KW and RD), with 
discussion until consensus was reached. 
 




4.5.1 Search Results 
A total of 1,534 unique records were found after duplicate removal (Figure 19) (197). 
After the exclusion of records based on title screening (n=631) and subsequent title 
and abstract screening (n=800), the remaining 103 full texts were assessed for 
eligibility. We excluded 85 records at this stage. In our final review, we included 18 
studies describing 17 study cohorts.  
4.5.2 Characteristics of Included Studies 
Table 7 outlines the characteristics of the 18 included studies. The studies were 
conducted in six different countries: UK (n =7) (64, 91, 307-311), US (n =5) (302, 312-
315), Australia (n = 3) (90, 316, 317), Canada (n = 1) (58), The Netherlands (n = 1) 
(301) and South Africa (n = 1) (318). Eleven of the studies employed a purely 
qualitative methodology, (64, 90, 91, 301, 302, 307, 308, 311, 316-318) while seven 
utilised mixed-methods (58, 309, 310, 312-315). A total of 1,609 unique participants 
were involved: nurses (n=479), other nursing home staff (n=657), family carers 
(n=239), physicians (n=144), pharmacists (n=49) and old age advocates (n=6). One 
study did not provide a disciplinary breakdown for its 35 participants (302). No study 
included the voice of the person with dementia. Of the 114 included nursing homes 
that had their ‘for-profit’ status described, 68 were for-profit, 40 were not-for-profit 
and 6 were described as “other”.
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Table 7: Characteristics of Included Studies 




Country Study Objectives Methods Data Collection Qualitative Data 
Analysis 
Participant characteristics (n) Setting (n) 
Foley (312) 2003 US To explore staff perceptions of 
successful management of severe 
behavioural problems in dementia SCUs 
M Structured 
interviews with 
some open ended 
questions 
Content analysis Nursing staff (19), Activities co-ordinator or Social 
Worker* (4), unit co-ordinators [Nurses or Social 
Workers]* (9), Unknown Staff Role (4). Total 
participants (36) 




2007 UK To assess the suitability of an American 
model of pharmaceutical care for 
nursing home residents for application 
in nursing homes in the UK 
Q Focus groups and 
semi-structured 
interviews 
Framework Clinical Pharmacists (6), Resident Advocates (6), 
Prescribing Support Pharmacists (14), GPs (8), Nursing 
Home Managers (10). Total participants (44) 
Participants worked 
in in-patient, GP, 







2008 UK To examine the process by which 
consultant old age psychiatrists 
prescribe for BPSD and explore the 
















2010 US To explore nursing, recreational therapy 
and medical staff perceptions of 
barriers to the implementation of non-
pharmacological interventions for BPSD 
Q Focus groups  Content and 
thematic 
Registered Nurses, Licensed Practical Nurses, Certified 
Nursing Assistants, Recreational Therapists, Activity 
Personnel and Medical Directors. Total participants 
(35)† 
Nursing Homes (6) 
Molinari 
(314)  
2011 US To explore the justification of 
psychoactive medication prescription 
for new nursing home residents  
M 
 
Chart review with 




Licensed Practical Nurses (8), Certified Nursing 
Assistants (20), Registered Nurses (13), Medical 
Directors (1), Social Workers (2). Total participants (44) 
Nursing Homes (7) 
Duxbury 
(308) 
2013 UK To explore the views of nurses, and 
relatives regarding the causes of, and 
most effective ways of responding to 
aggressive behaviour from people with 
dementia in residential care settings 
Q Semi-structured 
interviews with 
staff. Focus Groups 
with relatives 
Thematic Dementia Care Unit Manager (4), Registered Nurses 




Nursing Homes (4) 
Harding 
(309) 
2013 UK To explore carers experiences of the 
use of antipsychotic medications in 
people with dementia  
M Surveys with open 
ended questions 
(online and paper), 
focus groups and 





Carers and former carers of people with dementia 
(190). Total participants (190) 
 
 
Mixture of own 






2013 Canada To investigate the perceptions of LTC 
staff regarding the current use of NPI 
for reducing agitation in seniors with 
M Focus groups, semi-
structured 
interviews  and a 
survey with some 
Hermeneutic 
phenomenology 
Registered Nurses (8), Registered Practical Nurses (13), 
Personal Support Workers (8), Recreation Specialist or 
Coordinators (6), Directors of Care (3), Unit 
Coordinators (2), Recreation Assistant (1), Resident 
LTC facilities (5) 
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dementia and to identify facilitators and 
barriers that guide NPI implementation 
open ended 
questions  
Assessment Instrument Coordinator (1), Dietary 
Specialist (1),  
Art Therapist (1). Total participants (44) 
Mavrodaris 
(310) 
2013 UK To investigate antipsychotic prescribing 
practices and patient review in primary 
care settings 
M Survey with some 
open ended 
questions. 
Thematic GPs (60), care home staff (28). Total participants (88) 
 
GP surgeries (60) 
and care homes (28) 
§ 
Ervin (316) 2014 Australia To explore residential aged care staff 
perceptions of the limitations to five 
commonly used methods of managing 
BPSD; pharmacological therapy and 
behavioural, emotional, cognitive and 
stimulation therapies 





Division 1 Registered Nurse (33), Division 2 Medication 
Endorsed Registered Nurse (29), Division 2 Registered 
Nurse (34), Personal Care Assistant (14), Students or 
Activities Coordinator (17), Not specified (3). Total 
participants (130) 
Residential aged 






To explore factors that elucidate 
reasons for psychotropic drug 
prescription for neuropsychiatric 






Elderly Care Physician (13), Resident in Elderly Care 
Medicine (1), Medical Doctor (1), Registered Nurses 
(4), Certified Nurse Assistants (9), Nurse Assistant (1). 
Total participants (29) 
Nursing Homes (12) 
Bonner 
(315) 
2015 US To describe the rationales that 
providers and family members cite for 
the use of Antipsychotic medications in 
people with dementia living in nursing 
homes 





content analysis  
Directors of Nursing (26), Registered Nurses and 
Licensed Practical Nurses (91), Certified Nursing 
Assistants (244), Physicians and Advanced Practitioner 
Prescribers (27), Pharmacists (23), Psychiatrists (14), 
Family Members (41). Total participants (466) 
Nursing Homes (26) 
 
 
Ellis (313) 2015 US To explore strategies that have been 
implemented, to assess which 
strategies are evidence-based, and to 
make recommendations to improve 
upon practice to reduce antipsychotic 
medication use 







Director of Nursing (109), Nursing Home Administrator 
(95), Social Worker (7), Other Nursing Home Staff (65). 







2015 UK To contribute to an optimised training 
programme for care staff that supports 
the implementation of evidence-based 
psychosocial interventions in long-term 
care 




Care Assistants (53), Senior Care Assistants (30), 
Activity Therapists (13), Registered Nurses (6), Deputy 
Managers (5), Managers (2), Other Staff (10). Total 
participants (119) 
 
Care Homes (16) 
Sawan (90) 2016  Australia To explore how visible artefacts in 
nursing homes influence the prescribing 
and use of psychotropic medicines, and 
how these artefacts were 
operationalised across nursing homes 
Q Semi-structured 
interviews 
Thematic Managers (8), Registered Nurses (8), Nursing 
Assistants (5), GPs (8), Pharmacists (6), Enrolled nurses 
(2), Specialist medical practitioner (1), Nurse 
Practitioner (1),  
Clinical Nurse Consultant (1). Total participants (40) ‡ 





2016  Australia To explore the key dimensions of 
organisational climate and their 




Thematic Managers (8), Registered Nurses (8), Nursing 
Assistants (5), GPs (8), Pharmacists (6), Enrolled nurses 
(2), Specialist medical practitioner (1), Nurse 
Practitioner (1),  
Clinical Nurse Consultant (1). Total participants (40) ‡ 
Nursing Homes (8) 
Shaw (91) 2016 UK To explore and understand treatment 
culture in prescribing of psychoactive 
medications for older people with 





Managers (5), Nurses (7), Care Assistants (13), GPs (2). 
Total participants (27) 
 
 





To gain an understanding of what care 
home staff perceive to be distressed 
behaviour, their coping strategies and 
how they learned to work with 






Care Assistants (17). Total participants (17) 
 
 
Care Homes (4) 
Q, Qualitative Methods; M, Mixed Methods; BPSD, Behavioural and Psychological Symptoms of Dementia; NPI, Non-pharmacological interventions; LTC, Long-term care; 
SCU, Specialist Care Unit; GP, General Practitioner (also known as Primary Care Physicians). 
* Study did not obtain specific degree affiliation, thus unable to distinguish between social workers and nursing staff. † Unknown breakdown of participants. § Research 




4.5.3 Quality Appraisal  
The overall quality of included studies was assessed to be moderate to high for 17 of 
the 18 studies (Table 8). A common weakness, found in twelve studies, was 
inadequate researcher reflexivity (301, 302, 307-314, 316, 318). The relationship 
between the researcher and participants had not been effectively addressed in these 
studies. The overall quality of one study was assessed to be low due to concerns 
across several CASP domains (309). Despite these weaknesses, we believed that on 
the whole, these studies were sufficiently robust to contribute to our meta-




Table 8: Quality Appraisal of Included Studies 














Value Overall Assessment of 
methodological quality 
Foley (2003) (312) √ √ √ ? ? x ? ? √ √ Moderate 
Patterson (2007)  (307) √ √ √ √ √ x √ √ √ √ Moderate-to-High 
Wood-Mitchell (2008) 
(64) 
√ √ √ ? √ √ ? ? √ √ Moderate-to-High 
Kolanowski (2010) 
(302) 
√ √ √ ? ? x √ √ √ √ Moderate-to-High 
Molinari (2011) (314) √ √ √ x ? x ? √ √ √ Moderate 
Duxbury (2013) (308) √ √ √ √ ? x √ √ √ √ Moderate-to-High 
Harding (2013) (309) √ √ √ √ x x ? x x x Low 
Janzen (2013) (58) √ √ √ √ √ √ √ √ √ √ High 
Mavrodaris (2013) 
(310) 
√ √ √ √ ? x ? ? √ √ Moderate 
Ervin (2014) (316) √ √ √ √ ? x √ √ √ √ Moderate 
Smeets (2014) (301) √ √ √ ? √ x √ √ √ √ Moderate-to-High 
Bonner (2015) (315) √ √ √ √ √ √ √ x √ √ Moderate 
Ellis (2015) (313) √ √ √ x √ x ? √ √ √ Moderate 
125 
 
Lawrence (2015) (311) √ √ √ √ √ x √ √ √ √ Moderate-to-High 
Sawan (2016) (90) √ √ √ √ √ √ √ √ √ √ High 
Sawan (2016) (317) √ √ √ √ √ √ √ √ √ √ High 
Shaw (2016) (91) √ √ √ ? √ √ √ √ √ √ High 
Van Wyk (2016) (318) √ √ √ ? ? x ? ? √ √ Moderate 




4.5.4 Translation  
We identified five key concepts (numbered 1-5 below) encompassing eight sub-
themes (underneath these concepts) that reflected the main influences on this 
decision-making process. These are reported below supported by first-order 
(italicised quotations) and second-order (non-italicised quotations) interpretations 
(Greater detail located in Appendix 4) 
The complexity of the decision-making process was evident throughout. Overall, “the 
aim of improving care” for residents was a priority (307), but there was tension as to 
how this was best achieved. The options for managing BPSD were generally perceived 
to be binary – antipsychotic prescribing or non-pharmacological interventions - with 
the former option considered to be the “quick-fix” (58, 64, 91).  
4.5.4.1 1. Organisational Capacity 
4.5.4.1.1 Resources and access to services:  
Understaffing and insufficient time to engage with residents, to conduct thorough 
assessments of underlying causes, and perform non-pharmacological interventions 
was mentioned throughout the reviewed studies: (58, 64, 90, 91, 301, 302, 308, 310, 
311, 313, 314, 316-318) "The greatest impact on good outcomes for behaviour 
management is time limits. Nurses are always under pressure to hurry" (316). In some 
studies there was a suggestion that medication was used to compensate for poor 
staffing levels: (91, 317) “sometimes [it’s] easier to give a tablet” (91). This 
understaffing issue was further compounded by a lack of access to specialist services 
such as psychiatrists, therapists and pharmacists (64, 307, 310, 313, 314). 
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In some studies, nursing home managers working in the public sector stated that 
there was very little they could do to solve staff shortages due to the lack of funding 
(310, 313, 317). Financial issues were a parallel concern in private sector nursing 
homes, and were associated with the use of antipsychotics as a means to deal with 
constrained expenditure on staff: (64, 301, 317) “The desire to make money means 
that [managers] have to make choices about staffing levels and staffing quality that 
is good for the money making side but not necessarily good for the patient side… 
That’s where controlling and managing the patient might come in” (317). 
4.5.4.1.2 Coping with the severity of behaviours:  
Many studies reported a struggle to manage residents with severe behavioral 
problems (58, 64, 301, 311, 312, 318). Nurses reported  that they were constantly 
“putting out fires”(58), causing them to feel “overwhelmed” (317). Prescribers 
reported that “they had little option but to prescribe” to help relieve these situations 
(64).  Consequently, staff felt they were “letting the residents down” (311), thus 
contributing to poor staff morale (311, 312, 314, 317, 318). 
Nursing home staff reported conflicting priorities. Dealing with escalating behavioral 
issues could be perceived as a barrier to completing other nursing tasks: (58, 302, 
311, 316) “Medications were viewed as a resource that allowed nurses… to reduce 






4.5.4.2 2. Individual Professional Capability 
4.5.4.2.1 Skills:  
Possessing the necessary skills was considered critical for effective BPSD 
management (58, 64, 91, 301, 302, 308-318). Staff and family members realised the 
importance of good interpersonal skills when dealing with residents (308, 312, 318), 
because approaching residents “in the wrong way” could trigger behavioral 
symptoms (308), while good interpersonal skills could have a positive effect (308). 
There was a belief that some staff, particularly newly qualified healthcare assistants, 
were not adequately trained to deal with behavioral symptoms (64, 302, 311, 317, 
318). Prescribers commented that these deficiencies were contributing towards the 
pressure to prescribe antipsychotics (64) “to ensure that there is no colourful 
behaviour”(317). 
In some studies, staff appeared unable to effectively apply a range of individualised 
non-pharmacological interventions to the residents (58, 302, 316). Participants noted 
that familiarity with the resident, training, sharing of experiences and practice 
improved their confidence in applying non-pharmacological approaches (58, 302, 
311, 313, 315-318). 
4.5.4.2.2 Knowledge:  
In several studies, both prescribers and staff were perceived to lack adequate 
knowledge on the risks and benefits of antipsychotics (91, 301, 309, 313, 315, 316), 
and to lack awareness regarding the nature and range of alternative approaches (58, 
64, 302, 310, 313, 315, 316). In one study, prescribers believed nurses and family 
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members expressed “unfounded high expectations” of the effectiveness of 
antipsychotics (301), while in other studies, staff felt that it was the prescribers who 
did not have enough knowledge (91, 310, 313). The authors of one study concluded 
“that poor staff knowledge of appropriate use of antipsychotics may underlie the 
high rate of administration, despite the reported limitations to its use”(316).  
There was a strong desire by participants for more hands-on, interdisciplinary 
training and education (58, 302, 310, 311, 313-318), that can “help staff relinquish 
the need for control in favour of understanding”(302). 
Knowing the resident and understanding their individual behaviours was critical to 
performing person-centred care (58, 90, 91, 301, 302, 307, 308, 311, 312, 316-318). 
However this took a lot of time, staff consistency and close involvement with the 
family, which was not always possible (58, 90, 91, 301, 302, 308, 311, 312, 318).  
4.5.4.3 3. Communication and Collaboration 
4.5.4.3.1 Communication within healthcare teams and with the family:  
Effective communication was viewed as an essential component to successful BPSD 
management (58, 64, 90, 91, 301, 302, 307-314, 317). Good communication between 
all those involved in the care of residents, with close involvement of the family, 
promoted a sense of trust and mutual respect (58, 64, 90, 301, 307, 308, 311-314, 
317). Listening to concerns and valuing everybody’s opinion was critical (90, 91, 301, 
307, 309-311, 317), and participants felt that “by jointly looking at the problems and 
by learning from each other… we gained more clarity, much more peace, and also 
had a significant decrease in prescribed medication”(301). 
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Working together, with a shared goal, was perceived to be essential (58, 90, 91, 301, 
307, 308, 310, 311, 313, 314, 317). Interdisciplinary medication reviews were good 
examples of different stakeholders working together to reduce inappropriate 
antipsychotic use (90, 301, 307, 313). 
In contrast, poor communication and collaboration led to sub-standard dementia 
care (90, 91, 302, 307, 309-313, 316, 317). Staff saw themselves as a “cog in a wheel”: 
if they all worked together everything ran smoothly, but if one person was not pulling 
their weight, the whole system fell apart (311). One study discussed issues regarding 
GPs not attending medication review meetings and the subsequent barrier this 
presented to reducing inappropriate antipsychotic prescribing (90). 
4.5.4.3.2 Clarity of Roles and Responsibilities:  
There was a sense of uncertainty regarding roles and responsibilities in relation to 
antipsychotic prescribing, particularly between different care settings (64, 307, 309-
311, 313, 316, 317). GPs felt that the responsibility for antipsychotic prescriptions 
belonged to the hospital physician who initiated them, “as the psychiatrist started it 
they will not stop prescribing it” (310). In some studies, this caused “confusion”(310), 
which promoted the belief that it was the  job of nursing home staff “to clean up the 
situation”(314).  
A perception of being a victim of professional hierarchy was raised in several studies 
(90, 91, 307, 310, 317, 318). In these studies, staff felt unable to question the 
prescriber in relation to the appropriateness of a prescription (90, 91, 317), due to 
the existence of “professional norms that were very traditional and hierarchical in 
nature”(317). However in other studies, it was the prescriber who did not feel 
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empowered to say no to a request from nurses (64, 301, 307, 310, 317), because 
“they [nurses] want it and it’s very difficult to refuse”(307).  
4.5.4.4 4. Attitudes towards people with dementia and the management of BPSD 
4.5.4.4.1 Personal Attitudes:  
Attitudes towards antipsychotics were on a spectrum (58, 91, 301, 302, 307-312, 314, 
316, 318, 319), ranging from being viewed as “really beneficial” (91) to “chemical 
cosh”(309). Participants in some studies were concerned by their usage and believed 
the side-effect profile to be unacceptable (58, 64, 90, 301, 302, 308, 309, 311, 314, 
316-318). Other participants had a more “pro medicine” attitude (58), and it 
appeared that they might have used antipsychotics for convenience (58, 91, 302, 
311).  
Participants in several studies believed that antipsychotics were required for the 
greater good (58, 302, 317). GPs in one study considered the potentially serious side 
effects “a worthwhile trade-off” if they improved residents’ quality of life (310), and 
in another study perceived them as a “necessary evil” to help staff deal with their 
high workload (317). 
Participants generally held positive views towards people with dementia (58, 308, 
311, 317, 318) and “expressed great empathy with residents”(318). However 
participants in some studies voiced dismissive attitudes towards people with 
dementia (91, 311, 312, 317, 318), and expressed a desire to manage the resident 
rather than assess the underlying cause (64, 91, 301, 302, 309, 311, 317). In one 
study, a staff member stated that they found residents’ behaviours “annoying” (91). 
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Fear of behaviour recurrence was expressed in several studies (301, 307, 309, 311, 
312, 318), hence “there can even be resistance from nurses and family to withdraw 
[antipsychotics], especially when considerable effort was put into stabilising the 
[behaviours]”(301). 
4.5.4.4.2 Organisational and Societal Attitudes:  
The pressure to prescribe from nursing homes was a key finding in a number of 
studies (58, 64, 90, 91, 301, 307, 310, 317). One GP admitted that this pressure to 
prescribe forced them to withdraw their medical services to a particular nursing 
home as they felt it was at odds with evidence-based practice (317).  
Managers were seen to play a key role in communicating messages about best 
practice (90, 308, 311, 317, 318). Managers that emphasised the value of non-
pharmacological approaches created a culture where alternative approaches were 
exhausted before antipsychotics were used. One pharmacist observed that: “If the 
attitude’s right at the top, then it filters through. If you have management that don’t 
really do the right thing or don’t really care, then that filters through as well”(317). In 
most studies management culture was highlighted as a driver of the quality of 
healthcare provided (58, 90, 91, 302, 308, 311-313, 315-318).  
4.5.4.5 5. Regulations and Guidelines:  
Regulations and guidelines produced mixed reactions (64, 90, 301, 302, 310, 313, 
314). Regulations were perceived as the “driving force” for improving standards in 
nursing homes (302), but prescribers expressed “ambivalence” towards the influence 
of guidelines (301). 
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Regulations were only mentioned in studies conducted in the US (302, 313-315) and 
Australia (90). According to one US study author: “regulatory oversight has altered 
the landscape”(302). In Australia, although the conduct of pharmacist-led medication 
reviews were mandatory for residential settings, there was great variability between 
nursing homes in how the resultant recommendations were utilised (90).  
Guidelines were perceived to be less influential with regards to changing 
antipsychotic prescribing (64, 301, 310). In one study, prescribers felt that guidelines 
were unhelpful as they often contradicted their own clinical experience and caused 
“more problems” (64). Prescribers from another study argued that some guidelines 
could be interpreted to allow for greater levels of prescribing (301). “What was more 
influential was past experience of a drug, although guidelines… were taken into 
account” (64).  
4.5.5 The Impact of Context on Findings 
The professional background of the research team of included studies tended to 
influence the focus of inquiry of included studies. In general, researchers from a 
nursing or social science background tended to focus on the person with dementia, 
in an attempt to understand these behavioral issues: (58, 302, 308, 309, 311, 312, 
318) “they’re frustrated because they can’t explain how they’re feeling”(308). 
Whereas researchers from a medical or pharmacy background tended to focus on 
more structural (e.g. resources) or organisational (e.g. interprofessional 
relationships) issues: (64, 90, 301, 307, 310, 313-315, 317) “homes are dealing with 
a greater level of illness and disturbance than they were designed for” (64). However 
there were some contradictions and not every study followed this pattern (91, 316). 
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Furthermore, the majority of included studies explored both perspectives to varying 
degrees (58, 90, 91, 301, 302, 308-311, 314, 316-318). 
Time has also impacted on the findings. The earliest of these studies, published in 
2003, discussed antipsychotics as an option for BPSD management, without 
necessarily attributing  positive or negative connotations to this practice (312). 
However studies published since (2007-2016), have generally advocated a more 
cautious approach (58, 64, 90, 91, 301, 302, 307-309, 311, 313-318). This is possibly 
due to the publication of a meta-analysis in 2005 providing evidence of the risks 
associated with antipsychotic prescribing in people with dementia (112). 
4.5.6 Synthesis 
Synthesising these first- and second-order interpretations resulted in 20 distinct 
third-order interpretations. Consequently, each key concept was linked to multiple 
third-order interpretations; Organisational Capacity (n=5), Individual Professional 
Capability (n=4), Communication and Collaboration (n=3), Attitudes (n=6) and 
Regulations and Guidelines (n=2). These third order interpretations, and the CERQual 
confidence levels associated with them are summarised in Table 9. There were eight 
third-order interpretations in which we have high confidence. Therefore, we believe 
it is highly likely that these third-order interpretations are reasonable 
representations of the phenomenon of interest.
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Table 9: CERQual Summary of Qualitative Findings  
Review finding/Third-Order Interpretations Relevant papers CERQual 
assessment of 
confidence in the 
evidence 
Explanation of CERQual assessment 
Organisational Capacity 
 1. Chronic under-staffing is a fundamental issue in Nursing Homes, leading to insufficient time and 
ability by Nursing Home staff to perform person-centered care. 
(58, 64, 91, 301, 
302, 310, 311, 
313, 316-318) 
High confidence Minor concerns regarding 
methodological limitations and 
adequacy 
2. The involvement of specialist services can influence antipsychotic prescribing, but there can 
sometimes be difficulty accessing these services. 
(64, 90, 301, 302, 
310, 313-317) 
High confidence Minor concerns regarding 
methodological limitations, 
coherence and adequacy. 
3. To circumvent the problems of inadequate resources and/or poor access to specialist services, 
antipsychotics are ‘employed’ as cheap, fast and effective staff members. 
(64, 91, 301, 302, 
310, 311, 313, 
314, 316, 317) 
High  confidence Minor concerns regarding 
methodological limitations and 
adequacy.  
4. As behaviours escalate, a ‘tipping-point’ is reached, after which an urgency to resolve the situation 
arises. This is particularly true when Nursing Home staff feel “overwhelmed” by these behaviors. In 
these situations antipsychotics are perceived by Nursing Home staff to offer a “more guaranteed 
result”. 
(58, 64, 301, 302, 
311, 312, 317) 
Moderate 
confidence 
Minor concerns regarding 
methodological limitations. Moderate 
concerns regarding adequacy 
5. The perceived acuteness of situations forces Nursing Home staff to focus their attention on the 
“aggressive” residents, while the “passive” ones are left behind. Antipsychotics can sometimes be 
viewed as a way of equalising attention given to both “passive” and “aggressive” residents. 
(58, 301, 302, 
311, 316-318) 
Low confidence Minor concerns regarding 
methodological limitations. Moderate 
concerns regarding coherence and 
adequacy 
Individual Professional Capability 
6. Both prescribers and Nursing Home staff are often perceived to be poorly equipped to deal with 
BPSD in terms of deficiencies in dementia-specific skills and/or a lack of knowledge on the 
risk/benefits of antipsychotics, and the range and nature of non-pharmacological interventions. These 
deficiencies enable inappropriate antipsychotic prescribing.  
(58, 64, 91, 301, 




Minor concerns regarding 
methodological limitations and 
relevance. Moderate concerns 
regarding coherence  
7. More training and education to help prescribers and nursing home staff to improve skills and 
knowledge with regards to BPSD management is desired. 
(58, 301, 302, 
311, 313-318) 
High confidence Minor concerns regarding 
methodological limitations  
8. Even in individuals with sufficient skills and knowledge regarding BPSD management, a tension can 
exist between ‘doing the right thing’ and doing what’s practical, especially if the resources or suitable 
alternatives are not perceived to be there to support adequate implementation. 
(58, 64, 90, 91, 
301, 302, 311, 
313, 317, 318) 
Moderate 
confidence 
Minor concerns regarding 
methodological limitations and 
coherence. Moderate concerns 
regarding adequacy.  
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9. Knowing the resident and understanding their behaviours contributes towards successful BPSD 
management. 
(58, 64, 91, 301, 
302, 308, 311, 
312, 317, 318) 
High confidence Minor concerns regarding 
methodological limitations and 
adequacy.  
Communication and Collaboration 
10. Effective communication and collaboration (involving sharing information and listening to others) 
between all members of the healthcare team are key enablers to reducing inappropriate prescribing 
of antipsychotics. The involvement of family members can also be important in this process.  
(58, 64, 90, 91, 
301, 302, 307-
315, 317) 
High confidence Minor concerns regarding 
methodological limitations, 
coherence and relevance 
11. A lack of empowerment at all levels of the healthcare team and among family members is a 
barrier to informed decision-making regarding antipsychotic prescribing. 
(58, 64, 90, 91, 
301, 307-313, 
317, 318) 
High confidence Minor concerns regarding 
methodological limitations, 
coherence and relevance.  
12. Fragmentation between different levels of care creates confusion surrounding roles and 
responsibilities, which can lead to inappropriate maintenance of antipsychotics. 
(64, 90, 302, 307, 




Minor concerns regarding adequacy. 
Moderate concerns regarding 
methodological limitations 
Attitudes towards people with dementia and the management of BPSD 
13. Although there is a preference to use non-pharmacological interventions in the first instance due 
to the unpleasant side effects of antipsychotics, it is acknowledged that antipsychotics are a 
“necessary evil” and are often unavoidable. 





Minor concerns regarding 
methodological limitations and 
relevance. Moderate concerns 
regarding coherence. 
14. Negative attitudes by individuals towards people with dementia can result in inappropriate 
antipsychotic prescribing. Conversely, empathy towards people with dementia can be protective. 
(58, 90, 91, 301, 





Minor concerns regarding coherence, 
relevance and adequacy. Moderate 
concerns regarding methodological 
limitations 
15. Fear of the recurrence of behaviours motivates maintenance of antipsychotic prescribing. 
(58, 301, 307, 
309, 311, 312, 
317, 318) 
Low confidence Minor concerns regarding relevance. 
Moderate concerns regarding 
methodological limitations and 
adequacy 
16. Organizational and societal attitudes towards people with dementia and the management of 
BPSD, exerts pressure on prescribers to make prescribing decisions. 
(58, 64, 90, 91, 
301, 302, 307-
311, 317) 
High confidence Minor concerns regarding 
methodological limitations and 
coherence.  
17. The attitude of the nursing home manager towards people with dementia and the management of 
BPSD dictates the treatment culture of that nursing home, and this has a strong influence on 
antipsychotic prescribing. 
(58, 90, 91, 308, 




Minor concerns regarding 
methodological limitations. Moderate 
concerns regarding  adequacy 
18. Tensions can arise due to incompatible beliefs towards antipsychotics between prescribers and 
nursing homes; in these cases a battle of wills develops where there is often pressure on prescribers 
to “do something” in order to restore control – doing nothing is not tolerated. However, sometimes 
(64, 90, 91, 301, 




Minor concerns regarding 
methodological limitations. Moderate 
concerns regarding adequacy 
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there is pressure on prescribers to discontinue antipsychotics, to which there can be resistance from 
prescribers. 
Regulations and Guidelines 
19. Regulations are perceived to be the driving force for antipsychotic reductions in nursing home 




Moderate concerns regarding 
methodological limitations. 
Substantial concerns regarding 
adequacy 
20. Guidelines exert little influence on antipsychotic prescribing, but may act indirectly to increase 
knowledge regarding the risk/benefits of antipsychotics. 
(64, 301, 310) 
 Very low 
confidence 
Moderate concerns regarding 
methodological limitations. 
Substantial concerns regarding 
adequacy 
BPSD, Behavioural and Psychological Symptoms of Dementia; CERQual, Confidence in the Evidence from Reviews of Qualitative Research.
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By linking all 20 third-order interpretations together we developed a ‘line of 
argument’, which is outlined below and expressed as a conceptual model in Figure 
20. This conceptual model describes the process of a dysfunctional negative feedback 
loop where any ‘challenging behaviour’ in a person with dementia promotes either 
antipsychotic prescribing or a non-pharmacological intervention, or sometimes both, 
all with the goal of suppressing the ‘challenging behaviour’ and restoring calm. The 
‘challenging behaviour’ may push decision-making towards an exclusively 
pharmacological solution, especially if staff feel overwhelmed. Once the ‘challenging 
behaviour’ is suppressed, the need for an intervention is reduced. However, the fear 
that these behaviours may return at any time, or confusion surrounding roles and 
responsibilities facilitates maintenance of antipsychotic prescribing, breaking the 
feedback loop.  
The five key concepts, and eight sub-themes described above, act as the overarching 
influences on this decision-making process as a whole.  The conceptual model 
illustrates that some or all of these influences may come into play when a 
‘challenging behaviour’ arises (Figure 20). These influences interact with each other, 
often in an unpredictable and complex manner, and ultimately determine the 
response behaviours from staff. 
Our synthesis indicates that different stakeholders struggle to see things from other 
stakeholders’ perspective and do not acknowledge the pressure the others are 
under. However, when all stakeholders come together to communicate and 
collaborate as equal and empowered partners the inappropriate use of 




Figure 20: Conceptual Model of Influences on Decision-Making Regarding Antipsychotic Prescribing in Nursing Home Residents with 
Dementia  
Key concepts are in shown in CAPITALS; sub-themes are in (italics) beneath the relevant key concept; and specific factors influencing response behaviours are in green 




This study is the first to our knowledge, to systematically review and synthesise the 
qualitative evidence surrounding antipsychotic prescribing in nursing home residents 
with dementia. Additionally, we believe that this study is the first to apply CERQual 
to a meta-ethnography. Our findings highlight the complexity of this topic and the 
various influences on decision-making. We have conceptualised these influences in a 
‘line of argument’ that moves beyond the findings of the individual studies, as a 
dysfunctional negative feedback loop, which we believe will be useful for clinicians, 
researchers and policy-makers.  
4.6.1 Comparison with Previous Research 
A systematic review exploring the quantitative relationship between facility 
characteristics and antipsychotic usage concluded that in general, as nursing staff 
levels decrease, antipsychotic usage increases (320). The authors also reported a 
positive association between for-profit nursing homes and antipsychotic usage (320).  
However these associations are not always clear-cut (92, 321-323). The focus on 
qualitative evidence in our review helped us to tease out these more complicated 
elements. Our findings reinforce that nursing homes are struggling with 
understaffing and poor access to important services. Consequently, staff can become 
overwhelmed by behaviours in these resource-poor environments. Nursing home 
managers, particularly in the for-profit sector, may be tempted to use antipsychotics 
as a more economical solution to the problem. However it is important to 
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acknowledge that the use of antipsychotics as a cost-saving measure appeared in 
not-for-profit nursing homes also. 
Knowledge of the risks and benefits of prescribing antipsychotics in dementia has 
been found to be quite variable, and often suboptimal (324-326). Some authors have 
commented that these deficits in knowledge may be contributing to a concerning 
belief that antipsychotics are highly effective for BPSD (324, 325). Furthermore, staff 
have often been found to be inadequately trained in person-centred care (324, 325, 
327). Our findings suggest that inadequate skills and knowledge are enabling 
inappropriate antipsychotic prescribing. Even in highly capable individuals, we found 
a tension between doing the ‘right thing’ and doing what’s practical, given resource 
limitations and their duty of care to other residents.  
Previous research has found that communication breakdown is an impediment to the 
delivery of person-centred care (328), and is also a barrier to deprescribing (329). 
Professional hierarchies in the nursing home setting have previously been reported 
as a barrier to evidence-based practice (328, 330, 331). Furthermore, GPs have 
expressed frustration at the lack of communication from hospital consultants with 
regards  to the management of antipsychotics (332), as well as the pressure to 
prescribe from nursing homes (325). Our findings add to this knowledge by 
identifying a lack of empowerment at all levels of the healthcare team and among 
family members as a barrier to informed antipsychotic prescribing decision-making.  
The concept of ‘treatment culture’ in nursing homes has been discussed in the 
literature in an attempt to explain why certain nursing homes continue to have high 
levels of antipsychotic prescribing independent of residents’ clinical characteristics 
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(333-335). Treatment culture can be defined as the “beliefs, values, and normative 
practices associated with medication prescribing and administration” (334). Nursing 
homes with a traditional culture (i.e. rigid routines) have been associated with higher 
levels of antipsychotic prescribing than those with a resident-centred culture (i.e. 
person-centeredness) (334). Our research confirms this notion of treatment culture 
and the impact of conformity on prescribing decisions. Our findings add to existing 
evidence by highlighting the important role of the manager, who can diffuse a 
philosophy of person-centred dementia care throughout the organisation (62).  
Our findings indicate that an underlying fear of behaviour recurrence may be one 
factor driving the desire for control. Negative connotations of dementia have been 
described in the literature, comparing the effect BPSD has on people to becoming 
“dehumanised” (49).  Based on the findings of our review, we believe that a lack of 
understanding of the nature and progression of dementia can lead to the 
inappropriate maintenance of antipsychotics.  
4.6.2 Implications 
The conceptualisation of decision-making as a dysfunctional negative feedback loop 
with the ultimate aim of controlling residents, challenges us in the way we perceive 
dementia. We need to re-frame the way we view so-called ‘challenging behaviours’. 
These behaviours may not necessarily be challenging to the person with dementia – 
only to us. There have been discussions surrounding the nuances of terminology in 
this area, with a term such as ‘responsive behaviours’ being preferable (34). There 
needs to be an appreciation that these behaviours are generally due to some unmet 
need (336), and often do not respond to antipsychotics (337, 338). Therefore it is 
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imperative that interdisciplinary training and education is delivered to all involved in 
the care of residents with dementia, including family members. 
Furthermore, communication structures and interdisciplinary practices need to be 
optimised in order to improve the flow of vital information. It is important that 
peripheral members of this interdisciplinary team are not excluded from decision-
making as they can often hold the key to successful behavioral management. There 
is also evidence to support the inclusion of pharmacists in these teams (151). Shared 
decision-making, a collaborative process that allows people with dementia, family 
members, and their healthcare team to make healthcare decisions together, should 
be encouraged (339). Shared decision-making takes into account the best clinical 
evidence available, as well as values and preferences of the person with dementia 
and the family (340). 
Our CERQual assessments identify areas that policy-makers can potentially target. 
For instance, policy-makers need to carefully re-examine resource allocation issues, 
as we have high confidence that nursing homes are utilising antipsychotics to 
substitute for inadequate resources and poor access to specialist services. Given that 
the use of antipsychotics in this population is not evidence-based, it is concerning 
that these agents are being used to cut costs. Therefore in light of the strength of our 
evidence, we argue that increasing the staff to resident ratio, or increasing access to 
services, may possibly result in a reduction in inappropriate antipsychotic 
prescribing.  
We now have a greater understanding of this complex prescribing behaviour. 
However it is still unclear how it can be sustainably changed (151). Behaviour change 
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interventions need to be guided by the best available evidence and appropriate 
theory (164). Important contextual issues unique to each healthcare system need to 
be explored before pilot studies can be conducted (163). More primary qualitative 
research is needed, focusing on aspects that are currently under-researched e.g. 
influence of national regulations. It is also crucial that the voice of the person with 
dementia is ethically and meaningfully included, either as participants of research 
(341) or as co-researchers in the intervention design process (342). Additionally, our 
conceptual model identified specific influencing factors, such as confusion 
surrounding roles and responsibilities, and fear of behaviour recurrence. These 
identified factors may be suitable for future targeted interventions.  
We believe that the interdisciplinary and interdependent nature of this decision-
making process is such that it is unlikely that targeting a single stakeholder group will 
result in any sustainable change in prescribing behaviours. Therefore, we argue that 
a holistic, person-centred approach to behaviour change is required, involving both 
the prescribers and requesters of antipsychotics.  
4.6.3 Strengths and Limitations  
The main strength of our study is its robustness (294). Measures were put in place to 
ensure the high quality of the analysis including maintaining reflexivity, utilising 
independent multiple analysts and transparency through careful adherence to the 
PROSPERO protocol. The study was conducted by an experienced multidisciplinary 
team. Consequently, we believe that our included studies were analysed to a high 
standard and the resultant conceptual model provides the reader with a rich, in-
depth and valid new interpretation of a complex phenomenon. 
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Another strength was the great number and diversity of healthcare professionals and 
family members represented in the included studies. The multiple perspectives 
allows for a more holistic view of the factors influencing this complex phenomenon. 
A limitation of our study, which is true of all systematic reviews of qualitative 
evidence, is the difficulty retrieving qualitative research from databases. Unlike RCTs, 
qualitative research has historically been inconsistently indexed in databases, 
preventing comprehensive and reproducible searches (343). Therefore it is possible 
that we may have missed a potentially relevant study. However, as our team 
conducted a systematic and thorough search, which was transparently reported, we 
are reasonably confident that we have captured all relevant studies. 
4.7 Conclusion 
Antipsychotic prescribing in nursing home residents with dementia occurs in a 
complex environment involving the interplay of various stakeholders (with differing 
levels of skills and knowledge, who often have conflicting views on the role of 
antipsychotics and who may not be equally empowered), the nursing home 
organisation (with its own treatment culture and level of resources) and external 
influences (such as guidelines, regulations and societal influences). In order to 
improve the quality of antipsychotic prescribing in this cohort, a paradigm shift is 
required towards a more holistic approach to BPSD management. While we have 
found the issue of antipsychotic prescribing has been extensively explored using 
qualitative methods, there remains a need for research focusing on how best to 
change the prescribing behaviours identified. It is also crucial that the voice of the 
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person with dementia is ethically and meaningfully included in such research, either 




4.8.1 Updated Search Results 
An updated search of the electronic databases was conducted on July 11th 2018 to 
search for all potentially relevant articles published since July 2016 (date of latest 
search prior to publication). A total of 906 records were identified. After duplicate 
removal, 398 records were screened by title and abstract and 15 full-text articles 
were subsequently assessed for eligibility. This resulted in nine new published 
articles meeting our inclusion criteria and hence were included in our updated 
systematic review (344-352). Furthermore, three additional articles which were 
manually located (353-355), also met our inclusion criteria, bringing our updated 
systematic review to a total of 12 new studies, and 30 studies overall (Figure 21).  
The characteristics of these 12 studies are outlined in Table 10 below. In brief, these 
12 studies include 623 unique participants from nine new study cohorts. Three of 
these new studies used the same dataset of 28 participants (344, 346, 347), while 
another study (351) used the same dataset of 40 participants that were previously 
included in two studies from our original search (90, 317). As before, no study 
included people with dementia as research participants. The 12 studies were 
conducted in five different countries: UK (n = 4), US (n = 4), Australia (n = 2), Canada 








Table 10: Characteristics of Included Studies from the Updated Search 




Country Study Objectives Methods Data Collection Qualitative Data 
Analysis 
Participant characteristics (n) Setting (n) 
Birney (353) 2016 Canada To determine how interprofessional 
collaboration was 
incorporated in the antipsychotic medication 





Thematic Analysis Healthcare assistants (5), Registered nurses (3), 
Licensed practical nurses (3), Pharmacists (4), 
Best practice lead (1), Care manager (1), Facility 
Director (1). Total participants (18) 
LTC facilities (4) 
Donyai (346) 2017 UK To explore the use of fallacious arguments in 
professionals’ deliberations about 




Content Analysis Psychiatrists (5), Geriatricians (2), GPs (5), Care 
home managers (5), Community psychiatric 
nurses (7), Primary-care pharmacists (2), 
Memory-clinic nurse (1), Social worker (1). Total 
participants (28) ‡1 
GP practices, care 
homes and hospitals 
(unknown number) 
§1 
Gill (347) 2017 UK To explore professionals’ deliberations about 
antipsychotic prescribing in dementia using 




Discourse Analysis Psychiatrists (5), Geriatricians (2), GPs (5), Care 
home managers (5), Community psychiatric 
nurses (7), Primary-care pharmacists (2), 
Memory-clinic nurse (1), Social worker (1). Total 
participants (28) ‡1 
GP practices, care 





2017 US To explore nursing home staff perceptions of 
antipsychotic medication use and identify 
both benefits and barriers to reducing 
inappropriate use from their perspective 
Q Focus Groups Hierarchical 
coding system 
Licensed practical nurse (11), Registered nurse 
(4), Social worker (4), Facility administrator (2), 
Nurse practitioner (2), Director of nursing (2), 
Certified nursing assistant (2), Assistant director 




Tjia (352) 2017 US To describe the extent to which nursing 
homes engaged families in antipsychotic 
initiation decisions in the year before surveyor 
guidance revisions were implemented 







Family members of nursing home residents (41) Nursing homes (20) 
Almutairi 
(344) 
2018 UK To develop an in-depth explanatory model 
about inappropriate prescribing of 
antipsychotics in dementia within care homes 
Q Semi-structured 
interviews 
Grounded Theory Psychiatrists (5), Geriatricians (2), GPs (5), Care 
home managers (5), Community psychiatric 
nurses (7), Primary-care pharmacists (2), 
Memory-clinic nurse (1), Social worker (1). Total 
participants (28) ‡1 
GP practices, care 





2018 Australia To identify the contextual elements that the 
nurse champions considered most critical in 
facilitating, adhering to and achieving success 
with the person-centred care component of 
the HALT intervention, and how this change 





Thematic Analysis Senior registered nurse (6), Clinical nurse 
specialist (4), 
Clinical nurse consultant (5), Nurse practitioner 
(1), 
Quality manager (3), Deputy director of nursing 
(1), Care unit manager (2). Total participants (22) 
Care homes (24) 
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2018 Ireland To establish the challenges GPs experience 
when managing BPSD, to explore how these 
challenges influence GPs’ management 
decisions, and to identify strategies for 
overcoming these challenges 
Q Semi-structured 
interviews 
Thematic Analysis GPs (16). Total participants (16) GP practices 
(unknown number) 
§2 
Kerns (348) 2018 US To assess experiences and perceptions of 
family and nursing caregivers regarding factors 








Family members of community patients (8), 
Family members of assisted living patients (7), 
Family members of nursing home patients (5),  
Nurses in assisted living facilities (6), Nurses in 
nursing home (6). Total participants (32) 
Mixture of own 
home (unknown 
numbers), assisted 
living facilities (4) 
and nursing homes 
(4) §2 
Kerns (349) 2018 US To evaluate how and why primary-care 
physicians employ non-pharmacologic 
strategies and 








Primary care physicians (26) [16 trained in family 






Mallon (350) 2018 UK To determine the views of care home  staff in 
relation to experiencing and managing 
behaviour that challenges in dementia, and 
their experiences of training 




Thematic Analysis Nurse (69), Care worker with formal 
qualifications (66), careworker without formal 
qualifications (15), other worker (38), manager 
(223). Total participants (411) 
Dementia Specialist 
Care homes (352) 
Sawan (351) 2018  Australia To identify the espoused values of nursing 
home staff regarding the ideals for the use of 
psychotropic medicines in residents with 
behavioural and psychological disturbances, 
and to uncover why the espoused values are 
in/consistent with described practices, by 
exploring the basic assumptions influencing 
psychotropic medicine use. 
Q Semi-structured 
interviews 
Thematic Analysis Managers (8), Registered Nurses (8), Nursing 
Assistants (5), GPs (8), Pharmacists (6), Enrolled 
nurses (2), Specialist medical practitioner (1), 
Nurse Practitioner (1),  
Clinical Nurse Consultant (1). Total participants 
(40) ‡2 
Nursing Homes (8) 
Q, Qualitative Methods; M, Mixed Methods; BPSD, Behavioural and Psychological Symptoms of Dementia; NPI, Non-pharmacological interventions; LTC, Long-term care; 
SCU, Specialist Care Unit; GP, General Practitioner (also known as Primary Care Physicians). 
* Study did not obtain specific degree affiliation, thus unable to distinguish between social workers and nursing staff. † Unknown breakdown of participants. §1 Research 
participants may not have been based in a Nursing Home Setting, but focus of study is on people with dementia in the Nursing Home Setting. §2 Research participants may 
not have been based in a Nursing Home Setting, but a component of study is concerned with people with dementia in the Nursing Home Setting, and we are focusing on this 
component. ‡1 The same study cohort in these three studies. ‡2 The same study cohort as a previously included study by the same authors
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4.8.2 Analysis Methods 
A deductive framework approach was utilised to explore how well, or otherwise, the 
findings of these 12 new studies fitted with our original key concepts, sub-themes 
and ‘line of argument’ (356). Using NVivo version 11 (304), the results and discussion 
sections of each new study were coded according to our predefined concepts, sub-
themes and ‘line of argument’, specifically focusing on areas of agreement and 
disagreement. Where novel concepts emerged these were coded separately 
(‘other’), and were explored in detail. We compared our updated findings to our 
existing conceptual model (Figure 20), to assess whether this model remained valid 
or whether modifications were needed. Importantly, none of the 12 studies cited our 
published systematic review (3), hence none of these studies are likely to have been 
biased by knowledge of our findings. 
4.8.3 Updated Analysis Results 
For the purpose of this update, each of the original key concepts and sub-themes 
shall be presented in turn, focusing on areas of agreement and/or disagreement with 
the new findings. Finally we shall comment on how these findings impact on our 
previously developed ‘line of argument’ and conceptual model.  As before, these are 
reported below supported by first-order (italicised quotations) and second-order 






4.8.3.1 1. Organisational Capacity 
4.8.3.1.1 Resources and access to services:  
There was strong agreement from almost all of these studies that under resourcing 
in nursing homes and inadequate access to specialist services impacted on 
participants’ decision to use antipsychotics (344, 345, 347-355): “And I think there 
has to be resource to provide alternative as well because unless there’s resource to 
provide trained carers who can manage behavioural symptoms the default scenario 
will often be medication” (344). The authors of this same study concluded that 
“within busy care homes, the many challenges of BPSD need a solution and the 
prescribing of antipsychotics provides a mechanism through which the multitude of 
work can be managed” (344). No study reported any conflicting findings with regards 
this sub-theme. 
4.8.3.1.2 Coping with the severity of behaviours:  
Once again there was strong agreement from these studies that antipsychotics were 
used as a means of coping with BPSD (344, 346-348, 351, 354, 355). One study 
concluded that “antipsychotic medications were characterised as a tool for managing 
uncontrollable and disruptive patients who are “hitting other patients or the staff,” 
“trying to break down the window” or have “ripped a radiator of the wall”. In this 
regard, antipsychotics are portrayed as helpful… within a care-home when faced with 
an even more harmful option of not being able to deal with an aggressive patient” 
(347). In this and a related study, the authors describe how participants constructed 
a “false dichotomy” surrounding the binary options of prescribing (to help alleviate 
the situation) or not prescribing (to let the situation escalate). Hence the prescription 
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of antipsychotics was considered the “lesser of two evils” (346, 347). No study 
contradicted this sub-theme. 
4.8.3.2 2. Individual Professional Capability 
4.8.3.2.1 Skills:  
Similar to our previous findings, the importance of having the skills to conduct non-
pharmacological behavioural management was viewed by participants in these 
studies as being key to preventing inappropriate antipsychotic usage (345, 349, 350, 
354). A lack of training was often seen as a barrier to implementing NPI. In one study, 
it was reported that “most [GPs] acknowledged they had little formal training in non-
medication therapies for dementia”, and this impacted on their willingness to 
recommend them for BPSD (349). Furthermore, the importance of delivering person-
centred care training to all nursing home staff was emphasised in several studies as 
a means of reducing inappropriate antipsychotic usage (345, 348, 350). No study 
contradicted this sub-theme. 
4.8.3.2.2 Knowledge:  
Having an appropriate level of knowledge surrounding the limited evidence of 
antipsychotic benefits and the substantial risks of their use in people with dementia 
was perceived to be essential in almost all of these new studies (344-350, 352-355). 
In one study which explored participants’ experiences of an intervention aimed at 
delivering education and support to nursing home staff, one participant commented 
on the perceived benefits of increased knowledge; “I think the project has created 
awareness that antipsychotic medications are dangerous and not always the answer. 
It has allowed staff to witness first-hand the behaviours of residents who have been 
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successfully deprescribed. It has shown that it is a myth that behaviours automatically 
increase when antipsychotic medications are decreased” (345). 
However one study suggested that it was confidence (that comes from experience) 
rather than purely knowledge that was more important in determining how GPs 
managed BPSD; “This confidence influenced their management, making them more 
willing to engage in trial prescribing, more cognisant of avoiding crisis presentations 
and more aware of their own limits” (354). One GP participant from this study stated 
that: “What I’ve learnt… is that you ‘give it as a trial’ and sometimes it’s absolutely 
bingo and sometimes it bounces off and you move off it pretty quickly and try the next 
one.” Interestingly though, the authors reported that for GPs “this confidence did not 
seem to extend to non-pharmacological management strategies” (354). 
4.8.3.3 3. Communication and Collaboration 
4.8.3.3.1 Communication within healthcare teams and with the family:  
Communication and teamwork involving all members of the interdisciplinary team 
with close involvement of family members was found to be important in reducing 
inappropriate antipsychotic prescribing, in almost all included studies (344, 345, 348-
355). Birney et al. observed that “work dynamics and processes… enabled effective 
[interprofessional collaboration] in the [antipsychotic] medication review. Staff 
engaged in collaborative decision-making by participating and being respectful of 
other members’ participation. Participants noted effective working relationships 
with other team members. Also, the participants were clear that different 
professional groups add another perspective to an issue” (353). One nurse 
participant from this study stated that: “It is interdisciplinary, we have people from 
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various disciplines. We have health care aides, LPNs [licensed practical nurses], RNs 
[registered nurses], management and physiotherapists. The medications we deal with 
affect every department in one way or another. Each discipline will see the patient in 
a different way than another” (353). No study contradicted this sub-theme. 
4.8.3.3.2 Clarity of Roles and Responsibilities:  
The importance of having clear roles and responsibilities was discussed throughout 
(344, 346, 347, 351, 353-355). One study discussed how in an interdisciplinary 
setting, a clear understanding of roles and responsibilities helped to reduce 
inappropriate antipsychotic prescribing in residents (353). In another study, the 
challenges presented when caring for residents across different settings, and hence 
roles and responsibilities were not clear, were also discussed; “What tends to happen 
with antipsychotics are people come in [to the hospital] with delirium and I [a 
psychiatrist] put them on an antipsychotic, not for BPSD, this is for delirium. And then 
they get discharged [to the nursing home] after about say seven, ten days. I think the 
problem arises when the antipsychotic never gets stopped because the GPs just let it 
continue” (344). No study contradicted this sub-theme. 
4.8.3.4 4. Attitudes towards people with dementia and the management of BPSD 
4.8.3.4.1 Personal Attitudes:  
There was a strong consensus among included studies that personal attitudes, 
specifically towards the management of BPSD had a significant influence on 
antipsychotic decision-making (344-350, 352-355). Family members’ attitudes 
towards antipsychotics were found to be important in determining prescribing 
decisions, especially if there was a perceived reluctance to deprescribe for fear of 
156 
 
behaviour recurrence. Simmons et al. reported that “family attitudes and/or beliefs 
in which they are either reluctant or opposed to reducing or withdrawing an 
antipsychotic medication were discussed as a major barrier to making changes” 
(355). One nursing home staff participant in this study explained why there can be 
resistance from certain family members: “Sometimes, families do not want the 
resident to come off of a medication because they’ve been on it for so long. They don’t 
want to upset the apple cart, so to speak, so they don’t want to change anything” 
(355). 
However a new concept which emerged in one of these studies which was not 
reported in any of the original studies was the idea that some family members were 
fully trusting of prescribers, and did not appear to have an opinion on antipsychotics, 
one way or the other (352). In this study “some family members had a hands-off, 
“doctor knows best about medications” attitude toward the antipsychotic decision,” 
hence explaining why some family members were happy to not get involved in these 
types of decisions (352). 
4.8.3.4.2 Organisational and Societal Attitudes:  
The influence of organisational and societal attitudes were discussed in several 
studies and were largely in agreement with our original findings (344-347, 351, 354, 
355). In particular the pressure on GPs to inappropriately prescribe antipsychotics 
from nursing homes was explored (344, 346, 347, 351, 354). A GP participant from 
one study discussed this challenging issue: “Doctors are prescribing this stuff 
(psychotropic medicines) all the time inappropriately pressured by these 
organisations …. I don't want to sell my soul. The minute I do something that I don't 
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feel is morally correct because it's going to make life easier for me or just easier when 
it's not right, I fear that my morality is compromised so I hold very fast to that” (351). 
No study contradicted this sub-theme. 
4.8.3.5 5. Regulations and Guidelines:  
The influence of regulation and guidelines on decision-making was more prominent 
in these newer studies, being discussed in 9 of the 12 studies (344, 346, 347, 349-
355). In line with our previous findings, the changing regulatory landscape was 
discussed in several studies e.g. “consistent with federal regulations, participants 
commented that efforts are made to avoid a newly prescribed antipsychotic 
medication whenever possible, particularly PRN antipsychotic use” (355). However, 
these regulations were sometimes viewed negatively as a way of keeping 
“administration happy”, and improving their nursing home star rating (355) rather 
than for the benefit of the resident and there were some unintended negative 
consequences reported which did not emerge in earlier studies. For example, in one 
study there was a suggestion that residents with dementia were having their 
diagnoses amended to include “some element of psychosis… [Because] you can’t use 
Alzheimer’s dementia to get Seroquel® [quetiapine] covered in the nursing home” 
(349). Furthermore, the GPs “also reported increasing their use of other medications 
that had rarely been used for dementia symptoms” in place of antipsychotics (349). 
In relation to guidelines, some of these studies reported that participants were 
dissatisfied with guidelines for BPSD and found them unhelpful (344, 346, 347, 349), 
in line with our previous findings. However, some studies reported that participants 
sought practical guidelines that supported prescribers and offered advice on 
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medication options: “It would be nice instead of having all of our guidelines say ‘don’t 
do, don’t do, don’t do,’ it’d be nice to find out what we can do” (349). 
4.8.3.6 ‘Line of argument’ 
Our original ‘line of argument’ visualised as a conceptual model (Figure 20 above), 
describes the process of a dysfunctional negative feedback loop where any 
‘challenging behaviour’ in a person with dementia promotes either antipsychotic 
prescribing or a non-pharmacological intervention, or sometimes both, all with the 
goal of suppressing the ‘challenging behaviour’ and restoring calm. The ‘challenging 
behaviour’ may push decision-making towards an exclusively pharmacological 
solution, especially if staff feel overwhelmed. Once the ‘challenging behaviour’ is 
suppressed, the need for an intervention is reduced. However, the fear that these 
behaviours may return at any time, or confusion surrounding roles and 
responsibilities facilitates maintenance of antipsychotic prescribing, breaking the 
feedback loop. 
We argue that our ‘line of argument’ remains valid in light of these new studies. One 
study in particular which we feel strengthens our argument is Donyai et al. who 
describe the concept of a “false dichotomy” whereby the binary options of a) 
prescribing antipsychotics or b) not prescribing antipsychotics, are framed in such a 
way that the perceived benefit of prescribing would always outweigh the substantial 
risk of not prescribing (346). Furthermore, Sawan et al. describe the “locus of control 
and necessity for efficiency or comprehensiveness” in participants, which could help 
to explain the motivations of individuals in our conceptual model e.g. a sense of 
helplessness in staff may trigger a request for an antipsychotic in order to restore a 
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sense of calm (351). Moreover the fear of behaviour recurrence as a rationale for 
inappropriate antipsychotic maintenance, has been discussed in several studies (344-
346, 348, 355). 
However, we found some novel concepts in these studies (coded as ‘other’), that 
suggests that our conceptual model may require some modifications. These two new 
concepts are ‘Different pathways for different residents’ and ‘Treatment goals’. In 
terms of the former concept, Simmons et al. described “three primary antipsychotic 
prescribing pathways, which lead to specific management strategies” (355). The 
three different pathways are 
1. Admitted on antipsychotics 
2. Psychiatric diagnosis 
3. Disruptive and dangerous behaviours 
The authors argue that the management approaches for these different populations 
may be different (355). Reflecting on our own conceptual model (Figure 20), it is clear 
that this model more closely resembles that of the third pathway (disruptive and 
dangerous behaviours). Our model may need to be slightly modified to encompass 
the possibility that residents may also be admitted on antipsychotics or have a pre-
existing psychiatric diagnosis. 
In terms of ‘treatment goals’, there was a wider variety mentioned in the newer 
studies: 
 improvement in quality of life and well-being (345, 348, 349, 353, 355)  
 reduction in symptom distress (345, 347-349)  
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 reduction in behaviours (345, 347, 349, 355) 
 improvement in alertness (345, 353, 355)  
 reduction in antipsychotic usage (353, 355)  
 reduction in falls (353, 355)  
 improvement in functional status (345, 349)  
 improvement in safety (349)  
 palliative care goals (348)  
 improvement in person-centred care (351)  
 improvement in family satisfaction (355)  
 improvement in regulatory compliance (355) 
 reduction in medication cost (353) 
Of note quality of life was seen as possibly the most important goal of treatment: 
“The focus should be on quality of life, not numbers. The benefit to a human being is 
bigger than any cost or number” (353). This is in contrast to earlier studies, and hence 
our conceptual model Figure 20, where the main goal of treatment appeared to be 
reduction or elimination of these ‘challenging behaviours’. Therefore it is evident 
that slight modifications to our conceptual model may be necessary to factor in these 
evolving preferences in treatment goals for residents with BPSD. 
4.8.4 Discussion 
In total, 12 studies were included in our updated systematic review, the findings of 
which were found to strengthen our original key concepts, sub-themes and ‘line of 
argument’. There has been an exponential increase of publications in this area in a 
relatively short period of time (from a single paper published in 2003, to 7 papers 
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published in the first six months of 2018 alone), indicating an increasing interest in 
this topic. In particular, there has been a greater focus on the influence of regulations 
and guidelines on decision-making since our initial search, highlighting the rapidly 
changing regulatory and policy landscape. This systematic review successfully 
collated these studies and provides clinicians, researchers and policy-makers alike 
with an up-to-date overview of the influences on decision-making in this complex 
area of healthcare. 
Reflecting on some of the novel concepts emerging from these new studies, there 
may be a requirement for us to slightly modify our ‘line of argument’ and conceptual 
model, based on developments in participants’ understanding of inputs (i.e. different 
types of residents) and outputs (i.e. goals of treatment) into this complex decision-
making process. To help us develop and validate this updated ‘line of argument’ and 
conceptual model, ‘member checking’ - asking authors of all included studies for 
feedback on the developing synthesis - may be helpful (357). This approach was 
successfully conducted in another meta-ethnography (296).   
Due to time constraints, the searches and data extraction for the updated search 
were conducted solely by the primary researcher. Furthermore, no grey literature 
searching, no quality appraisal and no CERQual assessments were conducted for this 
updated search. Hence it is possible that important studies were unintentionally 
omitted from this updated search, that the new studies may be methodologically 
flawed and that the confidence in our individual review findings may have changed. 
Therefore, I recommend that an updated systematic review be conducted, involving 
multiple reviewers, prior to dissemination of the updated findings. 
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Chapter 5. Exploring Antipsychotic 
Prescribing Behaviours for Nursing Home 
Residents with Dementia: A Qualitative 
Study 
5.1 Chapter Description 
In Chapter 4, I conducted a meta-ethnography and concluded that there were five 
key concepts influencing  decision-making regarding antipsychotic prescribing in 
nursing home residents with dementia: Organisational Capacity; Individual 
Professional Capability; Communication and Collaboration; Attitudes; Regulations 
and Guidelines. Upon scrutinising these findings, it was evident that there were two 
important, interlinked target behaviours that required deeper investigation through 
further primary qualitative research (appropriate requesting and appropriate 
prescribing of antipsychotics by nurses and GPs respectively). In this chapter, I 
conduct semi-structured interviews based on the Theoretical Domains Framework 
(TDF), to explore the determinants of these target behaviours, with a view to 
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5.2.1 Objectives:  
Caution is advised when prescribing antipsychotics to people with dementia. This 
study explored the determinants of appropriate, evidence-based antipsychotic 
prescribing behaviours for nursing home residents with dementia, with a view to 
informing future quality improvement efforts and behaviour change interventions.   
5.2.2 Design:  
Semi-structured qualitative interviews based on the Theoretical Domains Framework 
(TDF).  
5.2.3 Setting and Participants:  
A purposive sample of 27 participants from four nursing homes, involved in the care 
of nursing home residents with dementia (eight nurses, five general practitioners, 
five healthcare assistants, three family members, two pharmacists, two consultant 
geriatricians and two consultant psychiatrists of old age) in a Southern region of 
Ireland.  
5.2.4 Measures:  
Using Framework Analysis, the predominant TDF domains and determinants 






Nine predominant TDF domains were identified as influencing appropriate 
antipsychotic prescribing behaviours. Participants’ effort to achieve “a fine balance” 
between the risks and benefits of antipsychotics was identified as the cross-cutting 
theme that underpinned many of the behavioural determinants. On one hand, 
neither healthcare workers nor family members wanted to see residents over-
sedated and without a quality of life. Conversely, the reality of needing to protect 
staff, family members and residents from potentially dangerous behavioural 
symptoms, in a resource-poor environment, was emphasised. The implementation 
of best-practice guidelines was illustrated through three explanatory themes 
(‘human suffering’; ‘the interface between resident and nursing home’; and ‘power 
and knowledge: complex stakeholder dynamics’) which conceptualise how different 
nursing homes strike this “fine balance”. 
5.2.6 Conclusions: 
Implementing evidence-based antipsychotic prescribing practices for nursing home 
residents with dementia remains a significant challenge. Greater policy and 
institutional support is required to help stakeholders strike that “fine balance” and 
ultimately make better prescribing decisions. This study has generated a deeper 
understanding of this complex issue and will inform the development of an evidence-




Guidelines advise against antipsychotics for the first-line management of BPSD (14, 
59), due to the increased risks of stroke and mortality (109, 112, 114). However, 
antipsychotics can be appropriate when behavioural symptoms are severe, 
dangerous, or distressing to the person with dementia (14, 59). Despite the existence 
of guidelines for over a decade and national level efforts to improve dementia care, 
antipsychotic prescribing is still common, especially in nursing home settings (80, 
147, 358). Global estimates of antipsychotic prescribing prevalence in nursing home 
residents vary from 16% in the US (139), 19% in England (147), to 27% across Western 
Europe (80). 
A systematic review examining the effectiveness of interventions to reduce 
inappropriate prescribing of antipsychotics to nursing home residents with dementia, 
reported that the majority of interventions were effective in the short-term (151). 
However the long-term effects were assessed in only four studies, with prescribing 
returning to baseline levels in two studies (359, 360).  
Successful implementation of evidence-based practice requires effective and 
sustained behaviour change, beginning with a thorough understanding of the 
problem (162). A body of qualitative research has explored problematic clinical 
decision-making in this area. As discussed in Chapter 4, we conducted a systematic 
review of this literature, and found that the use of antipsychotics in nursing homes is 
the culmination of a range of healthcare professional behaviours (3). The two main 
behaviours identified were appropriate requesting and prescribing of antipsychotics. 
However, there has been a lack of exploration of these behaviours as standalone 
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processes and in terms of how they influence each other. Furthermore, there has 
been limited exploration of how different stakeholders perceive these interacting 
behaviours. Hence gaps in our understanding remain, which will be best answered 
by further qualitative research.  
The TDF is an integrative framework of influences on behaviour, identified by 
synthesising multiple behaviour change theories (361). The TDF consists of 14 
domains (Table 11), and provides a comprehensive, theory-informed approach to 
identifying the determinants (i.e. barriers and facilitators) which influence clinical 
behaviours (361). Utilisation of the TDF will help us to identify the determinants 
which influence prescribing behaviours and hence support progression from 
exploration to intervention (362).  
The aim of this qualitative study was to explore and interpret the determinants of 
appropriate prescribing behaviours (requesting and prescribing) among a range of 
individuals involved in the care of nursing home residents with dementia, with a view 























Acceptance of the truth, reality, or validity about an ability, talent, or 
facility that a person can put to constructive use 
Beliefs about 
Consequences 
Acceptance of the truth, reality, or validity about outcomes of a 
behaviour in a given situation 
Emotion 
 
A complex reaction pattern, involving experiential, behavioral and 
physiological elements, by which the individual attempts to deal with a 





Any circumstance of a person’s situation or environment that 
discourages or encourages the development of skills and abilities, 
independence, social competence, and adaptive behaviour 
Goals Mental representations of outcomes or end states that an individual 
wants to achieve 
Intentions A conscious decision to perform a behaviour or a resolve to act in a 
certain way 




The ability to retain information, focus selectively on aspects of the 
environment and choose between two or more alternatives 
Optimism 
 
The confidence that things will happen for the best or that desired goals 
will be attained 
Reinforcement 
 
Increasing the probability of a response by arranging a dependent 
relationship, or contingency, between the response and a given stimulus 
Skills An ability or proficiency acquired through practice 
Social Influences 
 
Those interpersonal processes that can cause individuals to change their 
thoughts, feelings or behaviours 
Social/Professional 
Role and Identity 
A coherent set of behaviours and displayed personal qualities of an 




5.4.1 Study Design 
We conducted semi-structured interviews, based on the TDF, with a range of 
healthcare workers and family members involved in the care of nursing home 
residents with dementia, in Cork, Ireland. Ethics approval was granted by the local 
ethics committee (Appendix 12). The ‘COnsolidated criteria for REporting Qualitative 
research’ (COREQ) statement guided study reporting (Appendix 5) (363). Two PPI 
advisory groups composed of four people with dementia in one group, and two 
family members in the other group, provided input into topic guide development and 
recruitment. Advisor eligibility criteria included being a person with dementia 
affiliated with the Alzheimer Society of Ireland or a family member of any nursing 
home resident with dementia, and having an interest in research aimed at improving 
the quality of medication usage in nursing homes. Written informed consent was 
obtained from all advisors. 
5.4.2 Study Setting and Sampling  
Nursing homes were chosen as the focus of this study as the prevalence of 
antipsychotic use is highest in these settings, as found in Chapter 3 (2, 364). 
Participants were purposively sampled, according to our sampling framework (Table 
12 below), to ensure a heterogeneous group with maximum variation according to 
two main pre-determined criteria (Professional/social role and nursing home type). 
We also used snowball sampling to fulfil our sampling framework requirements. 
170 
 
Six different nursing home sites were selected based on our sampling framework, 
through publicly available directories of registered nursing homes on the HIQA (134) 
and Nursing Home Ireland websites (365). The Directors (Nursing or Medical) of each 
nursing home were contacted about the study. Once access was agreed, the Director 
and other consenting participants connected to that nursing home were interviewed. 
The Directors approached family members initially before recommending that they 
were suitable to be contacted.  
Eligibility criteria for healthcare workers included being a physician (GP, geriatrician 
or psychiatrist of old age), a nurse, a pharmacist or a HCA who was involved in the 
care of nursing home residents with dementia. Eligibility criteria for family members 
included being a relative of a nursing home resident with dementia (alive or 
deceased), who had been prescribed an antipsychotic for BPSD.  
5.4.3 Data Collection 
We developed separate topic guides for healthcare professionals, HCAs and family 
members (Appendix 6). Topic guides were iteratively developed using findings from 
our systematic review (3), the TDF, advisor recommendations and five pilot 
interviews. The topic guides underwent revisions throughout the study to ensure 
that emerging themes were captured in subsequent interviews. All interviews were 
conducted by the primary researcher. Written informed consent was obtained prior 
to interviews. All interviews were audio-recorded and transcribed verbatim. The 
author wrote detailed field notes immediately after interviews, to refine topic guides 
and inform data analysis. We sampled until no new ideas emerged and conducted 
three more interviews without any new ideas emerging to ensure that data 
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saturation had been reached (366). The interviews were conducted between July 
2016 and April 2017.  
There were no established relationships between any participants and the research 
team prior to study commencement. The primary author informed all participants 
prior to commencing interviews, that he was a pharmacist undertaking this study as 
part of his PhD, and for the purpose of the interview, he was asking questions as a 
researcher, and not as a pharmacist. 
5.4.4 Data Analysis 
Data analysis followed the principles of Framework Analysis (356)  and utilised NVivo 
version 11 for data management purposes (304). We utilised both deductive and 
inductive approaches to analysis throughout the five stages of Framework Analysis 
(familiarisation, identifying a thematic framework, indexing, charting, and mapping 
and interpretation). First, the author became familiar with the data by reading 
transcripts and field notes and open coded across the entire dataset. During indexing, 
data from the transcripts were deductively coded into one or more TDF domains 
according to the definitions for each domain (Table 11). Simultaneously, concepts 
emerging from the open coding were categorised inductively. These simultaneous 
indexing steps were conducted independently by three authors (KW, AF, JMcS) for 
seven transcripts, who met to discuss differences in TDF application or interpretation 
of emerging concepts, and came to consensus. The indexing of the remaining 
transcripts was conducted by the primary author.  
Charting of the data, with distilled summaries in matrix format was used to identify 
the predominant TDF domains influencing the target behaviours (appropriate 
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requesting and prescribing) (362). This was performed independently by two authors 
(KW and CS), who then discussed any disagreement until consensus was reached. 
From these predominant domains, the determinants (i.e. barriers and facilitators) of 
the target behaviours were identified.  
For the mapping and interpretation step, we iteratively developed links between 
determinants, predominant domains, categories and theory to provide overall 
explanations for the findings. This was achieved by constructing conceptual mind 
maps exploring possible relationships between all these different factors. By 
iteratively examining these evolving conceptual mind maps as an interdisciplinary 
research group (consisting of pharmacists, a GP, a health psychologist, a 
methodologist and a geriatrician), we were able to condense our findings into three 
explanatory themes and one overarching theme. Therefore the behavioural 
determinants were the ‘building blocks’ for the themes, and an overarching theme 
was identified, explaining the relationship between behavioural determinants and 
explanatory themes. These stages were not linear (Figure 22), and the data collection 
and analysis phases occurred concurrently, to enable the exploration of emergent 
















We invited six nursing homes to participate and four agreed - two private nursing 
homes, one with and one without a dementia specialist care unit (SCU); one 
voluntary nursing home (state-funded but charitable organisation governance) 
without a SCU; and one public nursing home (state-run) without a SCU (Table 12). Of 
38 individuals contacted, 27 agreed to participate (eight nurses, five GPs, five HCAs, 
three family members, two pharmacists, two consultant geriatricians and two 
consultant psychiatrists of old age) (Table 12). The median interview length was 23 
minutes (range 12-56 minutes). The characteristics of the 27 interview participants 
are outlined in Table 13.  
Table 12: Sampling Framework 
 
The number in each box refers to the number of participants recruited, according to the two main 
pre-determined criteria (Professional/social role and nursing home type). 















2 1 2 5 
Nurse  5 2 
 
1 8 
Pharmacist  1 1 0 2 
Healthcare 
Assistant 
2 2 1 5 
Family member 3 0 0 3 
Consultant 






TOTAL   27 
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Table 13: Characteristics of Interview Participants 
* N/A for n=3 family members 
 
 
Characteristics of total participants (n=27) Participants, n  
Professional/social role  
Nurse 8  
General Practitioner 5  
Healthcare Assistant 5  
Family Member 3 
Pharmacist 2  
Consultant Geriatrician 2  
Consultant Psychiatrist of Old Age 2 
Gender  
Female  17 
Male 10 
Other 0 
Category of Nursing Home participant worked in*  
Private only 9  
Public only 4  
Voluntary only 3  
Multiple 8 
Years of professional experience (since qualification)*  
<10 years 3  
10-19 years 10  
≥20 years 10  
Information not provided 1  
Received specialist dementia training*  
Yes 16  
No 8 
Presence of dementia specialist care unit (SCU) in any nursing home participant 
worked in* 
 




Characteristics of Family Member Participants (n=3) Participants, n 
Gender  
Female  2 
Male 1  
Other 0  
Category of Nursing Home person with dementia resides/resided  
Private  3  
Role  
Current carer 1 
Former carer 2  
Age of participant  
40-49 1  
50-59 1  
60-69 1 
Relationship to person with dementia  
Son/daughter 2  
Nephew/niece 1  
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We identified nine predominant TDF domains, encompassing 38 behavioural 
determinants that influenced our target behaviours (Table 14 below). Broadly 
speaking, these nine TDF domains were relevant across both requesting and 
prescribing behaviours. We also developed three explanatory themes and one over-
arching theme, which are discussed below and illustrated in a conceptual model 
(Figure 23). The nine predominant TDF domains and the more seminal determinants 
are discussed below; detail on the remaining determinants is presented in Table 14. 
Professional differences were not the primary focus of this study, however if any 
differences were noticeable, we have reported on these below. 
5.5.1 Predominant TDF domains 
5.5.1.1 Behavioural Regulation 
Participants believed that HIQA, the independent nursing home regulator in Ireland, 
has put antipsychotics under scrutiny. Regulation now requires nursing homes to 
notify HIQA, on a quarterly basis, of any occasion when restraint (chemical or 
physical) is used (137). Some participants believed that these regulations made them 
re-evaluate how they manage BPSD, with positive outcomes for residents.  
“I think HIQA is brilliant... because I really think they force people to look at 
their practice, and to challenge their own practice and to change.” [HCA 1] 
However, GPs in particular, felt that there was over-regulation by HIQA, resulting in 
increased administrative burden, which did not necessarily translate into good care. 
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Furthermore, some participants were confused by the regulatory requirements, and 
were concerned about unintended negative consequences, because of the mistaken 
belief that only psychotropic medications used for acute episodes were reportable.  
“Now, conversely, what it has made some nursing homes do is, if somebody 
was on a PRN psychotropic, because the resident might only need it once or 
twice per month and because it becomes reportable, they get prescribed 
regularly.” [Nurse 5] 
Healthcare workers reported that interdisciplinary medication reviews, audits and 
internal registries also provided an opportunity for self-monitoring. When in place, 
these systems assisted with the identification of patterns of inappropriate usage. 
Prescribers found international guidelines helpful in their decision-making (14). 
However, succinct guidelines specific to the Irish context were sought. 
5.5.1.2 Beliefs about Capabilities 
Participants struggled to find solutions to BPSD other than antipsychotics in part 
because they felt that they lacked necessary training. Nursing home staff struggled 
with the daily management of BPSD and some admitted that they needed 
antipsychotics to cope. GPs often felt out of their comfort zone and regularly needed 
input from specialists.  
“In some ways I don’t feel I have the sufficient expertise to make those 
decisions so I’ll look to specialists at that point if I’m struggling with 
something.” [GP 3] 
5.5.1.3 Beliefs about Consequences 
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Both healthcare workers and family members were worried about side effects such 
as sedation and falls. Some viewed these side effects as undignified and inhumane, 
and hence were reluctant to request or prescribe antipsychotics.  
A fear of negative consequences (i.e. adverse behavioural events from residents) if 
antipsychotics were not prescribed was expressed by prescribers. They were 
conscious of the safety of their nursing home colleagues who were often at the 
receiving end of behaviours.   
“Because you don't know what precipitated the [behaviour], and then, when 
you're trying to pull back and you walk away, are you leaving your colleagues 
in the height of it then?” [GP 4] 
5.5.1.4 Emotion 
Participants, particularly family and nursing home staff, spoke emotively about BPSD, 
and how these symptoms deeply impacted upon them personally. Sometimes 
participants believed that antipsychotics were the only solution to alleviating this 
distress. 
“It was very hard to listen to [the BPSD]… so as far as I’m concerned, if there 
was a medication that would sort this thing anyway, I certainly was 
completely open to it.” [Family member 2] 
Nursing home staff were deeply affected by behaviours leading to burn-out, 
frustration and poor morale. Staff sometimes took behaviours personally, which 
could increase the propensity to request prescribing of antipsychotics. Empathy as 
opposed to sympathy was viewed as an important trait when dealing with BPSD. It 
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was seen to be important to be able to step back, evaluate the situation and 
determine the best course of action for the resident, without emotions clouding 
one’s judgement.  
“I feel that certain people take huge offence if a person who is cognitively 
impaired lashes out, punches, screams, whatever, and you have to let it go.” 
[Nurse 8] 
5.5.1.5 Environmental Context and Resources 
The overall picture was one of poor resources in nursing homes. Although non-
pharmacological interventions were generally seen as the gold standard, there was 
consensus that these interventions were staff-intensive and not always feasible. 
“You need to have the time to be with somebody, staffing levels don’t really 
give you the opportunity to sit with somebody all day long or all afternoon… 
you can come and go but you can’t stay with the person.” [Nurse 4] 
The physical environment was believed to have a profound impact on residents. 
Some participants believed that if the environment was better suited to meet the 
needs of the resident, then there would be less of a need to prescribe. 
“I think if we had properly designed purpose built modern dementia units that 
allowed us to offer a different environment than the standard ward 
environment…  I do think that would be far more humane and you’ll probably 
get better overall results than resorting to the old fashioned chemical 
restraints.” [Consultant geriatrician 2] 
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Participants described how treatment culture impacted on the resident in terms of 
prescribing, both positively (e.g. being resident-centred) and negatively (e.g. being 
task-orientated). There was a general agreement that every nursing home was 
completely different, and what may be acceptable in one nursing home may not be 
acceptable in another. 
5.5.1.6 Knowledge 
Both healthcare workers and family members were aware that antipsychotics cause 
side effects. However, non-consultants in particular, acknowledged their own limited 
knowledge on this topic, and welcomed further education. Furthermore, GPs 
believed that a better understanding of the risk/benefit profile among nursing home 
staff would reduce requests for antipsychotics.   
“If you can tell someone what the potential complications [of antipsychotics] 
are, they may be a little bit less likely to ask for them.” [GP 1] 
In-depth knowledge of the resident was believed to be paramount. Knowing the 
resident and understanding their life story helped nursing home staff to adapt the 
environment to meet the needs of the resident, and often prevented unnecessary 
prescribing.  
“I think just knowing the person.  Knowing that they have been on them 
[antipsychotics] for years.  Looking at them now, their state of deterioration 
and you know in your heart and soul they don't need them.” [Nurse 5] 
5.5.1.7 Memory, attention and decision-processes 
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The importance of conducting a holistic assessment of the resident was emphasised 
by participants. There was agreement that antipsychotics were only appropriate 
after all potential reversible causes of BPSD were ruled out. In one nursing home, 
where a comprehensive assessment protocol was recently introduced, nurses 
explained how this protocol assisted them with their decision-making. 
5.5.1.8 Social Influences 
Prescribers were based off-site so they relied on accurate and objective information 
about residents from nurses. Prescribers largely valued and trusted the nurses’ 
judgements and tended to make prescribing decisions based on the information 
provided. However this could lead to a perception that behavioural symptoms were 
being exaggerated in order to increase the likelihood of prescription. 
“I think people can be a little bit biased in how they can present a case to you 
at times to get to the ends that they want. I know there has been one incident 
where… a staff member [was overheard] saying ‘sure just tell her she’s had 
hallucinations.’” [GP 3] 
Prescribers reported that pressure to prescribe antipsychotics arose from many 
sources including individual staff members, family members, the nursing home 
organisation, and from society itself. 
“So I feel under pressure to knock this person out, anaesthetise this patient, 
who they see as, shouldn't be challenging.  And they're already completely 
over-sedated and the staff want them to be even more sedated.”  [Consultant 
psychiatrist of old age 2] 
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There was a perception by some of a prevailing culture where all behaviours may be 
attributed to the disease rather than an unmet need. However, other participants 
felt that, due to the influence of HIQA, nursing homes were moving towards a more 
social model of care. This shift in culture was broadly welcomed. However, some 
physicians feared that the pendulum had “swung too far” [Consultant psychiatrist of 
old age 1], and that GPs, in particular, may be fearful of using antipsychotics due to 
the perceived anti-medication climate. 
5.5.1.9 Social/Professional Role and Identity 
Nursing home staff and family members viewed themselves as the resident’s 
advocate. This role empowered them to speak up on behalf of the resident. 
“See mom didn’t have a voice, nobody would listen to her even when she was 
speaking, she wasn’t listened to and I was her voice.” [Family member 1] 
There was a hierarchy described by participants in the nursing home environment. 
HCAs were often not involved in any degree of decision-making despite their in-depth 
knowledge of residents. Furthermore, one pharmacist felt disregarded in this area, 
despite her pharmacological expertise. Decisions were perceived as being made 
between GPs and nurses, with input from consultants when needed.  
“As it stands and we're talking about the real world, it's really the nursing staff 
and the GP.  I don't have an influence there.  If I get the script, we just have to 
hand it over.” [Pharmacist 2] 
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The importance of leadership from the nursing home manager was emphasised. 
Good leaders were perceived as those with experience who provided adequate 
training and support to staff.  
 
 
Table 14: Determinants of appropriate antipsychotic prescribing behaviours  
Determinants (i.e. barriers 
and/or facilitators) of 
appropriate antipsychotic 
prescribing behaviours 
(requesting and prescribing) 
Illustrative quotes 
1. Behavioral Regulation  
HIQA regulation as a stimulus 
for change (facilitator) 
I think HIQA is brilliant... because I really think they force people to look at their 
practice, and to challenge their own practice and to change.” [HCA 1] 
Perception of HIQA over-
regulation by GPs (barrier) 
 
“I think HIQA are a scurge. I wonder what they bring to the table. I think they’re self-
fulfilling... Ya I think most GPs would not [be happy with them]. I don’t think they bring 
a whole lot to the table unfortunately. I think they bully private nursing home and 
private institutions…Ya I think it’s all very, very good and ivory tower stuff and 
politically correct. But, could I think [sic] the money spent on HIQA could be spent 
better on direct services? Probably.” [GP 1] 
Uncertainty regarding HIQA 
reporting requirements 
(barrier) 
“Now, conversely, what it has made some nursing homes do is, if somebody was on a 
PRN psychotropic, because the resident might only need it once or twice per month 
and because it becomes reportable, they get prescribed regularly.” [Nurse 5] 
Self-monitoring (using local 
systems) of antipsychotic 
prescribing (facilitator) 
“So, for me it would be to monitor the scripts as they come in and maybe their charts 
and we do at the request of the Director of Care, we do a psychotropic audit every 
month.  So we see where they're being reviewed.” [Pharmacist 2] 




“Guidelines is a good thing, and licensing, because you know there isn't any license.  
Grade one, grade two evidence, meta-analyses… You can certainly use them to say 
why you're not prescribing an antipsychotic.  You just say there's no evidence and it's 
not national policy.” [Consultant Psychiatrist of Old Age 2] 
2. Beliefs about capabilities 
Poor self-efficacy in the 
management of BPSD among 
non-specialists (barrier) 
“So I suppose in some ways I don’t feel I have the sufficient expertise to make those 
kind of decisions so I’ll look to specialists at that point if I’m struggling with 
something.” [GP 3] 
Belief that assessing whether 
an antipsychotic prescription 
is ‘appropriate’ or not is 
challenging (barrier)  
“It's a difficult one to decipher.  When it's appropriate and when it's not appropriate.” 
[Nurse 6] 
 
Belief that deprescribing 
antipsychotics is difficult 
(barrier) 
“And it’s very easy starting these things but the discontinuation of them not quite so 
clear cut.” [Consultant Geriatrician 2] 
3. Beliefs about consequences 
Concerns about side-effects 
(facilitator) 
“She was just asleep looking, absolutely drugged out of her tree looking, sitting in a 
chair.” [Family member 1] 
Belief that antipsychotics are 
highly effective (barrier) 
“I know the drugs can fix these things. Now not completely right. But I know that 
drugs can fix these things.” [Family member 2] 
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Belief that NPIs are not a 
feasible alternative (barrier) 
“But if you have somebody at 2 o clock in the morning that you’re pacing the floor 
with until 6 o clock in the morning, where are your therapies then?” [HCA 2] 
Belief that the return of 
symptoms are caused by the 
reduction of antipsychotic 
dosage (barrier) 
“I think people often think, that if something doesn’t work straight way or if there 
happens to be a coincidental problem as soon as you start to reduce it, suddenly there 
is this complete fear that this has caused it, they expect more immediate, they see the 
immediate things as being either absent or present so when you start a new drug if it 
hasn’t worked straight away there is a bit of ‘oh it’s not working.’” [GP 3] 
Anticipated regret (barrier) “Because you don't know what precipitated the [behaviour], and then, when you're 
trying to pull back and you walk away, are you leaving your colleagues in the height of 
it then?” [GP 4] 
4. Emotion 
Fear of dementia (barrier) “It was very hard to listen to [the BPSD]… so as far as I’m concerned, if there was a 
medication that would sort this thing anyway, I certainly was completely open to it.” 
[Family member 2] 
Taking behaviours personally 
(barrier) 
“I feel that certain people take huge offence if a person who is cognitively impaired 
lashes out, punches, screams, whatever and you know, you have to let it go.” [Nurse 8] 
Burn-out and frustration 
(barrier) 
“You’ll get staff who are burned out, they just can’t cope.  They’re sick of saying X, Y 
and Z and they’re not being listened to, and they just don’t care anymore.” [Nurse 3] 
Empathy toward people with 
dementia (facilitator) 
 
“I think people with a very empathetic view of dementia would be less likely to 
encourage, prescription of antipsychotics, because there is that, ‘oh it's, you know, you 
don't have to give them drugs for it, it's just their dementia, we can get around it,’ and 
then, some people… will see the more negative side of the dementia, and be like, ‘isn't 
it awful for them, God wouldn't you just give them something to relax them.’ [Nurse 6] 
Emotions of healthcare 
professionals tend to reflect 
those of family members 
(barrier) 
“I’ll get [a phone call], ‘The family were in today they’re very worried about mammy. 
She’s very upset and agitated’. I never get those phone calls to say that they’re 
worried that’s she’s just sitting there staring into space.” [GP 1] 
Personal experience of 
dementia 
(barrier/facilitator)* 
“We’re all human, we all bring our own stuff.” [HCA 3] 
5. Environmental Context and Resources 
Lack of adequate resources 
(barrier) 
“You need to have the time to be with somebody, staffing levels don’t really give you 
the opportunity to sit with somebody all day long or all afternoon… you can come and 
go but you can’t stay with the person.” [Nurse 4] 
Perception that it’s cheaper 
to give antipsychotics than 
deliver NPIs (barrier) 
“They haven’t enough staff and they seem to think that the cheapest way is to dose 
them, and keep them quiet” [Family member 1].   
Impact of the built 
environment on the person 
with dementia (facilitator/ 
barrier)* 
“I think if we had properly designed purpose built modern dementia units that allowed 
us to offer a different environment than the standard ward environment…  I do think 
that would be far more humane and you’ll probably get better overall results than 
resorting to the old fashioned chemical restraints.” [Consultant geriatrician 2] 
Each nursing home is 
different 
(facilitator/barrier)* 
“You go to different nursing homes and attitudes are very different.” [Nurse 3] 
 
Impact of treatment culture 
on residents 
(facilitator/barrier*) 
“Sometimes it can feel like the person is there as…  I don't know how to say this 
politely, but they're in the bed and they have to acquiesce or be compliant with the 
system around them, be good children or good grown-ups and play the game.  And if 
you don't do that, then you get labelled and your behaviour gets labelled.” [Consultant 
Psychiatrist of Old Age 1] 
6. Knowledge 
Knowledge of antipsychotics 
(facilitator) 
“If you can tell someone what the potential complications [of antipsychotics] are, they 
may be a little bit less likely to ask for them.” [GP 1] 
Knowledge on the cause and 
nature of BPSD (facilitator) 
“I think if people understood… why [residents] have behaviours that challenge I think 
that would go a long way for a lot more understanding and people not wanting just to 
sedate somebody.” [Nurse 3] 
Knowledge of the resident 
(facilitator) 
“I think just knowing the person.  Knowing that they have been on them 
[antipsychotics] for years.  Looking at them now, their state of deterioration and you 
know in your heart and soul they don't need them.” [Nurse 5] 
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7. Memory, attention and decision-processes 
Decision-making based on a 
thorough assessment 
(facilitator) 
“Then with the physical as well, we do the PINCH ME acronym so we...pain, infection, 
constipation, hydration, nutrition, medications, environment, we look at real holistic 
view of the person and try and rule out any triggers there [sic].”  [Nurse 6] 
Paying attention to where the 
challenge lies with regards to 
the behavioral symptoms 
(facilitator) 
“Sometimes it just ultimately again it takes me back, you need to take a step back, 
who are you treating? Are you treating the carer who wants a certain amount given 
so somebody is peaceful or a certain amount of investigation is done, or are we 
treating the staff who are treating the patient because they want a peaceful night or a 
peaceful day on the ward, or are we making a decision to make our own lives easier? 
And we just have to take a step back sometimes.” [GP 5] 
8. Social Influences 
Social Pressure to prescribe 
(barrier) 
“So I feel under pressure to knock this person out, anaesthetise this patient, who they 
see as, shouldn't be challenging.  And they're already completely over-sedated and the 
staff want them to be even more sedated.”  [Consultant psychiatrist of old Age 2] 
Reliance on accurate 
information from nursing 
home staff 
(facilitator/barrier)* 
“I think people can be a little bit biased in how they can present a case to you at times 
to get to the ends that they want. I know there has been one incident where… a staff 
member [was overheard] saying ‘sure just tell her she’s had hallucinations.’” [GP 3] 
Modelling of prescribing 
behaviour 
(facilitator/barrier)* 
“A lot of our learning seems to come from the consultations and referrals that we 
actually see what the psychiatry of the elderly prescribe in these situations, and we 
have been led by that, so quetiapine just seems to be one they seem to use.” [GP 5] 
Prevailing culture of care 
(facilitator/barrier)* 
“Medication comes first in Ireland. ‘Give it to them as much as possible’”. [Family 
member 1] 
9. Social/Professional Role and Identity 
Advocacy role of nursing 
home staff and family 
members (facilitator) 
“See mom didn’t have a voice, nobody would listen to her even when she was 




“It depends on what background you are coming from and when you trained, how you 
view the medications and the use of medications.  I think there is a difference, 
between the younger generation of nurses and the older generation of nurses.  There 
appears to be more of a reluctance, I think, in the younger generation of nurses with 
giving out, I suppose the high risk medications like [antipsychotics]…  And I think there 
is a difference there then because you're not seeing your nursing profession as a 
medical profession, you’re almost a facilitator...and when you see it from that 
perspective then medication isn't always the first kind of thing that pops into your 
head.” [Nurse 6] 
Variable sense of 
responsibility for prescribing 
decisions 
(facilitator/barrier)* 
“But I suppose it’s up to the prescriber to be able to sort the wheat from the chaff and 
see what’s a good grounded opinion and what’s maybe not as reliable you know.” 
[HCA 3] 
 
Leadership role of nursing 
home manager (facilitator) 
 
“You need a manager who is supporting staff and is knowledgeable and roles out 
good training to the staff.  And has good experience so, and ideally good mental 
health experience because that's, not all of them have good mental health experience 
but it is important for the manager. If you meet the manager, you can usually see the 
tone of the home.” [Consultant Psychiatrist of Old Age 2] 
Traditional hierarchy (barrier) “As it stands and we're talking about the real world, it's really the nursing staff and 
the GP.  I don't have an influence there.  If I get the script, we just have to hand it 
over.” [Pharmacist 2] 
* This determinant could be a barrier or a facilitator depending on the individual circumstance 
BPSD: Behavioural and Psychological Symptoms of Dementia; GP: General Practitioner; HCA: 
Healthcare assistant; HIQA: Health Information and Quality Authority; NPIs: Non-pharmacological 




5.5.2 Explanatory themes 
We identified “a fine balance” [HCA 1] as the over-arching theme. On one hand, 
neither healthcare workers nor family members wanted to see residents over-
sedated and without a quality of life. Conversely, the reality of needing to protect 
staff, family members and residents from potentially dangerous behavioural 
symptoms, in a resource-poor environment, was emphasised. We found that nursing 
home staff and prescribers struggled with this constant tension throughout their 
daily practice.  
Beneath the over-arching theme of “a fine balance”, we developed three explanatory 
themes as a means of illustrating why this implementation issue, non-adherence to 
best-practice guidelines, persists. Within these themes, opposing perspectives and 
trade-offs were evident which can tip the “fine balance” in favour of undertaking one 
behaviour over another (e.g. prescribe versus not prescribe). We argue that the 
perspective of each nursing home towards these three explanatory themes, 
determines how they strike this “fine balance” (Figure 23). 
5.5.2.1 Human Suffering 
Participants described suffering related to both the disease and antipsychotic 
medications. Some viewed dementia as a terrible affliction: “I think it’s the hardest 
disease out there, to manage. It’s one I would NOT like to get myself” [HCA 2]. Not 
only was dementia perceived to cause suffering to the resident, but often 
participants reported being physically and emotionally affected themselves. 
Antipsychotics were viewed through this perspective as a way of alleviating suffering 
for everyone. Conversely, others acknowledged that antipsychotics can cause severe 
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side effects for the resident, and were used primarily for “staff-focused” [Consultant 
psychiatrist of old age 2] as opposed to resident-focused purposes. From this 
perspective, the use of antipsychotics were frowned upon.  
5.5.2.2 The Interface between Resident and Nursing Home 
The perceived effect that the resident has on the nursing home, and vice versa, was 
the second explanatory theme. A resident exhibiting BPSD was perceived by some to 
have a negative impact on the nursing home environment, ultimately requiring 
additional staff and money: “They haven’t enough staff and they seem to think that 
the cheapest way is to dose them, and keep them quiet” [Family member 1].  From 
this perspective, antipsychotics were perceived as necessary to enable staff to care 
for all residents in an efficient manner. Conversely, the nursing home environment 
was perceived by others to have an important impact on the resident.  From this 
perspective, placing the resident in “the right place” [Nurse 3], i.e. a more dementia-
friendly environment, was perceived to be more beneficial to the resident than any 
medication. 
5.5.2.3 Power and Knowledge: Complex Stakeholder Dynamics 
The final theme refers to the complex interplay between the many different 
stakeholders involved in the care of residents. The symbiotic concepts of power and 
knowledge can help us to understand these complex stakeholder dynamics.  There 
were different types of knowledge valued by participants: knowledge of the disease, 
the drug and the resident. Often primacy was given to the latter. Hence from this 
perspective, nurses’ in-depth knowledge of residents legitimised their power to 
request that an antipsychotic be started or stopped: “The GP's will do it [deprescribe], 
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no problem, we need to instigate it, and it's just the experience of knowing the 
person” [Nurse 5]. Conversely, others argued that those in higher positions of power 
had knowledge that was more important (i.e. knowledge of drug and disease), in 
determining the best outcomes for residents: “Old age psych usually make a 
recommendation and then the GP will sign the prescription” [Nurse 8]. From this 
perspective, those in positions of power were perceived to have the most important 
knowledge in determining the appropriateness of antipsychotic prescribing. 
 
Figure 23: Conceptual model of explanatory themes 
Opposing perspectives and trade-offs (in white) can tip the “fine balance” in favour of undertaking 
one behaviour over another (e.g. prescribe versus not prescribe). The perspective of each nursing 
home toward these three explanatory themes (in blue), determines how they strike a “fine balance” 





Using a novel multi-perspective approach, we have generated a deeper 
understanding of the behavioural components of antipsychotic use in nursing home 
residents with dementia, the professional interactions that occur between different 
stakeholders and the determinants of implementation of best-practice guidelines. 
Our findings highlight how implementing evidence-based practice in this area 
remains a significant challenge, despite advances in knowledge and stricter 
regulations. We identified that stakeholders strive to strike “a fine balance” but 
ultimately, as humans, are influenced by interacting emotional, environmental, 
organisational and societal issues.  
5.6.1 Comparison with Previous Research 
This study builds on the findings of Chapter 4, where we identified five key concepts 
influencing decision-making: organisational capacity; individual professional 
capacity; communication and collaboration; attitudes; and regulations and 
guidelines. In this current study, we found all of these concepts also play a role in 
implementing evidence-based practice. With regards to organisational capacity, the 
fundamental issue of inadequate resources was discussed in almost all of our 
interviews. This current study also extends our understanding of the influence of 
regulations on practice. Our study confirms the important role of regulations, but 
also highlights unintended negative consequences that may occur as nursing homes 
undertake various workarounds. Similar workarounds have been reported in the US, 
where increasing diagnoses of schizophrenia in nursing home residents have been 
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observed, in a suspected attempt to exempt antipsychotics from regulatory reporting 
requirements (150). Almost 40% of US nursing home surveyors (who evaluate 
nursing home regulatory compliance through on-site inspections) have observed the 
creation of a new, but false diagnosis of psychosis in residents (367). Urick et al. 
surmise that the motive for falsification of records may be to improve a facility’s ‘five-
star’ quality rating, as residents with schizophrenia and other select psychiatric 
conditions are exempt from the calculation of this quality metric (367) 
We identified nine TDF domains that influenced our target behaviours, which are 
similar to those found in previous TDF studies exploring prescribing behaviours for 
various conditions (368-372). The key difference is our identification of ‘emotion’ as 
a predominant domain which is absent in the majority of other prescribing studies 
(368-371). The emotional impact of BPSD on family members (49) and nursing home 
staff (373) is established in the literature. The concept that people with dementia 
inevitably lose their identity to dementia and thus become ‘dehumanised’ has been 
hypothesised as a rationale for why family members often struggle with BPSD (49).  
In our study, this fear of dementia emerged as an important issue. It is evident that 
this impacts not only on family members, but also nursing home staff. Prescribers 
believe that sometimes it is challenging to decipher who precisely is distressed by the 
BPSD.  
Foucault wrote that power and knowledge are not independent entities but are 
inextricably linked — ‘knowledge is always an exercise of power and power always a 
function of knowledge’ (374).  This theory may help us to understand the complex 
dynamics between hierarchical stakeholders and how different types of knowledge 
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are valued by different stakeholders. Knowledge of the resident tends to be 
prioritised, and sometimes this can contradict with treatment goals set by those in 
higher positions of power (with different types of knowledge). Hence, advocating on 
behalf of the resident, particularly by nurses, is central to decision-making, and a key 
target for potential intervention (375, 376).  
Previous studies have explored the challenges GPs experience when managing BPSD 
(9, 354, 377).  Jennings et al. identified three main challenges:  lack of clinical 
guidance; stretched resources; and difficulties managing expectations (354). Our 
study corroborates these findings by highlighting the multitude of difficulties GPs 
face when deciding whether to prescribe antipsychotics or not. However, our study 
goes further by exploring the perspectives of a wider range of stakeholders, allowing 
us to gain a more holistic insight into this implementation problem.  
5.6.2 Implications 
It is evident that greater policy and institutional support is required to help 
stakeholders strike that “fine balance” and ultimately make better prescribing 
decisions. Development of national clinical guidelines may be one appropriate policy 
intervention. Such guidelines are currently being developed in Ireland as a priority 
action point of the national dementia strategy (378). An important implication of our 
study is the need to clarify existing regulations for stakeholders, as it is evident that 
they are unsure as to which prescribing scenarios are reportable and which are not, 
and residents may be adversely affected by this confusion. 
Further consideration should also be given to the design of future nursing homes. 
Our findings highlight the importance stakeholders attribute to dementia SCUs in 
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terms of meeting the needs of residents with dementia. However, resident outcomes 
from SCUs have been mixed, along with concern over higher levels of antipsychotic 
usage (320, 379). Therefore, although SCUs may be desired by stakeholders, more 
evidence of the quality and safety of this approach is required before widespread 
adoption.  
The perceived impact of treatment culture on antipsychotic usage featured heavily 
throughout this study. In line with previous systematic review findings (3, 380), the 
Nursing home manager was seen as a key determinant of nursing home treatment 
culture, as they possessed both a position of power and knowledge of the resident. 
We recommend that nursing home managers take advantage of their influential role 
by providing/organising ongoing training to staff as well as encouraging the 
involvement of peripheral stakeholders (i.e. HCAs, pharmacists, family members) in 
decision-making. 
Despite guidance on avoiding antipsychotics in dementia, they can play an essential 
role in certain situations (14, 59). Our study shows that due to the stigma attached 
to antipsychotics, some prescribers are fearful of prescribing them at all, risking 
unnecessary distress for a resident for whom the medications are indicated. A recent 
study demonstrated that discontinuation of antipsychotics, without non-
pharmacological substitution, can have a detrimental impact on residents’ health-
related quality of life (381). Our findings suggest that an evidence-based, 
standardised approach involving interdisciplinary collaboration, careful 
documentation and regular review is needed to ensure the most appropriate use of 
both pharmacological and non-pharmacological interventions (382). One such model 
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programme is the DICE (describe, investigate, create, and evaluate) approach, which 
promotes a holistic, person-centred approach to managing BPSD (32, 382).   
Educational programmes are the most common intervention type utilised to tackle 
inappropriate antipsychotic prescribing (151) e.g. the OASIS programme (383), the 
HALT (Halting Antipsychotic use in Long-Term care) study (384) and the RedUSe 
(Reducing Use of Sedatives) project (359). Ongoing education and training to both 
nursing home staff and prescribers is an important aspect of ensuring appropriate 
antipsychotic prescribing, but is not sufficient on its own. Drawing from these existing 
programmes (359, 382-384) as well as our own findings, we recommend that future 
programmes should include training on the assessment and management of BPSD, 
dealing with emotions and managing expectations. It is important for prescribers to 
be empathetic and acknowledge the emotional and physical impact of BPSD, while 
assertively conveying, the limited benefit and serious risks associated with 
antipsychotics. Likewise, nurses as the key influencer on prescribing, should be aware 
of and communicate these issues to others within the nursing home and to family 
members. In  particular, the OASIS communication training programme enforces 
these key messages (383). Consideration should also be given to the professional 
status of the person delivering the intervention, as it was evident that some 
healthcare professions were perceived as being more influential than others in terms 
of changing behaviour, in an Irish context (e.g. GP vs. pharmacist). Future research 
should focus on determining how best to deliver educational interventions, by 




5.6.3 Strengths and Limitations 
The trustworthiness of our findings are underpinned by the involvement of different 
disciplines on our research team, our PPI advisory groups and the participation of 
multiple stakeholders from different organisations during the interviews. 
Triangulation of analysts and participants also contributed towards the credibility of 
the results. Interviews took place in one region in Ireland, but transferability is 
supported by the provision of sufficient contextual information to enable readers to 
determine how applicable our findings are to their own situation. Detailed reporting 
of well-established methods with diagrammatical audit-trails contributed towards 
the dependability of our findings. Finally, in terms of confirmability, detailed 
reporting of participants’ quotations, helped ensure that our findings were primarily 
borne from the data (385). 
Although 66% of nursing homes contacted and 71% of individuals contacted, agreed 
to participate in our study, it is possible that only those with strong views on this 
topic took part. Furthermore, although we employed a purposive sampling approach, 
Directors may have recommended individuals for participation who were more likely 
to provide favourable responses about practices in their nursing home. Hence the 
possibility of selection bias cannot be excluded. Random sampling of participants 
along with a larger sample may have reduced this problem, and may have allowed us 
to explore differences in perceptions between respondent groups and settings in 
greater detail (385). 
Another limitation was the small number of family members recruited. The 
challenges of recruiting family members of residents with dementia to research 
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studies have been previously reported (386). Despite engaging with our advisors on 
this issue, and reminding Directors to identify potential participants, we only 
managed to recruit three family members. It is possible that family members were 
apprehensive about taking part due to the emotive nature of this topic. Furthermore, 
it is possible that the Directors may have been over-protective of family members. 
5.7 Conclusions 
Implementing evidence-based antipsychotic prescribing practices for nursing home 
residents with dementia remains a significant challenge, despite advances in 
knowledge and stricter regulations. In striving to strike “a fine balance”, stakeholders 
are influenced by interacting emotional, environmental, organisational and societal 
issues. Greater policy and institutional support is required to help stakeholders strike 
that “fine balance” and ultimately make better prescribing decisions. This study 
provides us with a deeper understanding of this complex issue and will inform the 
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Appendix 1. Search Strategy for Chapter 2 
Medline (OVID) 
1. Elderly.mp. OR “care of the elderly”.mp. OR “old age”.mp. OR “geriatric patients”.mp. 
OR exp Aged/ OR exp “Aged, 80 and over”/ OR exp Frail Elderly/ OR exp Age Factors/ 
OR exp Health Services for the Aged/ OR exp Geriatrics/ OR exp Aging/ OR exp 
Dementia/ OR exp Alzheimer Disease/ 
2. “Medication appropriateness index”.mp. OR “screening tool of older persons 
prescriptions”.mp. OR “screening tool to alert doctors to right treatment”.mp. OR 
“assessing care of vulnerable elders”.mp. OR “potentially inappropriate 
prescribing”.mp. OR “potentially inappropriate medication”.mp. OR “inappropriate 
medication”.mp. OR “beers criteria”.mp. OR exp Inappropriate Prescribing/ OR 
“suboptimal prescribing” OR underprescribing.mp. OR overprescribing.mp. 
3. Exp Secondary Care/ OR exp Emergency Service, Hospital/ OR exp Patient Discharge/ 
OR exp Hospitalization/ OR exp Hospitals/ OR exp Patient Admission/ OR exp Academic 
Medical Centers/ OR exp Hospital Units/ OR exp Internal Medicine/ OR “hospital 
patient”.mp. OR hospitali*ed.mp. OR exp Inpatients/ 
4. 1 AND 2 AND 3 
 
PubMed 
1. "geriatric nursing"[MeSH Terms] OR "pharmacies"[MeSH Terms] OR 
"pharmacists"[MeSH Terms] OR "professional role"[MeSH Terms] OR 
"physicians"[MeSH Terms] OR "patient care team"[MeSH Terms] OR "clinical 
pharmacy"[All Fields] OR "hospital pharmacist"[All Fields] OR "hospital pharmacy"[All 
Fields] OR "pharmacy"[MeSH Terms]  OR pharmacist* [All Fields] OR "multi-disciplinary 
team"[All Fields] OR "medical specialist"[All Fields]  
2. "medication appropriateness index"[All Fields] OR "screening tool to alert doctors to 
right treatment"[All Fields]) OR "assessing care of vulnerable elders"[All Fields] OR 
"potentially inappropriate prescribing"[All Fields] OR "beers criteria"[All Fields] OR 
"suboptimal prescribing"[All Fields] OR underprescribing [All Fields] OR 
overprescribing[All Fields] OR "inappropriate prescribing"[MeSH Terms] OR 
"inappropriate medication"[All Fields] OR "potentially inappropriate medication"[All 
Fields] 
3. "pharmaceutical services"[MeSH Terms]  OR "pharmaceutical care"[All Fields] OR 
"medical care"[All Fields] OR "screening"[All Fields] OR "drug monitoring"[MeSH 
Terms] OR "patient counseling"[All Fields] OR "patient counselling"[All Fields] OR 
"continuity of patient care"[MeSH Terms] OR "decision support techniques"[MeSH 
Terms] OR "evidence-based medicine"[MeSH Terms] OR "health promotion"[MeSH 
Terms] OR "practice guidelines as topic"[MeSH Terms] OR "self care"[MeSH Terms] OR 
"drug interactions"[MeSH Terms] OR "medication therapy management"[MeSH Terms] 
OR "integrated medicines management"[All Fields] OR "drug administration"[All Fields] 
OR "patient satisfaction"[MeSH Terms] OR "case management"[MeSH Terms] OR "drug 
therapy"[MeSH Terms] OR "drug utilisation review"[All Fields] OR "drug utilization 
review"[MeSH Terms] OR "pharmaceutical services"[MeSH Terms] OR "pharmacy 
service"[All Fields] OR "drug prescriptions"[MeSH Terms] OR "polypharmacy"[MeSH 
Terms] OR "medication errors"[MeSH Terms] OR "medication reconciliation"[MeSH 
Terms] OR "pharmaceutical preparations"[MeSH Terms] OR "quality assurance, health 
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care"[MeSH Terms] OR "risk factors"[MeSH Terms] OR "geriatric assessment"[MeSH 
Terms] OR "health services misuse"[MeSH Terms] OR "drug utilisation"[All Fields] OR 
"drug utilization"[MeSH Terms] OR "drug-related side effects and adverse 
reactions"[All Fields] OR "interdisciplinary studies"[MeSH Terms]  OR "interdisciplinary 
communication"[MeSH Terms] OR "clinical pharmacy information systems"[MeSH 
Terms] OR "decision support systems"[All Fields] OR "drug information services"[MeSH 
Terms] OR "physician's practice patterns"[MeSH Terms]  
4. “aged"[MeSH Terms] OR "elderly"[All Fields] "age"[All Fields] OR "frail elderly"[MeSH 
Terms] OR "dementia"[MeSH Terms] OR "health services for the aged"[MeSH Terms] 
OR "geriatrics"[MeSH Terms] OR "old age"[All Fields] OR "elderly care"[All Fields] OR 
"geriatric patients"[All Fields] OR "geriatric disorder"[All Fields] OR "aging"[MeSH 
Terms] OR "age factors"[MeSH Terms]  
5. “secondary care"[MeSH Terms] OR "emergency service, hospital"[MeSH Terms] OR 
"patient discharge"[MeSH Terms] OR "hospitalisation"[All Fields] OR 
"hospitalization"[MeSH Terms] OR "hospitals"[MeSH Terms OR "patient 
admission"[MeSH Terms] OR "academic medical centers"[MeSH Terms] OR "hospital 
units"[MeSH Terms] OR "internal medicine"[MeSH Terms] OR "hospital patient"[All 
Fields] OR "patient readmission"[MeSH Terms] OR hospitalized[All Fields]) OR 
hospitalized [All Fields] OR "inpatients"[MeSH Terms]  
6. “intervention studies"[MeSH Terms] OR "clinical trials as topic"[MeSH Terms] OR 
"randomized controlled trials as topic"[MeSH Terms] OR ("research design"[MeSH 
Terms] OR "single-blind method"[All Fields] OR "follow-up studies"[All Fields] OR 
"prospective studies"[MeSH Terms] OR "health services research"[MeSH Terms] OR 
"random allocation"[MeSH Terms] OR "randomization"[All Fields] OR 
randomisation[All Fields] OR "control groups"[MeSH Terms]  
7. 1 AND 2 AND 3 AND 4 AND 5 AND 6 
 
EMBASE 
1. ((('dementia'/exp or 'dementia') or ('alzheimers disease'/exp or 'alzheimers disease')) 
or (('aged'/exp or 'aged') or ('aging'/exp or 'aging') or ('geriatric disorder'/exp or 
'geriatric disorder') or ('geriatric patient'/exp or 'geriatric patient') or ('elderly care'/exp 
or 'elderly care') or ('old age'/exp or 'old age') or ('elderly'/exp or 'elderly') or 
('geriatrics'/exp or 'geriatrics') or ('frail elderly'/exp or 'frail elderly') or ('age 
factors'/exp or 'age factors'))) 
2. (('internal medicine'/exp or 'internal medicine') or ('hospital admission'/exp or 
'hospital admission') or ('hospital department'/exp or 'hospital department') or 
('hospital discharge'/exp or 'hospital discharge') or ('hospital'/exp or 'hospital') or 
('hospitalization'/exp or 'hospitalization') or ('hospital patient'/exp or 'hospital 
patient') or ('emergency ward'/exp or 'emergency ward') or ('university hospital'/exp 
or 'university hospital') or ('hospital readmission'/exp or 'hospital readmission') or 
('hospital utilization'/exp or 'hospital utilization') or ('emergency care'/exp or 
'emergency care') or ('ward'/exp or 'ward') or ('secondary care'/exp or 'secondary 
care') or hospitali*ed or inpatient*)  
3. (('controlled study'/exp or 'controlled study') or ('follow up'/exp or 'follow up') or 
('intention to treat analysis'/exp or 'intention to treat analysis') or ('major clinical 
study'/exp or 'major clinical study') or ('randomized controlled trial'/exp or 
'randomized controlled trial') or ('health services research'/exp or 'health services 
research') or ('control group'/exp or 'control group') or ('clinical trial'/exp or 'clinical 
trial') or ('evaluation study'/exp or 'evaluation study') or ('controlled clinical trial'/exp 
or 'controlled clinical trial') or ('intervention study'/exp or 'intervention study') or 




4. (('clinical pharmacy'/exp or 'clinical pharmacy') or ('physician'/exp or 'physician') or 
('pharmacy'/exp or 'pharmacy') or ('pharmacist'/exp or 'pharmacist') or ('hospital 
pharmacy'/exp or 'hospital pharmacy') or ('medical specialist'/exp or 'medical 
specialist') or pharmacist* or ('pharmacies'/exp or pharmacies) or 'multidisciplinary 
team') 
5. (('inappropriate prescribing'/exp or 'inappropriate prescribing') or 'medication 
appropriateness index' or 'screening tool of older persons prescriptions' or 'screening 
tool to alert doctors to right treatment' or 'assessing care of vulnerable elders' or 
inappropriate next/1 medic* or overprescribing or underprescribing or 'beers criteria' 
or 'suboptimal prescribing')  
6. (('medical care'/exp or 'medical care') or ('pharmaceutical care'/exp or 'pharmaceutical 
care') or ('screening'/exp or 'screening') or ('drug therapy'/exp or 'drug therapy') or 
('prevention'/exp or 'prevention') or ('prescription'/exp or 'prescription') or 
('professional standard'/exp or 'professional standard') or ('interpersonal 
communication'/exp or 'interpersonal communication') or ('risk reduction'/exp or 'risk 
reduction') or ('risk factor'/exp or 'risk factor') or ('consultation'/exp or 'consultation') 
or ('health care utilization'/exp or 'health care utilization') or ('drug response'/exp or 
'drug response') or ('drug use'/exp or 'drug use') or ('patient care'/exp or 'patient care') 
or ('drug'/exp or 'drug') or ('health care delivery'/exp or 'health care delivery') or 
('health care facility'/exp or 'health care facility') or ('health care quality'/exp or 'health 
care quality') or ('health care utilization'/exp or 'health care utilization') or ('medical 
assessment'/exp or 'medical assessment') or ('medical information'/exp or 'medical 
information') or ('drug information'/exp or 'drug information') or 'lund integrated 
medicines management model' or ('health program'/exp or 'health program') or 
('medication therapy management'/exp or 'medication therapy management') or 
('patient counseling'/exp or 'patient counseling') or ('polypharmacy'/exp or 
'polypharmacy') or ('evidence based medicine'/exp or 'evidence based medicine') or 
('medication reconciliation'/exp or 'medication reconciliation') or ('health 
promotion'/exp or 'health promotion') or ('pharmaceutical services'/exp or 
'pharmaceutical services') or ('pharmacy service'/exp or 'pharmacy service') or 
collaboration or ('team work'/exp or 'team work')) 
7. 1 AND 2 AND 3 AND 4 AND 5 AND 6 
 
Centre for Reviews and Dissemination 
1. (ward pharmacist) OR (geriatric nursing) OR MeSH DESCRIPTOR Geriatric Nursing 
EXPLODE ALL TREES OR (pharmacies) OR (pharmacists) OR (pharmacist) OR (pharmacy) 
OR (professional role) OR (physicians) OR (patient care team)  
2. (inappropriate prescribing) OR (potentially inappropriate prescribing) OR MeSH 
DESCRIPTOR Inappropriate Prescribing EXPLODE ALL TREES OR (medication 
appropriateness index) OR (beers criteria) OR (stopp/start) OR (stopp) OR 
(screening tool to alert doctors to right treatment) OR (screening tool of older persons 
prescriptions) OR (overprescribing) OR (underprescribing) OR (suboptimal prescribing) 
OR (acove) OR (assessing care of vulnerable elders) OR (inappropriate medication) OR 
(inappropriate medications) OR (inappropriate medication*) OR (priscus) OR 
(prescribing criteria) OR (screening tools for the elderly)  
3. 1 AND 2 
 
Cochrane Database of Systematic Reviews 
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1. MeSH descriptor: [Geriatric Nursing] explode all trees, OR MeSH descriptor: 
[Pharmacies] explode all trees, OR MeSH descriptor: [Pharmacists] explode all trees, OR 
MeSH descriptor: [Professional Role] explode all trees OR MeSH descriptor: [Physicians] 
explode all trees OR MeSH descriptor: [Patient Care Team] explode all trees OR clinical 
pharmacy OR  hospital pharmacy OR multidisciplinary OR interdisciplinary  
2.  MeSH descriptor: [Inappropriate Prescribing] explode all trees OR inappropriate 
prescribing OR "medication appropriateness index" OR "screening tool to alert doctors 
to right treatment" OR "beers criteria" OR potentially inappropriate prescribing OR 
suboptimal prescribing OR over-prescribing OR under-prescribing  
3. MeSH descriptor: [Aged] explode all trees OR MeSH descriptor: [Aged, 80 and over] 
explode all trees OR MeSH descriptor: [Frail Elderly] explode all trees OR MeSH 
descriptor: [Health Services for the Aged] explode all trees OR MeSH descriptor: 
[Geriatrics] explode all trees OR old age OR old OR aging OR elderly OR MeSH 
descriptor: [Dementia] explode all trees OR MeSH descriptor: [Alzheimer Disease] 
explode all trees 
4. MeSH descriptor: [Patient Discharge] explode all trees OR MeSH descriptor: [Hospitals] 
explode all trees OR MeSH descriptor: [Patient Admission] explode all trees OR MeSH 
descriptor: [Academic Medical Centers] explode all trees OR MeSH descriptor: [Hospital 
Units] explode all trees OR MeSH descriptor: [Secondary Care] explode all trees OR 
secondary care OR hospitalization OR university hospital  OR geriatric ward  OR 
emergency department OR hospital OR secondary care setting  
5. 1 AND 2 AND 3 AND 4 
 
CINAHL 
1. alzheimer's disease OR  dementia OR frail elderly OR geriatrics OR age factors  OR aged, 
80 and over  aged OR old age OR health services for the aged OR care of the 
elderly OR elderly care OR "geriatric patient" OR "geriatric disorder" OR aging 
2. academic medical centers OR emergency department OR "care of the elderly ward" OR 
geriatric ward OR secondary health care OR "secondary care setting" OR secondary 
care OR patient admission OR hospitals OR patient discharge OR readmission OR 
inpatients OR hospitalization  OR hospital units 
3. overprescribing OR underprescribing  OR "suboptimal prescribing” OR 
"potentially inappropriate medication" OR "potentially inappropriate prescribing" OR 
"assessing care of vulnerable elders" OR “screening tool of older persons prescriptions” 
OR "screening tool to alert doctors to right treatment" OR beers criteria OR 
"medication appropriateness index” OR inappropriate prescribing  
4. 1 AND 2 AND 3 
 
Web of Science 
1. Inappropriate prescribing OR potentially inappropriate prescribing 
2. Patient discharge OR hospitalization OR hospitals OR patient admission OR academic 
medical centers OR hospital units 
3. Dementia OR alzheimers disease OR aged OR frail elderly OR age factors OR health 
services for the aged OR geriatrics 
4. Pharmacies OR pharmacists OR patient care team 
5. Prospective studies OR single-blind method OR follow-up studies OR health services 
research OR randomized 
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6. 1 AND 2 AND 3 AND 4 AND 5 
 
Science Direct 
1. "clinical pharmacy" OR physician OR pharmacy OR pharmacist OR "hospital pharmacy" 
OR "medical specialist"  
2. "medical care" OR "pharmaceutical care" OR screening OR "drug therapy" OR 
prevention OR prescription OR "professional standard" OR "interpersonal 
communication" OR "risk reduction" OR  "risk factor" OR consultation OR "health care 
utilization" OR "drug response" OR "drug use" OR  "patient care" OR drug OR "health 
care delivery" OR "health care facility" OR "health care quality" OR "medical 
assessment" OR "medical information" OR "drug monitoring" OR "integrated 
medicines management" OR "health program" OR "medication therapy management" 
OR "patient counseling" OR polypharmacy OR "evidence based medicine"  
3. "inappropriate prescribing" OR "medication appropriateness index" OR "screening tool 
of older persons prescriptions" OR "screening tool to alert doctors to right treatment" 
OR "assessing care of vulnerable elders" 
4. aging OR "geriatric disorder" OR "geriatric patient" OR "elderly care" OR dementia OR 
"alzheimers disease" 
5. "internal medicine" OR "hospital admission" OR "hospital department" OR "hospital 
discharge" OR hospital OR "surgical ward" OR hospitalization OR "hospital patient" OR 
"emergency ward" OR "university hospital" OR "hospital readmission" OR "hospital 
utilization" OR "emergency care" OR ward  
6. "controlled study" OR "follow up" OR "intention to treat analysis" OR "major clinical 
study" OR "randomized controlled trial" OR "health services research" OR "control 
group" OR "clinical trial" OR "evaluation study" OR "controlled clinical trial" OR 
"intervention study" OR randomization OR "prospective study" 




ClinicalTrials.gov and metaRegister of Clinical Trials 
“Medication appropriateness index” OR “beers criteria” OR “screening tool of older persons 
prescriptions” OR “screening tool to alert doctors to right treatment” OR “inappropriate 





ProQuest Dissertation and Theses 
1. "prospective study" OR "randomized controlled trial" OR "randomised controlled trial" 
OR "single-blind" OR "follow-up studies" OR "cohort studies" OR "health services 
research" OR "controlled study" OR "intervention study" 
2. "patient discharge" OR hospitals OR "patient admission" OR "academic medical 
centers" OR "hospital units" OR "secondary care" OR hospitalization OR "university 
hospital" OR "geriatric ward" OR "emergency department" OR "secondary care setting" 
3. aged OR "frail elderly" OR "health services for the aged" OR geriatrics OR "old age" OR 
aging OR elderly OR dementia OR alzheimers disease  
4. "inappropriate prescribing" OR "potentially inappropriate prescribing" OR "medication 
appropriateness index" OR "screening tool to alert doctors to right treatment" OR 
"screening tool of older persons prescriptions" OR "beers criteria" OR "suboptimal 
prescribing" 
5. pharmacies OR pharmacist* OR "patient care team" OR "clinical pharmacy" OR 
"hospital pharmacy" OR multidisciplinary OR multidisciplinary OR interdisciplinary 
6. 1 AND 2 AND 3 AND 4 AND 5 
 
Index to Theses in Great Britain and Ireland 
“Inappropriate prescribing” OR “potentially inappropriate prescribing” OR stopp/start OR “beers 
criteria” OR “medication appropriateness index” OR “suboptimal prescribing” 
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Appendix 2. Search Strategy for Chapter 4 
PubMed 
  
1 "neuropsychiatric symptoms"[Title/Abstract] OR "neuropsychiatric 
symptom"[Title/Abstract] OR challenging behaviour[Title/Abstract] OR challenging 
behaviours[Title/Abstract]) OR "challenging behaviour"[Title/Abstract] OR 
"challenging behavior"[Title/Abstract] OR challenging behavior*[Title/Abstract] OR 
"behavioural and psychological symptoms of dementia"[Title/Abstract] OR 
"behavioral and psychological symptoms of dementia"[Title/Abstract] OR 
alzheimer*[Title/Abstract] OR "bpsd"[Title/Abstract] OR "alzheimer disease"[MeSH 
Terms] OR alzheimer disease[Title/Abstract] OR "dementia"[MeSH Terms] OR 
dementia[Title/Abstract] 
2  "prescriptions"[MeSH Terms] OR prescriptions[Title/Abstract] OR 
deprescribing[Title/Abstract] OR "inappropriate prescribing"[MeSH Terms] OR 
inappropriate prescribing[Title/Abstract] OR prescrib*[Title/Abstract] 
3 "antipsychotic agents"[MeSH Terms] OR "chemical restraint"[Title/Abstract] OR 
"pharmacological intervention"[Title/Abstract] OR antipsychotic 
agents[Title/Abstract]) OR neuroleptic*[Title/Abstract] OR "psychotropic 
drugs"[MeSH Terms] OR psychotropic drugs[Title/Abstract] OR 
psychotropic*[Title/Abstract]) OR anti psychotic*[Title/Abstract] 




1 'dementia'/mj OR 'alzheimer disease'/mj OR bpsd:ab,ti OR 'behavioural and 
psychological symptoms of dementia':ab,ti OR 'behavioral and psychological 
symptoms of dementia':ab,ti OR (challen* NEXT/1 behav*):ab,ti OR 
alzheimer*:ab,ti 
OR 'neuropsychiatric symptoms':ab,ti OR 'neuropsychiatric symptom':ab,ti OR 
dementia:ab,ti 
2 'neuroleptic agent'/mj OR 'psychotropic agent'/mj OR antipsychotic*:ab,ti OR 
neuroleptic*:ab,ti OR psychotropic*:ab,ti OR  'chemical cosh':ab,ti OR 
'tranquilizer'/mj OR 'pharmacological intervention':ab,ti OR 'chemical 
restraint':ab,ti  
3 'prescription'/mj OR 'inappropriate prescribing'/mj OR prescrib*:ab,ti OR 
deprescribing:ab,ti 









MEDLINE (through OVID)  
 
1  exp Dementia/ OR exp Alzheimer Disease/ OR dementia.ti,ab. OR 
alzheimer*.ti,ab. OR BPSD.ti,ab. OR "behavioural and psychological symptoms of 
dementia".ti,ab. OR "behavioral and psychological symptoms of dementia".ti,ab. 
OR (challeng* adj1 behav*).ti,ab. OR "neuropsychiatric symptoms".ti,ab. OR 
"neuropsychiatric symptom".ti,ab. 
2 exp Antipsychotic Agents/ OR  exp Psychotropic Drugs/ OR antipsychotic*.ti,ab. OR 
psychotropic*.ti,ab. OR neuroleptic*.ti,ab. OR anti-psychotic*.ti,ab. OR 
"pharmacological intervention".ti,ab. OR "chemical restraint".ti,ab. OR "chemical 
cosh".ti,ab.  
3 exp Drug Prescriptions/ OR  exp Inappropriate Prescribing/ OR  prescrib*.ti,ab. OR 
deprescribing.ti,ab.  
4 1 AND 2 AND 3 
 
Academic Search Complete/CINAHL Plus/PsycINFO (EBSCO)  
 
1 SU dementia OR TI dementia OR AB dementia OR SU alzheimer disease OR TI 
alzheimer disease OR AB alzheimer disease OR  SU alzheimer* OR TI 
alzheimer* OR AB alzheimer* OR SU bpsd OR TI bpsd OR AB bpsd OR SU (challeng* 
N1 behav*) OR TI (challeng* N1 behav*) OR AB (challeng* N1 behav*) OR SU ( 
"behavioural and psychological symptoms of dementia" ) OR TI ( "behavioural and 
psychological symptoms of dementia" ) OR AB ( "behavioural and psychological 
symptoms of dementia" ) OR SU ( "behavioral and psychological symptoms of 
dementia" ) OR TI ( "behavioral and psychological symptoms of dementia" ) OR AB 
( "behavioral and psychological symptoms of dementia" ) OR SU "neuropsychiatric 
symptoms" OR TI "neuropsychiatric symptoms" OR AB "neuropsychiatric 
symptoms" OR SU "neuropsychiatric symptom" OR TI "neuropsychiatric symptom" 
OR AB "neuropsychiatric symptom"   
2 SU ANTIPSYCHOTIC AGENTS OR TI ANTIPSYCHOTIC AGENTS OR AB ANTIPSYCHOTIC 
AGENTS OR SU antipsychotic* OR TI antipsychotic* OR AB antipsychotic* OR SU 
psychotropic drugs OR TI psychotropic drugs OR AB psychotropic drugs OR  SU 
psychotropic* OR TI psychotropic* OR AB psychotropic* OR SU neuroleptic* OR TI 
neuroleptic* OR AB neuroleptic* OR SU anti-psychotic* OR TI anti-psychotic* OR 
AB anti-psychotic*  OR SU "pharmacological intervention" OR TI 
"pharmacological intervention" OR AB "pharmacological intervention" OR SU 
"chemical restraint" OR TI "chemical restraint" OR AB "chemical restraint" OR SU 
"chemical cosh" OR TI "chemical cosh" OR AB "chemical cosh"  
3 SU prescribing OR TI prescribing OR AB prescribing OR SU inappropriate prescribing 
OR TI inappropriate prescribing OR AB inappropriate prescribing OR SU prescrib* 
OR TI prescrib* OR AB prescrib* OR SU deprescribing OR TI deprescribing 
OR AB deprescribing   











4 “Qualitative Research” 
5 1 AND 2 AND 3 AND 4 
 
Journals Hand Searched and Alzheimer's Societies Contacted 
Journals (Nov 2015 – July 2016) International Alzheimer’s  
Societies (contacted March 2016) 
International Psychogeriatrics Alzheimer’s Society of Ireland 
International Journal of Geriatric 
Psychiatry 
Alzheimer Society UK 
Age and Aging Alzheimer Disease International 
Dementia: International Journal 
of social research and practice 
Alzheimer’s Association  
Alzheimer’s and Dementia: The 
Journal of the Alzheimer’s 
Association 
Alzheimer Society of Canada 
Alzheimer’s and Dementia: 
translational research and  
clinical interventions 
Alzheimer’s New Zealand 
Aging and mental health Alzheimer’s Australia 
Journal of the American  Medical 
Directors Association 
 
Journal of clinical nursing  
Journal of the American 
Geriatrics Society 
 
Drugs and Aging  
British Journal of Psychiatry  
Social Science and Medicine  
Implementation Science  
BMJ open  
American Journal of Alzheimer’s 
& Other Dementias 
 






Appendix 3. ENTREQ Statement for Chapter 4 
Item Guide and description 
 
1. Aim To synthesize the findings from individual qualitative studies in order 
to develop novel interpretations of the influences on decision-making 
regarding the prescribing of antipsychotics in nursing home residents 
with dementia, with a view to informing intervention development and 
quality improvement in this field. 
2. Synthesis 
methodology 
Meta-ethnography as described by Noblit & Hare.  This systematic 
interpretive approach was chosen as it is particularly useful for 
generating new theories or concepts, which can ultimately influence 
policy and practice 
3. Approach to 
searching 
Pre-planned, comprehensive search strategy to seek all available 
studies in the published literature according to a pre-planned, online 
PROSERO protocol (protocol registration CRD42015029141) 
4. Inclusion criteria Phenomenon of Interest: Antipsychotic prescribing in nursing home 
residents with dementia for the purpose of managing BPSD 
Population: Any person (healthcare professional, carer, patient) 
discussing the phenomenon of interest 
Language:  English-language only 
Year: No exclusion based on year of publication 
Types of studies:  Primary studies using qualitative research methods 
of data collection and data analysis, including mixed-methods studies. 
Articles published in full in peer-reviewed journals 
5. Data sources Electronic Databases: Medline (through OVID), PubMed, EMBASE, 
CINAHL, PsycINFO and Academic Search Complete. 
Supplementary methods: Hand-searching key journals and conference 
proceedings, citation searching of highly cited key papers, scanning 
reference lists of key papers and by contacting authors of relevant 
conference abstracts. 
Grey literature search:  Google Scholar and by consulting the websites 
and key personnel from the various international Alzheimer’s Societies 
(Appendix 2) 
Last search July 2018.  
An exhaustive search of the literature was conducted. 
6. Electronic search 
strategy 
Search strategy is described in detail in Appendix 2 
7. Study screening 
methods 
For the first stage of study selection, one reviewer (KW) conducted a 
preliminary screening of titles to exclude citations that were clearly not 
relevant (e.g. pre-clinical studies, systematic reviews). For the second 
stage, two reviewers (KW & RD) independently screened titles and 
abstracts, against inclusion criteria, to identify potentially relevant 
papers. In the third stage, two reviewers (KW & RD) independently 
reviewed the full texts of papers. Consensus on inclusion in stages two 
and three was reached by discussion between reviewers, with 
arbitration by a senior supervisor if required  
8. Study 
characteristics 
Details of the study characteristics are provided in Chapter 4. 
9. Study selection 
results 
Chapter 4 outlines the study selection process in a PRISMA flow 
diagram.  
10.  Rationale for 
appraisal 
The purpose of quality appraisal was to assess the quality of study 
conduct.  
11.  Appraisal items The CASP tool was used to appraise the included studies  
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12.  Appraisal process The quality assessment was conducted independently by two 
reviewers (KW & JB) and consensus reached by discussion. 
13.  Appraisal results Study quality assessments are available in Chapter 4. We did not 
exclude studies on the basis of quality, as we believed all studies may 
still contribute some important insights to our phenomenon of 
interest. Critical weaknesses in study conduct were captured in the 
CERQual assessments and may have lessened confidence in certain 
review findings (Chapter 4). 
14.  Data extraction All content in the results, discussion and conclusion sections of 
included papers were considered as data for analysis. These data were 
extracted onto a standardised word document by two reviewers 
independently, any discrepancies were resolved by discussion and 
then the data were uploaded onto a computer software programme.  
Information regarding: date of publication, country of conduct, setting, 
study objectives, participants, methodology, method of data collection 
and data analysis were extracted from the included studies and is 
presented in Chapter 4 to provide contextual information.  
15.  Software NVivo version 11 
16.  Number of 
reviewers 
Four reviewers were involved in reading all included studies in detail 
and constructing the initial key concepts (KW, RD, EC & CS). All 8 
reviewers were involved in the translation and synthesis steps. 
17.  Coding Comprehensive, line by line coding to search for concepts 
18.  Study comparison In line with the constant comparative method of qualitative analysis 
the data were compared and contrasted across primary studies, to 
identify similarities and disagreements. Overarching concepts that 
represented the entire dataset were formulated after initial readings 
of the included papers. The specific contribution of each paper to each 
key concept was then determined (Appendix 4) 
19.  Derivation of 
themes 
The process of developing the key concepts and sub-themes was 
inductive and iterative, moving from specific observations to broader 
generalizations or theories. 
20.  Quotations Direct quotes from participants, and the interpretations of the authors 
of the primary studies are presented in the results section of the 
manuscript and in more detail in Appendix 4. 
21.  Synthesis output Novel third-order interpretations were synthesized, which were 
subsequently linked together to develop a ‘line of argument’ 
representing the influences on decision-making regarding the 
prescribing of antipsychotics to nursing home residents with dementia. 
A conceptual model which illustrates this line of argument is presented 
in Chapter 4.  
CASP, The’ Critical Appraisal Skills Programme assessment tool for qualitative 
research’; CERQual, ‘Confidence in Evidence from Reviews of Qualitative Research’; 
PRISMA, ‘Preferred Reporting Items for Systematic Reviews and Meta-Analyses’; 





Appendix 4. Translation between Included Studies for Chapter 4 
Author 
(year) 
Organisational Capacity Individual Professional Capability Communication & Collaboration Attitudes towards people with dementia and 






access to services 
Coping with the 
Severity of  
Behaviours 
Skills Knowledge Communication 
within the 
healthcare team 
and with the family  
Clarity of Roles & 
Responsibilities 
Personal Attitudes  Organizational & 








are so terrible. He has 
it in him to kill 
somebody; it’s scary. I 
don’t think he’d mean 
to, he just doesn’t 
understand. He gets 
mad enough. I’ve 
caught him choking 
another resident in 
our dining room area, 
where the little quiet 
ladies sit, he was 
choking one of those 
little ladies. It’s 
happened a number of 
times.” (NH Staff  
member) (Page 111) 
 
A sense of 
‘helplessness’ 




severe, when the 
resident has a true or 
suspected psychiatric 
comorbidity, and/ or 
when the size and 
Physical aggression 
is the most difficult 
behaviour to 
manage, yet SCU 
[Specialist Care 
Unit] staff members 
in this study 
reported that they 






interventions.  This 
may be because of 




some external event 
and are therefore 
predictable. (Page 
120)  
“We actually had 
more family history 
on him [the 
successful resident], 
even though his wife 
was not here a lot, 
plus he had hobbies 
and things that we 
could zero in on. On 
the other hand, the 
other resident was a 
bachelor and lived 
by himself; the 
family didn’t know 
him well. . . . That 
might have had 
some bearing on our 
success.” (NH Staff 












“Always, at any 
point in time, there 
was support from 
the family… They 
gave us a lot of 
background 
information on this 
particular resident, 
and that’s so very 
important... He [the 
husband] is there 
daily and is very 
supportive. It’s nice 
to see that he can 
see her through the 
dementia.” (NH 







through visits with 
the resident and 
communication with 
the staff, and that 
family support was 
critical to successful 
behaviour 
- “…When he gets really 
bad, I just wish we had 
a padded room we 
could lock him in and 
let him go.” (NH Staff 
member) (Page 116) 
  
“‘We learned not to 
force her into doing 
things, but to let her 
decide when she 
was ready. For 
example, just 
because everybody 
else ate at 7:00 
didn’t mean that 
she had to get up 
and eat then.” (NH 















‘‘So you know a 
specialist, 
somebody coming 
in there and 
looking at all the 
medication you 
know who knows 
medication, the 
pharmacology 
inside out, outside 
in, that’s their job 
[a pharmacist], 
that’s bound to be 










supported by all 
participants. 
(Page 520) 
- - ‘‘Cause you know 
the resident, you’re 
working with them, 
you see the 





The majority of 
nurse participants 
agreed that nurses 
were well placed to 
assess a resident’s 
pharmaceutical care 
needs. (Page 523) 
‘‘I think it’s 
important to go 
back to the 
prescriber and say 
‘look do you realise 







recognised the need 
to involve the 
prescribing GP in 
the pharmaceutical 
care process and 
this will require the 
establishment of 
pragmatic lines of 
communication. 
(Page 523) 




enforced on me, 
you know, I would 
have thought a 
consultant 
geriatrician 
would’ve sort of 
drastically cut 
drugs, you know, 
but whenever we 
get discharge 
from physicians or 
more you still find 
there are 6, 7, 8, 










Advocate) (Page 520) 
 
Many participants 
raised concerns over 
the use of these 
[antipsychotic] drugs, 
particularly with 
regard to their 
potential to cause 
adverse reactions with 
serious consequences 
for the elderly e.g. 
over-sedation and 
falls. (Page 520) 
 
 
‘‘Doctors have said 
to me-‘look I don’t 
really want to 
prescribe 
temazepam, but 
they [nursing staff] 
want it and it’s very 
difficult to refuse so 
9 times out of 10 














these drugs were 
prescribed for the 
convenience of 
nursing staff, which 
was also reported 






“If you go to do 




it’s a lot of man 
power- sort of 
“I think that at all 
levels homes are 
dealing with a greater 
level of illness and 
disturbance than they 
were designed for.” 
“Yeah, the difficulty 
is, you know, there 
are good homes and 
bad homes, and 
often staff, both in 
terms of numbers of 
staff and their 
“I think it’s actually 
more of a problem 
of application of 
evidence actually. I 
think most of my 
colleagues would be 
aware of the 
“Umm, and I would 
personally say [to a 
colleague], ‘‘What 
[psychotropic] do 
you use? Do you use 
this a lot? Any 
problems you’ve 
“It’s actually quite 
difficult 
sometimes to say 
to staff ‘well I’m 
not gonna give 
you any 
medication’ cos 
“I think there’s a 
tendency to just to say 
well if someone has a 
dementia then the 
symptoms they’re 
presenting with are 
just down to BPSD, it’s 
“Depending on 
which home you go 
to, there’s probably 




“There are times when 
I do go against the 
guidelines and do 
prescribe 
[Haloperidol]. But 
when there’s been 





coming back and 
checking, 
education for the 












A number of 
participants 






because using the 
medical model 
was seen as 
potentially a 







believed that in order 
to reduce prescribing 
for this group, issues 
had to be addressed, 
particularly the nature 
and culture of care 
settings... (Page 551) 




The nature of care 
settings was viewed 




often the result of … 
inadequate staff 
training… (Page 548) 
 
limitations of the 













where they believed 
there was no 
alternative [to 
antipsychotics] to 
offer. (Page 551) 
found with it.” 









medications to use, 
asking for advice on 









condition, where I’ve 
never believed that is 
the case. It almost 
seduces you to 





A number of 
participants had an 
issue with regard to 
the concept of BPSD, 
believing it to be too 
broad. Owing to the 
use of such a poorly 
defined term, the 
psychiatrists believed 
that many ‘unusual’ 
behaviours could 
potentially be labelled 
as BPSD, thus meaning 
people missed the real 
cause of the 
behaviour (e.g. pain). 
(Page 548) 
 
All participants felt 
strongly that there 






varied in intensity. 
Psychiatrists 
thought the 
pressure from staff 














What was more 
influential was past 
experience of a drug, 
although guidelines 
such as (Crosswalk 
Student Ministry) CSM 
were taken into 
account. (Page 551) 
Kolanows
ki (2009)  
“…Getting the 
interventions out 
there even in the 
middle of the 





“They don’t keep 
residents in the 
hospital a long time. 
So you know you’re 
dealing with a lot of 
medical things. That 
unfortunately has to 
be our priority and the 
poor resident that’s 
“I don’t think that 
new CNAs [certified 
nursing assistants] 
come out of class 





“We’re learning new 
stuff all the time 
from the way that 
nursing homes used 
to be in the early 
80’s and how we 
treated residents 
with dementia. I 
mean they were all 
Interdisciplinary 
approaches to BPSD 
are quite effective, 
but there was scant 
evidence that these 
care providers were 
functioning as a 








Nurses and CNAs 
are at the bedside 
around the clock; 
“Just a little touch of 
something 
(medication) is helping 
her get to activities, 
not crying, not upset 
all evening and night 
you know ... So I don’t 
think no 
pharmacology 
“We don’t tie them 
down. We find other 
ways.” (NH Staff 





and culture change, 
“The first time I took 
[the restraint off] the 
resident fell and broke 
their hip. Again that 
was in ’89 with OBRA 
when we first started, 
but I had to learn to 
take safety off the top 













first ordered for 
the BPSD because 
there is 
insufficient staff 
at these times to 




here with dementia is 
sort of left 
behind.”(NH Staff 
member) (Page 216) 
 
The rise in resident 
acuity level 
necessitates a careful 
balance of chronic and 
acute care in the same 
environment, and 
impacts the amount of 
time staff is able to 
spend with long-term 
residents. (Page 216) 
residents… they 
don’t seek to 
understand the 
behaviour; they just 
try to address it and 
I think that’s when 
you come up on 













emotions and to 
deal with BPSD. A 
majority 
emphasized that a 
lack of “education in 
terms of dealing 
with persons with 
behavioral 
management 














that physical and 
chemical restraints 
are now regulated 
and that nursing 
homes need to 
provide 
individualized care 
when responding to 
BPSD. (Page 216) 




not. (Page 219) 
whatsoever is the 
answer.” (NH Staff 
member) (Page 218) 
 
The findings of this 
study confirm the 
nursing home staff’s 
perceptions of 
pharmacological 
intervention as an 
efficient and reliable 
intervention to control 
behaviours in order to 
promote a calm 
environment for 
others. (Page 219) 
for many staff the 
goal of care hasn’t 
changed; control of 
behaviour is still a 
priority. Page 216) 
quality of life up there 
and put safety down 
here further.” (NH 





culture change are 
driving forces in the 
nursing home, setting 
the standard for 











The need for 
continued mental 
health training of 
staff… render[s] 
psychopharmacolog
Focus group data 
suggest that the NH 
staff are reasonably 
knowledgeable 
about how to 
“Teamwork is key”. 
(NH Staff  member) 
(Page 908) 
 
“We often get 
dementia patients 
doped up from 
the hospital. It’s 
convenient for 
Medications were 
viewed as a last resort 
by some; others 
suggested that in crisis 
- Cost-efficient quality 
assurance 
mechanisms must be 
developed and a 
variety of valid non-
372 
 
assess, diagnose,  




ogical care as the 
primary way of 
attempting to 




ical care as the 
primary way of 
attempting to 
resolve a NH 
resident’s distress. 
(Page 910) 
address the mental 
health problems of 
residents (e.g. to 
individualize 
treatment, be 
flexible, don’t use 
psychopharmacolog




modules on how to 
improve staff 
communication and 
teamwork on all 
staffing levels. (Page 
910) 




There was at least 
one comment in 
almost all of the 
groups regarding 
the perception 
that some of the 
NH residents 




that it was their 
job ‘to clean up 
the situation’. 
(Page 908) 
situations one has to 




programs be made 
available to assure 
that the spirit and 
intent of OBRA is 













staff to get to 
know residents 
well. (Page 799) 
 
 
-  “[You need to know] 
when to back-off a 
little bit from 
somebody who’s 
aggressive, not 
argue, because I 
have seen people, 
they’ll labour a 
point with a 
resident...” 











with dementia in 
“Staff really put 
100% in here and 
they have their own 
individual patients 
who they know 
well.” (Family Carer) 
(Page 797) 
“We said if you hold 
her [down] we’re 
happy, you know, it 
was awful; it really 
was awful.” (Family 
Carer) (Page 798) 
 
It was evident that 






- “I don’t think it should 
just be prescribed as a 
matter of course really 
but I think with careful 
handling there is a role 
for it. I think if you 
have asked me that 
before she went in and 
before I knew what I 
know now, I would 
have said definitely 
not.” (Family Carer) 
(Page 798) 
 
It was accepted… that 
controlling strategies 




“I’ve been in homes 
where they’ve been I 
would say drugged 
up. You know they 
have a policy [here] 
that that doesn’t 
happen and I admire 
them for that 
because they like 
the person to be the 
person.” (Family 
Carer) (Page 798) 
 
Both staff and 




restraint) should be 






the wrong way. 
(Page 797) 
aggressive 
behaviour… it was 
evident that staff 
had communicated 
this philosophy to 
relatives. (Page 798) 
Harding 
(2013) 30 
- - - “I did speak with Dr 
[name] about the 
drug [antipsychotic] 
he’d prescribed he 
said it was for my 
dad’s depression 
(my dad has never 
suffered from 
depression) …  I  
went  to  my  dad’s 
doctor and strongly 
requested that my  
dad  came  off  this  
drug …  I  was  angry  
that  this  drug was 
given to my dad in 
the first place.  I 
think some doctors 
and nursing staff  
have  very  little  
knowledge  if  any  
about  caring  for  
dementia  people.” 






antipsychotics to a 
lack of knowledge, 
training, or 
awareness of the 
negative effects on 
people with 
“During the sixth 
week [of respite] she 
started having 
nightmares, and so 
they wanted to give 
her antipsychotics, 
and I said ‘no’. But 
the doctor actually  
prescribed  them,  
and  I  think  she  
was  given one 
tablet and it gave 
her the runs, and 
they didn’t give her 
anymore. But as 
soon as they said 
that, I- although I 
wasn’t fit enough    
to bring her home, I 
brought her home.” 




including those with 
power of attorney, 
reported not being 
consulted prior to 






profile of the drugs 
“They call it Pisa 
Syndrome [a side 
effect]… Put it 
down purely to 
drugs. So care 
home, well it were 
nursing home, 
that Kate was in 
at that time, I told 
GP about drugs, 





“I was strongly against 
the use of this drug 
[Seroquel] after it left 
my dad in a zombie 
state.” (Family Carer) 
(Page 259) 
 
Clearly, carers find the 







highlight that the use 
of antipsychotic 
medication as a means 
of controlling 
behaviour can be 
experienced as 
harmful even in the 
absence of ‘severe’ 
side effects. (Page 
259) 
“Another occasion 
he went to a unit for 
assessment which 
was totally lacking 
in dementia care, he 
was drugged [with 
quetiapine] and put 
in a nappy when he 
had no continence 
problems, he fell 
and sustained a 
head injury as a 
result of this so next 
night he was put on 
the floor on a 
mattress. When I 
visited the staff 
supposedly caring 
for him were sitting 
watching TV while 
he was wandering 
up and down in a 
dazed state and 
when I removed him 
the staff became 
very defensive and I 
subsequently found 
that this was not an 
isolated incident.” 
(Family Carer) (Page 
262) 
 
The way she (the 
family carer) 
describes his (the 
Our argument is that 
because there is a 
potentially higher risk 
of harm to patients 
from off-label 
prescription, it should 
be subject to greater 
regulatory control, 
and that there should 
be redress available 
where a patient is 











suggests that the 
treatment he 
received may have 
been inappropriate, 
and was unlikely to 
have been in his 




‘‘At times there’s 
so little staff and 
there’s a lot of 
behaviours all at 
once. It’s just kind 
of putting out 
fires and keep 








staff was unable 
to individually 
minimize triggers 
for each resident 




Nursing staff in this 
study felt that they 
were constantly 
‘‘putting out fires’’ 
and stated that 
although they usually 
knew why the 
agitation was 
occurring, they did not 
have time to address 
the situation until the 
behaviour escalated. 
At such a point, 
medications offered a 




application of NPIs 
improved the staffs’ 
confidence in their 
ability to use NPIs 
effectively.  (Page 
530)  
Although the LTC 
staff possessed a 
high awareness of 
common NPIs, the 
use of NPIs was 
dependent on the 
staffs’ perceptions 
of the effectiveness, 
past success with 
the NPI use, and the 
number of other 
duties competing 




within the team and 
sharing successful 
strategies increased 
the likelihood that 
NPIs will 
subsequently be 
used by other staff. 
(Page 529) 
- “... the benefits [of 
NPIs] are [related to] 
quality of life which is 
what you are looking 
for. The harms [of 
NPIs]? I don’t see any 
of them. I think any 
time you can be 
individually with a 
person, you are 
helping them.’’ (Unit 
Manager) (Page 528) 
 
Empathy of the staff 
appeared to coincide 
with openness to 
using NPIs. (Page 529) 
 
“We [nurses] are 
pro medicine, we 
are very medicine 
prone. Take a pill 







stated that relying 
on medications to 
manage behaviours 
was a significant 
part of nursing 






ris (2013)  
“Often requires 




when we have 
looked to social 
services for extra 
- ‘‘Most times 
behavioural issues 
are a cry for a need. 
How does a person 
with dementia who 
has got a 
communication 
deficit tell you he 













and care home staff 
at each level of care 
is fundamental and 
‘‘We find that 





when not used 
and discarded 
According to many of 
the GPs an increased 




worthwhile trade-off if 
prescription of the 
‘‘Often it is pressure 
from nursing homes 
or carers for 
medication to calm 
a patient down that 
is trigger for 
prescribing.” (GP) 
(Page 36) 
It is apparent that the 
current 
recommendation by 
the MHRA advocating 
the sole use of 
risperidone for six 
week intervals is not 




to account for 
needing 
additional care 
staff it has not 
been successful. If 
this arrangement 
was more flexible 












on resource. All 
participants 
reported limited 
access to support 
services and the 











In people with 





of other underlying 
are even more 
difficult to 
elucidate. (Page 36) 
by this study. (Page 
37) 




therapy. (Page 37) 
every month. 
Saying as the 
psychiatrist 
started it they will 
not stop 
prescribing it. But 
then never follow 
it up with a 
referral to have 
the medication 


















improve the patient’s 
mental wellbeing and 
quality of life. (Page 
35) 
 
A culture of blaming 
was expressed in 
this study. GP’s 
reported pressure 
from care home 
staff to maintain a 
patient on 
antipsychotics, 
whereas care home 
staff reported GP’s 
insisting on 
maintaining use of 
antipsychotic 
therapy. (Page 37) 
primary care. This 
indicates that GPs may 
be finding it difficult to 
manage patients with 
BPSD using only one 








time limits. Nurses 
are always under 
pressure to hurry. 
We need more 
staff allocated to 
‘‘…I feel others miss 
out while time is 
devoted to the person 
with behaviour.’’ (NH 











Staff education as a 
limitation to using 
behaviour oriented 
Staff reported that 
they would treat 
BPSD which is 
unlikely to respond 
to antipsychotics 
and also reported 
withholding 
antipsychotics when 
BPSD indicate its 
use. It is reasonable 
- ‘‘Diversional 





nursing staff are 







mobility and weight 
loss due to 
drowsiness.’’ (NH Staff 
Member) (Page 203) 
 
Staff rarely used 
person-centred care 
terminology, 
















were often voiced 
as a reflection of 
general poor 
staffing levels in 
Residential Aged 






contribute to the 





strategies was often 
cited. (Page 204) 
to assume that poor 
staff knowledge of 
appropriate use of 
antipsychotics may 




















their usual role, 




Adverse drug effects 
for residents were 
reported as a 
limitation to using 
antipsychotic 




concerned with issues 
such as drowsiness 


















It was felt that the 





“That gentleman is so 
restless and they are 
all getting crazy and 
something must 
happen, NOW. That is 
how it goes.” 
(Physician) (Page 838) 
 
. 
“I think …that there 
is a very hesitant 
reaction to problem 
behaviour by the 
nursing staff. That in 
general there is little 
knowledge and few 
skills related to 
dementia and types 
of dementia. Thus, 

















result from limited 
knowledge in the 
public field: on the 
mechanism of 
“At a certain 
moment we started 




looking at the 
problems and by 
learning from each 
other…we gained 
more clarity, much 
more peace, and 




“Look, a physician 
does not see the 
residents, I see 
them all day long. 
We, altogether, 
see a resident 24 
hours per day, so 
if we accurately 
register their 
behaviour, then . . 
. The physician is 
very reliant upon 
us.” (Nurse) (Page 
838) 
 
“Because you simply 
are afraid that the 
same behaviour will 
come back. And at 
that moment, you are 
actually glad someone 
is doing well. And then 
you think like, gosh, 
should you take the 
risk to - so to say - 
stop and see [does] 
the problems return?” 
(Physician) (Page 838) 
 
Once residents are 
using PDs and the NPS 
“Personally, I have 
the feeling that the 
tendency is to 
prescribe less PDs 
and less quickly. As 
little as possible, 
actually; the less the 
better. This is, in my 
opinion, also 






the public tends 
Physicians expressed 
ambivalence about 
the influence of the 
Dutch professional 
guideline. According 
to some, it limits PD 
prescription; others 
believe that when 
followed routinely and 
interpreted as 
“allowance” to 





















shifts. (Page 838) 




primarily of nursing 
staff, and the need 
for PDs. There 
seems to be a 
greater need for 
PDs in cases where 
nurses have limited 
knowledge, either 
or not from formal 
education, on the 
nature and 
occurrence of NPS 
or less experience in 
managing NPS. 
(Page 838) 
action of PDs, lack 
of data on PDs in 
the NH population, 
and the impression 
that trials are 
selective and test 
only PDs in the 


















the need for 
prescription of PDs. 
(Page 838) 




clear reporting by 
nurses of 
occurrence and 
severity of NPS 
because 
physicians mostly 
use this as a base 
to decide on 
starting PDs. 
(Page 838) 
are… no longer 
perceived as too 
troublesome, there is 
a preference to 
continue. There can 
even be resistance 
from nurses and 
family to withdraw 
PDs, especially when 
considerable effort 
was put into 




possibly leads to a 
withdrawal of PDs; 
they assumed that 
the zeitgeist favors 
limiting the 




Staff and leaders 






services as having 





Staff and leaders 
of facilities with 
high antipsychotic 
medication use 
tended to identify 
consultant 
psychiatry more 
often than staff 
from lower-use 
- - The wide variety of 
rationales found in 




suggests that NH 
teams articulate and 
understand the 
rationales for their 





explanations is a 
particular concern 
because, in many 
cases, safer 
alternatives exist for 
managing these 
Families of residents 
in NHs with lower 
use of antipsychotic 
medications were 
more likely to 
indicate that they 
knew when the 
medication was 
started. (Page 306) 
- - - Off-label uses for 
“behaviours” in 
general, emotional 
states… and “cognitive 








under current federal 
NH guidelines unless 
specific criteria are 
met. (Pages 306-307) 
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staffing to provide 
around the clock 
person-centred 









within NH care; 










ability to adapt 
new practices and 













care practices. Skills 
training must be 
ongoing, involve 
hands on 
supervision and be 
provided 
immediately to all 
new NH staff due to 
high volume of staff 
turnover. (Page 515) 
“[We need to] 
educate physicians 
that the use of 
antipsychotics are 





activities are  
needed on a regular 
basis for dementia 






physicians were not 












“I would like to see 
hospitals be part of 
this process. Too 
often residents 
come to us with 
anti-psych meds and 
they seem to remain 
with the resident.” 








and NHs were cited 






was little to no 
mention of the 
role of certified 
nursing 







care teams is one 
of the greatest 
impediments to 
person-centred 
care and alienates 
one of the richest 




care. (Page 514) 
NH administrators and 
Directors of Nursing 
often stated they 
want residents to be 
on the lowest dose [of 
antipsychotics] 
possible. (Page 511)  
- “We have renewed 
our focus and utilize 
an interdisciplinary 







This study explores 
how NHs responded 
to the 2012 [Centres 
of Medicare and 
Medicaid] CMS 




Results confirm the 
majority of NHs are 






e (2016)  
“There has been 
so much focus on 
it recently, dealing 
with challenging 
behaviour, 
“You feel like you’re 
not doing your job 
properly. You actually 
feel that you’re letting 
the residents down. 
“Some of them can 
be quite aggressive 
if they won’t take 
that medication 
[antipsychotic], and 
“It will really help to 
raise awareness 
among them [the 
prescribing GP] 
because they would 
“We all work as a 
cog in a wheel and if 
one of those cogs 
breaks then the 
wheel doesn’t turn 
“Some of them 
have the attitude, 
‘It’s [performing 
NPI]  not my job, I 
am just here to 
“Most of them you see 
them drowsy at times, 
at times it is a 
sedative, I wouldn’t 
like antipsychotics or 










but what people 
need to realise is 
that to do that 
costs a lot more 
money. To give 
one to one 
intervention is 
very expensive. 
Whereas it’s dead 
easy isn’t it if you 


















Yeah that you’re 
letting them down. 
You say, ‘I’ll be with 
you in a minute, I’ll be 
back’…and you’re not, 
you’re running off for 
something else.” (NH 
Staff member) (Page 
286) 
 
Low staffing numbers 
and a perceived rise in 
the proportion of 
residents with 
dementia contributed 
to the view that 
‘physically and 
mentally it is 
draining’. Participants 
explained that being 
‘fully staffed, but 
understaffed’ limited 
their involvement in 
activities, the 
feasibility of spending 
one-to-one time with 
residents and their 
ability to implement 
person centred care. 
(Page 288) 
it’s how to deal with 
the aggression from 
them because we  
can all  do 
‘Yesterday,  Today    
and Tomorrow’, 
which is a lovely 
course, it is brilliant, 
but we never 
actually had training 
where I worked of 
how to deal with the 
aggression side of 
it.“ (NH Staff 
member) (Page 287) 
 
 








their everyday work.  
(Page 292) 
never change the 
medication if it 
weren’t for this.” 




does it? So what we 
do is we all work 
together it’s like 
they work upstairs 
with the carers and 
if something is 
wrong they report 
here and then it gets 
reported to the 
doctor.” (NH Staff 
member) (Page 287) 
 
The cohesiveness of 
staff within the care 
home was 
considered key to 
the provision of 
high-quality care. 
Three groups 
argued that the 
shared ethos of the 
team helped to 
mitigate the 
challenges posed by 




clean him, feed 
him, that’s it, I 
don’t need to do 
anything else, it’s 




A recurring issue 
was the potential 
disjuncture 
between carers, 
who in some 
instances seemed 
to provide the 
majority of daily 
care, and nurses,  
who were 
responsible for 
writing care  plans  
and  daily 
reports… (Page 
288) 
wish…so  they need to 
review and do 
something about it.” 
(NH Staff member) 
(Page 287) 
 
Participants in roughly 
half the care homes 
hoped that the 
training programme 
would help to reduce 
the use of 
antipsychotics within 
the home. (Page 289) 
 
care home itself, as 
it was not always 
possible to give 
residents the 
“positive attention” 




uncertain how they 
would have time to 
attend to residents 
if antipsychotics 





(2016 A)  
GP participants 







they were limited 
by time and other 
work 
- - “We ensure that at 
our [MAC] meetings 
we have the 
[accredited] 
pharmacists there 






“There are some 
families that say, 
‘you think it 
[psychotropic 
medication] might 
be too much? Every 
time I come and 
visit, he’s just 
sleeping or is just 
not into it’. We say 
to them ‘if you are 




meet a couple of 
GPs… I’m meeting 
exactly the same 




- “Everybody else 
raised the issue (at 




medications and to 
reduce the load of 
medications 
including 
Although it is a 
requirement for 
Australian nursing 
homes that every 




[RMMR] as soon as 
possible after 




such as managing 
their own 
surgeries... As a 
result, discussions 
on the 
appropriate use of 
psychotropic 
medicines were 
not conveyed to 
all GPs. (Page 
1730) 
 
[In this Australian 
setting] In all, but 
one nursing home, 
accredited 
pharmacists’… 












then we will get the 
doctor to review it 
again.’” (Healthcare 





concerns to on-site 
staff…The concerns 
of families would be 
noted by on-site 
staff to request the 







the vast majority 




indicated that it 








Our study identified 
MAC meetings as an 
important artefact 
of organizational 
culture related to 
the use of 
psychotropic 
medicines in nursing 
homes. (Page 1732) 
clinical needs basis to 
current residents, we 
found variability in the 
way nursing homes 
utilized the specific 
recommendations 
from the RMMRs.  
(Page 1730) 
Sawan 
(2016 B)  
“The desire to 
make money 
means that they 
[nursing homes] 
have to make 
choices about 
staffing levels and 
staffing quality 
that is good for 
the money 
making side but 
not necessarily 
good for the 
patient side. Then 
of course they 
might want 
shortcuts to 
enable them to 
cope with the less 
qualified staff or 
the less numbers 
of staff. That’s 
“Staff often reported 
feeling frustrated as 
the care that should 
be provided is not 
being given due to 
insufficient staff hours, 
insufficient staff, lack 
of specialized training; 
because they only had 
minimal basic 
training, and because 
they found it difficult 





These perceptions [of 
feeling overwhelmed 
and unqualified to 
handle residents with 
BPSD] were more 
“In the nursing 
home, it is very hard 
to use the other 
means to help with 
sleeping problems. 
After giving a few 
weeks’ trial off [the 
psychotropic 
medicine], the staff 
keep on telling me 
that they’re not able 
to cope with the 
patient, so what do 
you do? The 
employees are not 
as well trained to 
handle these kinds 
of patients.” (GP) 
(Page 5) 
 
A number of visiting 
staff perceived that 
“We are not 
supposed to know 
what it 
[psychotropic 
medicine] is or what 
it does. We’re just 






assistants felt that 
their involvement 
was not supported 
by their manager as 
they were expected 
to not know the 
indications of 
psychotropic 
medicines. In other 
cases, they felt 
“Nursing Home X is 
open to having us 
communicate with 
doctors if we can, 
and trying to reduce 
medication load for 
all their patients. 
That’s one of the 
manager’s main 




they want us to be 
involved in meetings 
and try to reduce 
medication burden 









anything that I 
notice that is not 















“They’re the necessary 
evil [psychotropic 
medication]. 
Sometimes we do 
have to use it for 
behaviour. Sometimes 
it’s not appropriate 
but you have the 
nursing staff 
requesting it to calm 
down the patients. 
Sometimes you use it 
unnecessarily a bit 
longer than we 
should.” (GP) (Page 5) 
 
The majority of GP 
participants viewed 
psychotropic 
medicines as a 
‘necessary evil’ to deal 
with the high 
“[Manager of 
Nursing Home Y] 
has a unique 
appreciation for the 
diversity of 
personality and 
character in the 
world and she 
actually celebrates 
this. She is far from 
normal and average 
in this industry. Staff 
are never asking me 
to sedate – they’re 
never asking me for 
sleepers. It’s a 
whole different 
world so actually I’m 
really at one with 
them. They will tell 
me that they’re 





and managing the 
patient might 
come in.” (GP) 
(Page 6) 
 
Some visiting staff 
perceived that it 
was the 
prioritization to 




in staff levels and 
staff skill mix. This 
created the work 
distress and 
workload for on-











pronounced in low 
care nursing homes 
with ‘ageing in place’ 
where residents 
would be permitted to 
remain in care even if 
their needs increased 
over time from low to 
high. (Page 5)  




BPSD and insomnia 
was limited due to 
minimal staffing and 
on-site staff not 
being adequately 





often requested by 
on-site staff as a 








their ability to 
participate because 
of their level of 
medical knowledge. 
They therefore did 




medicines. (Page 6) 




















medicines. (Page 8) 
medicines. They 
felt that they 
were listened to 
by their managers 
(and RNs) and felt 
empowered to 
report any 
changes in the 
residents’ 
condition as they 
were encouraged 
to follow their 
intuition. 
Participation in 
the monitoring of 
psychotropic 
medicines 






workload of on-site 
staff due to lower 
staffing levels, 
primarily during the 
night. They reported 
to receive requests for 
the initiation of 
psychotropic 
medicines to address 




medicines were seen 
to be required for the 
sake of peace and 
calm for on-site staff 
and other residents. 
(Page 5) 

















by on-site staff, 
either hindering or 
facilitating 






the potential harm 
associated with 
psychotropic 
medicines may be 
linked to these 
attitudes. (Page 8) 
Shaw 
(2016)  
“If they just would 
put an extra 
member of staff 
on each shift, it 
would make an 











cared for, that the 
room is 
“There are some 
GPs who is not well 




under the sun.” 
(Nursing Home 




together with the 




“It’d be my 
saying…that I 
don’t think this is 
right for this 
person…but who 
are we to argue 
with the higher 
[prescribers]?” 
(Nursing Home 
 “Their behaviour is 




The attitudes of 
nursing home staff 
towards residents 
with dementia may 
“[Nursing homes] 
always need to have 
some sort of 
routine…so if one 
person does one 
thing that way, then 
everybody else will 
participate  and do    



































team members are 










to be dissatisfied 
with prescribing 




discuss it, possibly 




Thus, the quality 
of the relationship 
between the staff 








influence how they 
are treated… This 
seemed to be borne 
out by staff in 
traditional homes; one 
participant saw older 
people with dementia 
as ‘‘annoying’’ and 
went on to say they 
would be given a 
psychoactive 
medication, which was 
beneficial for them. 
(Page 128) 
thing…and, to be 
honest with you, I 
think  it’s good for 
them, the residents, 







expressed the need 
for certain routines 
to be carried out... 
Participants placed 
importance on 
having set meal 
times and bed 
times, and showed a 
regimented 
approach to daily 








Participants in this 
study indicated 
the need for more 
staff so that they 







reported that it 
“They will attack you, 
be aggressive, grab 
you, pinch you and 
spit at you. It is not 
always easy.” (Care 
assistant) (Page 6) 
 
 
“I did a workshop, it 
wasn’t too involved, 
only one day, but it 
really helped me. I 
am calmer and 
know better what to 
do. Before I had the 
training I would just 
pick up and go, but 
now I know you 
have to first tell the 
person what you are 
The majority of 
participants had 
basic school 
education and little 
or no dementia 
training. (Page 7) 
- Some care home 
managers were 
said to limit 
access to 
residents’ 
personal files to 
the Sister in 
charge, this was 
indicative of other 
data in the 
interviews of a 
hierarchical 
“Sometimes they are 
so overmedicated and 
are like ‘zombies’. It is 
not nice if they are like 
that, because you 
cannot work with 
them if they are in 
that state.” (Care 
assistant) (Page 7) 
 
Participants thought 
that doctors often 
The findings suggest 
that staff in care 
homes varied in 
their perceptions of 
working with people 
with dementia, but 
there were not 
many within-home 
differences. These 
aspects could be 




takes longer to 
care for people 
with dementia as 




care than other 







going to do, not just 




There seemed to be 
consensus among 
care staff that 
dementia-specific 
training would 
greatly benefit their 
practice and 
enhance their ability 




care staff and 
management. 
(Page 9) 
prescribed too high 
doses of tranquilisers 
resulting in 
unresponsive 
residents who were 
difficult to work with. 
The use of medication 
and restraint was 
reportedly to be a last 
resort if interpersonal 
approaches were 
ineffective. (Page 7) 
leadership and 
culture in these 
homes, contributing 
to staff satisfaction 





 Chronic under-staffing is a 
fundamental issue in NHs, leading to 
insufficient time and ability by NH 
staff to perform person-centred care 
 The involvement of specialist 
services can influence antipsychotic 
prescribing, but sometimes there can 
be difficulty accessing these services 
 To circumvent the problems of 
inadequate resources and/or poor 
access to specialist services, 
antipsychotics are ‘employed’ as 
cheap, fast and effective staff 
members.  
 As behaviours escalate, a ‘tipping-
point’ is reached, after which an 
urgency to resolve the situation 
arises. This is particularly true when 
NH staff feel “overwhelmed” by 
these behaviours. In these situations 
antipsychotics are perceived by NH 
staff to offer a “more guaranteed 
result” 
 The perceived acuteness of 
situations forces NH staff to focus 
 Both prescribers and NH staff are often 
perceived to be poorly equipped to 
deal with BPSD in terms of deficiencies 
in dementia-specific skills and/or a lack 
of knowledge on the risk/benefits of 
antipsychotics, and the range and 
nature of NPI. These deficiencies 
enable inappropriate antipsychotic 
prescribing.  
 More training and education to help 
prescribers and NH staff to improve 
skills and knowledge with regards to 
BPSD management is desired 
 Even in individuals with sufficient skills 
and knowledge regarding BPSD 
management, a tension can exist 
between ‘doing the right thing’ and 
doing what’s practical, especially if the 
resources or suitable alternatives are 
not perceived to be there to support 
adequate implementation 
 Knowing the resident and 
understanding their behaviours 
contributes towards successful BPSD 
management 
 Effective communication and 
collaboration (involving sharing 
information and listening to others) 
between all members of the 
healthcare team are key enablers to 
reducing inappropriate prescribing of 
antipsychotics. The involvement of 
family members can also be 
important in this process  
 A lack of empowerment at all levels 
of the healthcare team and among 
family members is a barrier to 
informed decision-making regarding 
antipsychotic prescribing 
 Fragmentation between different 
levels of care creates confusion 
surrounding roles and 
responsibilities, which can lead to 
inappropriate maintenance of 
antipsychotics 
 
 Although there is a preference to use NPI 
in the first instance due to the unpleasant 
side effects of antipsychotics, it is 
acknowledged that antipsychotics are a 
“necessary evil” and are often 
unavoidable  
 Negative attitudes by individuals towards 
people with dementia can result in 
inappropriate antipsychotic prescribing. 
Conversely, empathy towards people 
with dementia can be protective 
 Fear of the recurrence of behaviours 
motivates maintenance of  antipsychotic 
prescribing 
 Organisational and societal attitudes 
towards people with dementia and the 
management of BPSD, exerts pressure on 
prescribers to make prescribing decisions  
 The attitude of the NH manager towards 
people with dementia and the  
management of BPSD dictates the 
treatment culture of that NH, and this has 
a strong influence on antipsychotic 
prescribing 
 Regulations are 
perceived to be the 
driving force for 
antipsychotic 
reductions in NH 
residents with 
dementia, but 
adherence to them 
can  be  challenging 
 Guidelines exert 
little influence on 
antipsychotic 
prescribing, but 










their attention on the “aggressive” 
residents, while the “passive” ones 
are left behind. Antipsychotics can 
sometimes be viewed as a way of 
equalising attention given to both 
“passive” and “aggressive” residents 
 
 Tensions can arise due to incompatible 
beliefs towards antipsychotics between 
prescribers and NHs; in these cases a 
battle of wills develops where there is 
often pressure on prescribers to “do 
something” in order to restore control – 
doing nothing is not tolerated. However, 
sometimes there is pressure on 
prescribers to discontinue antipsychotics, 
to which there can be resistance from 
prescribers 
 
BPSD, Behavioural and Psychological Symptoms of Dementia; NPI, Non-pharmacological interventions; LTC, Long-term care; NH, Nursing Home; 
SCU, Specialist Care Unit; GP, General Practitioner; CAN, Certified Nursing Assistant; OBRA, Omnibus Budget Reconciliation Act; MHRA, Medicines 




Appendix 5. COREQ Checklist for Chapter 5 








interview or focus 
group? 
KW conducted the interviews 




At the time of undertaking the interviews KW’s credentials were 
BPharm, MPharm, MPSI 
3. Occupation What was their 
occupation at the 
time of the study? 
KW is an Irish registered pharmacist, who was undertaking a PhD in 
Population Health and Health Services Research, when this study 
was conducted.  
4. Gender Was the researcher 
male or female? 
Male 
5. Experience and 
training 
What experience or 
training did the 
researcher have? 
KW completed training in utilisation of NVivo software and received 
qualitative research methods training at Oxford University, UK. KW 
has also conducted and published a systematic review and synthesis 
of qualitative evidence previously. 




Was a relationship 
established prior to 
study 
commencement? 
There were no established relationships between any of the 27 











reasons for doing 
the research 
KW had disclosed to all participants that he was a pharmacist 








reported about the 
interviewer/facilitat
or? e.g. Bias, 
assumptions, 
reasons and 
interests in the 
research topic 
KW is a registered pharmacist with community pharmacy and 
qualitative research experience, and was conducting this study as 
part of his PhD exploring antipsychotic prescribing in nursing home 
residents with dementia. This information was disclosed to 
participants ahead of the interview. 
In order to minimise the potential for KW’s information bias, 
entering the analysis, a mix of professionals (clinical and non-
clinical) were involved in the analysis, with varying levels of 
knowledge on this specific topic.  
Our research team consisted of a broad range of disciplines: 
pharmacists (KW, AF, SB); a general practitioner (CS); a health 
psychologist (JMcS); a methodologist (JB); and a geriatrician (ST). 
Triangulation of analysts contributed toward the credibility of the 
results, and minimised bias from any one particular researcher. 












stated to underpin 






Framework Analysis as described by Ritchie and Lewis, utilising the 











Participants were purposively sampled to ensure a heterogeneous 
group with maximum variation according to two main pre-
determined criteria (Professional/social role and nursing home 
type). We also used snowball sampling to fulfil our sampling 
framework requirements.  
Six different nursing home sites were selected based on our 
sampling framework, through publicly available directories of 
registered nursing homes on the Health Information and Quality 
Authority (HIQA) and Nursing Home Ireland websites 








The Directors of each nursing home (Directors of Nursing or Medical 
Directors) were contacted by KW by email initially and informed 
about the study, with a follow up phone-call if no response. Once 
the Directors agreed access, they were interviewed themselves by 
KW and they then recommended other potential participants 
connected to their nursing home, whom KW would approach face-
to-face or via email/telephone with information about the study. All 
relevant visiting staff (i.e. GPs, consultant psychiatrists of old age, 
consultant geriatricians and pharmacists) serving each of the sites 
were invited to participate in the study. The Directors approached 
family members initially about the study before recommending to 
KW that they were suitable to be contacted. 
 
12. Sample size How many 










Of 6 nursing homes contacted by KW via their respective Director, 
4 participated and 2 did not respond. 
 
Of the 4 pharmacists serving the 4 different nursing home sites, 2 
participated. 1 said they was too busy and 1 did not respond. 
 
Of the 9 GPs serving the 4 different nursing home sites, 5 
participated. 2 initially agreed but never followed up with a definite 
date for interview and 2 did not respond. 
  
Of 10 nurses across the 4 different sites who were contacted by KW, 
8 participated. 1 said they were too busy and 1 did not respond. 
 
Of 5 family members who were contacted by KW, 3 participated. 1 
initially agreed but never followed up with a definite date for 
interview. 1 initially agreed but then cancelled because the rest of 
the family didn’t want to be involved. An unknown number of family 
members were informally approached about the study by the 
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Directors of each nursing home site, but did not agree to 
participate. 
 
Of 3 Consultant Geriatricians contacted by KW, 2 participated. 1 
initially agreed but never followed up with a definite date for 
interview. 
 
Of 2 Consultant Psychiatrists of Old Age contacted by KW, both 
participated. 
 
Of 5 Healthcare assistants contacted by KW, all 5 participated. 
 
Total non-participators: n=2 nursing homes, n=11 individuals 
directly contacted by KW 
Setting 
 
14. Setting of data 
collection 




All interviews took place either in the participant’s place of work, 
home or an office in the researcher’s university, depending on 
participant’s preference. 
15. Presence of non-
participants 
Was anyone else 




16. Description of 
sample 
What are the 
important 
characteristics of 
the sample? e.g. 
demographic data, 
date 
Refer to table of demographics in Chapter 5 
Data collection 
 
17. Interview guide Were questions, 
prompts, guides 
provided by the 
authors? Was it 
pilot tested? 
Three types of topic guides were in circulation at any one time. They 
were broadly similar for content, but differed primarily for 
language:  
 1 for healthcare professionals (physicians, nurses, and 
pharmacists),  
 1 for healthcare assistants   
 1 for family members. 
 
The topic guides were pilot tested by 5 participants (1 nurse, 1 
healthcare assistant, 1 pharmacist, 1 GP and 1 family member) to 
ensure appropriate content and language for the different groups. 
All topic guides were revised slightly after every pilot interview. 
Only the latter interview conducted with a family member was 
subsequently included in the analysis, as this topic guide was agreed 
to be close enough to the final version. 
 
Throughout the remainder of the study, the topic guides underwent 













Did the research 
use audio or visual 
recording to collect 
the data? 
All interviews were audio recorded. 
20. Field notes Were field notes 
made during and/or 
after the interview 
or focus group? 
Field notes were written immediately after the interviews, and were 
referred to during analysis, and refinement of topic guides. 
21. Duration What was the 
duration of the 
interviews or focus 
group? 
The median interview length was 23 minutes and the range was 12-
56 minutes. 
22. Data saturation Was data saturation 
discussed? 
The Francis et al method was used to determine when data 
saturation had been reached. We sampled until no new ideas 
emerged from the interviews and then conducted a further three 
interviews without any new ideas emerging to ensure that data 













24. Number of data 
coders 
How many data 
coders coded the 
data? 
Four (KW, CS, AF, JMcS) 
25. Description of 
the coding tree 
Did authors provide 
a description of the 
coding tree? 
The Theoretical Domains Framework (TDF) was used as a basis for 
the coding tree 




advance or derived 
from the data? 
We utilised both deductive and inductive approaches to analysis 
throughout the five framework stages (familiarisation, identifying a 
thematic framework, indexing, charting, and mapping and 
interpretation). First KW became familiar with the data by reading 
and re-reading transcripts and field notes and open coded across 
the entire dataset. The 14 TDF domains were then deductively 
applied systematically to the data during indexing while emerging 
concepts were coded and categorized inductively. These indexing 
steps were conducted independently by at least two authors for 
seven transcripts (KW and AF/JMcS), who met to discuss differences 
in application of the TDF or interpretation of emerging concepts, 
and came to consensus. The indexing of the remaining transcripts 
was conducted by KW using agreed understandings of the TDF 
domains.  
Charting of the data, with distilled summaries in matrix format was 
used to identify the predominant domains influencing the target 
behaviours (appropriate requesting and prescribing). This activity 
was performed independently by two authors (KW and CS), who 
then discussed any disagreement until consensus was reached. 
From these predominant domains, the determinants (i.e. barriers 
and facilitators) of the target behaviours were identified by KW, 
with input from the whole team.  
For the final mapping and interpretation step, we iteratively 
developed links between barriers and facilitators, predominant 
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domains, initial categories and theory to provide overall 
explanations for the findings. This was conducted by KW, with input 
from the whole research team.  
27. Software What software, if 
applicable, was 
used to manage the 
data? 















themes / findings? 









between the data 
presented and the 
findings? 
Quotes are presented in a manner consistent with findings 
31. Clarity of major 
themes 
Were major themes 
clearly presented in 
the findings? 
Major (explanatory) themes are presented in the results section. 
32. Clarity of minor 
themes 
Is there a 
description of 
diverse cases or 
discussion of minor 
themes? 
The predominant TDF domains that feed into the major 
(explanatory) themes are explored in detail in the results section 
COREQ, COnsolidated criteria for REporting Qualitative research.
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1. In your own words, tell me what your views are regarding the use of antipsychotics in nursing 
home residents with dementia. (Prompts: Is it appropriately prescribed in all cases? Is it necessary? ) 
(What impact, if any, do resources and financial issues have an AP prescribing, in your experience?) 
2. In the context of NH residents with dementia, what you would you define as an “appropriate” 
usage of these agents? (Prompts: indication, frequency of review, duration, who needs to be consulted?) 
3. [If not mentioned] Can you talk me through your general approach to: prescribing (physician)/ 
requesting (nurses)/ dispensing (pharmacist) a prescription for, AP medications to a typical resident with 
dementia, who may be exhibiting behaviours that challenge? (Rephrase: Talk me through one situation 
where this occurred. Prompts: How would you start this process or journey for a NH resident with 
dementia? What is the first thing you would always do? Use of NPI? What would you do next? Would you 
always do this? Anything else? What about reviewing? What about PRN usage) 
4. Can you tell me about a case where you were able to successfully reduce someone’s dosage of 
these agents or manage someone without medications. What do you believe were the main facilitators? 
(What do you believe enables “appropriate” usage?) (Rephrase: What facilitates the use of alternative 
non-pharmacological approaches in residents who may not necessarily need AP/P medications?)  
5. Now can you tell me about a case where you were perhaps less successful. What do you believe 
were the main barriers in this case? How is it different? (What do you believe to be the main barriers to 
“appropriate” usage?) (Rephrase: What prevents the use of alternative non-pharmacological approaches 
in residents who may not necessarily need meds?)  
6. What are your views on non-pharmacological approaches? (Prompts: Are they effective?  Whose 
role is it? Are they being used first-line?) 
7. Do you believe that everyone involved in the care of residents with dementia knows enough 
about these medications? (Prompts: Why do you think this? Is there any group of people in particular that 
you feel could benefit from more training and education? What specifically do you think they need to know 
more about?) 
8. What about having the skills to effectively manage someone who is exhibiting behaviours that 
challenge? (Prompts: Why do you think this? Is there any group of people in particular that you feel could 
benefit from more training and education? What specifically do you think they need to know more about?) 
9. What would you consider your responsibilities to be as a _ in ensuring that the residents receive 
these medicines appropriately?  
10. [If not answered] What strategies or resources are currently available to support you in ensuring 
their usage is appropriate? (Rephrase: What resources would you use/consult with first to ensure 
appropriateness e.g. guidelines, pharmacists, GP.  
11. As you may be aware, we are planning to undertake an intervention study in your NH to help 
support nurses, HCAs and doctors in ensuring prescribing of antipsychotics is to a high quality. What would 
you like to see in this intervention programme?(Prompts: What would be helpful to you as a X? What 
would not be helpful to you?) 
12. Who would influence your decision about whether or not to prescribe an AP to a resident with 
dementia? What about guidelines? (Physician only) (Prompts: Why/ Why not? Individuals/groups of HCPs/ 
finance/Nursing Home itself/ public opinion/guidelines. Anyone else) (Rephrase: How, if at all, does the 




12. How do you think that your views and opinions, and that of others, influence the prescriber, in 
relation to AP prescribing? What about guidelines? (Nurses and Pharmacists) (Prompts: Individuals/groups 
of HCPs/finance/Nursing Home itself/ public opinion/guidelines. Anyone else?) 
13. Some people say that if a healthcare professional has a greater understanding of dementia then 
they might be less inclined to use antipsychotics. What do you think about that? 
(Rephrase: Some studies in the literature found that HCPs with a positive attitude toward PwD were less 
likely to use APM. Would you agree with this statement?)  
14. Do different nursing homes have different cultures? If so, what impact does this have on AP 
prescribing? [If working in multiple sites] 
15. [If not mentioned already] (You may or may not be aware but HIQA have recently started 
conducting Dementia-themed inspections of Nursing Homes, and have released updated standards with 
an increased emphasis on chemical restraints.) What is your opinion on the influence of HIQA on AP 
prescribing in the NH setting? Prompts: HIQA have released new updated Standards with an increased 
emphasis on restraint use in NH residents with dementia, are you familiar with them? Any thoughts? 
Negative or Positive Light?) 
16. That brings us to the end of the interview. Is there anything else I haven’t asked you today that 




1. In your own words, tell me what your views are regarding the use of antipsychotic medications 
in dementia residents who are exhibiting challenging behaviours. (Prompts: Antipsychotics such as 
Zyprexa and Seroquel. Other relaxers such as Xanax or Ativan.  Is it appropriately prescribed in all cases? 
Is it necessary? What are the benefits and harms?) 
2. In these residents, what would you define as an “appropriate” use of these kind of medications? 
(Prompts: indication, frequency of review, duration, who needs to be consulted?) 
3. [If not mentioned] Can you talk me through your general approach to requesting a prescription 
for these agents to a dementia resident, who may be exhibiting challenging behaviours? (Prompts if 
necessary: Is that something you would normally do as a HCA? How would you start this process or 
journey for a NH resident with dementia? What is the first thing you would always do? Use of NPI? What 
would you do next? Would you always do this?  Anything else? What about reviewing?) 
4.  Can you tell me about a case where the team were able to successfully reduce someone’s 
dosage of these agents and you were able to manage them without medications? What do you believe 
were the main facilitators? (What do you believe enables “appropriate” usage?) (Rephrase: What 
facilitates the use of alternative non-pharmacological approaches in residents who may not necessarily 
need AP/P medications?)  
5. Now can you tell me about a case where you were perhaps unable to manage the patient 
without some form of medication? What do you believe were the main barriers in this case? How is it 
different? (What do you believe to be the main barriers to “appropriate” use?) (Rephrase: What prevents 
the use of alternative non-pharmacological approaches in residents who may not necessarily need meds?)  
6. What are your views on alternative approaches to managing behaviours, such as distraction, 
massage therapy, reminiscence therapy and music therapy? (Prompts if required: Do they work?  Whose 
role is it? Are they being used before medications?) 
7. Do you believe that everyone involved in the care of residents with dementia know enough 
about these meds? (Prompts: Why do you think this is? Is there any group of people in particular that you 
feel could benefit from more training and education? Consultants, GPs, Nurses, Pharmacists, HCAs and 
family members. What specifically do you think they need to know more about?) 
8. What about having the skills to effectively manage these challenging behaviours? (Prompts: Why 
do you think this is? Is there any group of people in particular that you feel could benefit from more 
training and education? What do you think they need to know more about?) 
9. What would you consider your responsibilities to be as a HCA in ensuring that all residents 
receive these meds appropriately?  
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10. [If not answered] What strategies or resources are currently available to support this nursing 
home in ensuring the usage of these meds are appropriate? (Rephrase: What resources would they 
use/consult with first to ensure appropriateness e.g. guidelines, pharmacists, GP.   
11. As you may be aware, we are planning to undertake an intervention study in your NH to help 
support nurses, HCAs and doctors in ensuring prescribing of antipsychotics is to a high quality. What 
would you like to see in this intervention programme? (Prompts: What would be helpful to you as a X? 
What would not be helpful to you?) 
12. How do you think that your views and opinions, and that of others, influence the prescriber, in 
relation to AP prescribing? (Prompts: Individuals/groups of HCPs/ finance/public opinion/guidelines. 
Anyone else?) 
13. Some people say that if a healthcare professional has a greater understanding of dementia then 
they might be less inclined to use antipsychotics. What do you think about that? 
 (Rephrase: Some studies in the literature found that HCPs with a positive attitude toward PwD were less 
likely to use APM. Would you agree with this statement?) 
14. [If not mentioned already] (You may or may not be aware but HIQA have recently started 
conducting Dementia-themed inspections of Nursing Homes, and have released updated standards with 
an increased emphasis on chemical restraints.) What is your opinion on the influence of HIQA on AP 
prescribing in the NH setting Strategy? (Prompts: HIQA have released new updated Standards with an 
increased emphasis on restraint use in NH residents with dementia, are you familiar with them? Any 
thoughts? Positive or negative light?) 
15. That brings us to the end of the interview. Is there anything else I haven’t asked you today that 




1. In your own words, can you describe what your views are towards the use of medications in the 
care of your loved one? (Prompts if necessary: have they been beneficial? Have you noticed any 
improvements? Have they caused any side effects?) 
The focus of my PhD research is on the usage of a group of medications called Antipsychotics in NH 
residents with dementia. Common examples of Antipsychotics include Zyprexa, Seroquel and Serenace. 
These drugs are sometimes prescribed to people with dementia if they are severely distressed or 
displaying some behaviours that others may find challenging such as aggressive or agitated behaviour.  
2. If you have any experience in the use of these medications in your loved one, I’d be very 
interested to hear your story. (If not, then this is absolutely fine we can still talk about medication use in 
general) (Prompts if necessary: Why was he/she prescribed these drugs? Can you remember what it was 
he/she was prescribed? Did it help the situation? Were there any side effects? Is he/she still on it? Who 
stopped it and why?) 
3. Whenever your loved one is a bit agitated or distressed, is there anything that helps to put them 
at ease? (Prompts if necessary: Reminiscing about the past? Activities? What about Medications?) 
4. Have you ever requested a prescription for such a medication or have you ever requested it to 
be stopped or reviewed? If yes, could you describe for me in general what happened? (Prompts if 
necessary: Why did you do this? Is that something you would normally do as a family member? Would you 
always do this?  Anything else?) 
5. From your perspective, what would constitute an “appropriate” use of such a medication? 
(Prompts if necessary: Who needs to be consulted in the process? How long should they be on it, in 
general?) 
6. What are your views on alternative approaches to managing behaviours, such as massage 
therapy, reminiscence therapy and music therapy? (Prompts if required: Do they work?  Whose role is it? 
Are they being used before medications?) 
7. Do you believe that everyone involved in the care of residents with dementia know enough 
about these drugs? (Prompts if necessary: Do family members know enough? Should they know more? Is 
there any group of people in particular that you feel could benefit from more training and education? 
What specifically do you think they need to know more about?) 
8. What about having the skills to effectively manage someone who is exhibiting behaviours that 
challenge? (Prompts if necessary: Without using medicines. Why do you think this? Is there any group of 
people in particular that you feel could benefit from more training and education? What do you think they 
need to know more about?) 
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9. What would you consider your responsibilities to be as family member in ensuring that he/she 
receives an appropriate prescription of these medications?  
10. How do you think that your views and opinions, influence the GP, in relation to prescribing of 
these agents? What about the views of others? (Prompts if required: Individuals/groups of 
HCPs/financial/ public opinion/guidelines/ dementia strategy. Anyone else?, How are your views and 
opinions communicated to the GP? 
11. Some people say that if a healthcare professional has a greater understanding of dementia then 
they might be less inclined to use antipsychotics. What do you think about that? 
 (Rephrase: Some studies have found that HCPs with a positive attitude toward PwD were less likely to use 
APM. Would you agree with this statement?) 
12. That brings us to the end of the interview. Is there anything else I haven’t asked you today that 










Appendix 7. TIDieR Checklist for Chapters 6/7 
Item 
number 
Item  Description 
BRIEF NAME 
1. Provide the name or a 
phrase that describes 
the intervention. 
The ‘Rationalising Antipsychotic Prescribing in Dementia’ (RAPID) complex intervention. 
WHY 
2. Describe any rationale, 
theory, or goal of the 
elements essential to the 
intervention. 
The RAPID complex intervention was developed using the Behaviour Change Wheel approach and was informed through theory 
(Theoretical Domains Framework) and evidence (qualitative and quantitative). 
The overall aim of the intervention is to improve the appropriateness of antipsychotic requesting and prescribing for nursing home 
residents with dementia. 
 
WHAT 
3. Materials: Describe any 
physical or informational 
materials used in the 
intervention, including 
those provided to 
participants or used in 
intervention delivery or in 
training of intervention 
providers. Provide 
information on where the 
materials can be accessed 
(e.g. online appendix, URL). 
The RAPID complex intervention includes 3 main components: 
1. Education and training sessions with nursing home staff  
2. Academic detailing with GPs  
3. Introduction of an assessment tool (the RAPID assessment tool) to the nursing home environment  
Materials provided for each component: 
1. The education and training sessions: Written educational material discussing 4 topics will be provided to participants 
(understanding and responding to the person with dementia, everyday ethics, antipsychotic drug use in dementia, and 
understanding emotion). The RAPID assessment tool (paper-based) along with sample case studies (paper-based) will also be 
provided to participants. A facilitator’s guide will be provided to facilitators. 
2. Academic detailing: A paper-based guidance document discussing appropriate antipsychotic prescribing will be provided to GPs. 
The RAPID assessment tool will also be provided 
3. Introduction of an assessment tool: The RAPID assessment tool will be provided to all participating wards. 




4. Procedures: Describe each 
of the procedures, 
activities, and/or processes 
used in the intervention, 
including any enabling or 
support activities. 
The procedures involved in the RAPID complex intervention are as follows (the 16 relevant behaviour change techniques [BCTs] are 
italicised in brackets): 
 The five intervention functions directed at nursing home staff will include: Education, Training, Persuasion, Environmental 
Restructuring and Modelling.  
 During education and training session, nursing home staff will be provided with written and oral information regarding the 
risks and benefits of antipsychotics (5.1 Information about health consequences) from experienced pharmacists and nurses 
(9.1 Credible source). After presenting the evidence, staff will be asked to consider antipsychotics as the last resort when 
dealing with the majority of behavioural symptoms, rather than the first-line treatment (13.2 Framing/re-framing) and will 
be encouraged to use non-drug alternatives instead of requesting antipsychotics in these instances (8.2 Behaviour 
substitution). Through group discussions, staff members will share with each other, occasions where non-drug strategies 
worked and antipsychotics were not needed (15.3 Focus on past success). 
 At the same education and training session, nursing home staff will be introduced to the newly developed RAPID 
assessment tool which has the aim of aiding staff with the assessment of behavioural symptoms and ultimately reduce 
inappropriate requests for antipsychotics. Staff will be directed how to complete the RAPID tool via demonstration (6.1 
demonstration of behaviour) and also through written instructions accompanying the tool (4.1 Instruction on how to 
perform a behaviour). The RAPID tool will focus staff’s attention on identifying and exploring patterns of events and triggers 
that occur in residents (e.g. repetitive actions, sun-downing, pain) (4.2 Information about antecedents) that may ultimately 
lead to an inappropriate request for an antipsychotic, and to develop non-drug strategies to use in these situations to 
address these factors (1.2 Problem solving). Staff will be encouraged to outline a detailed plan of how and when non-drug 
and/or drug interventions will be utilised in such situations (1.4 Action Planning). Staff will practice using the RAPID tool 
based on case studies provided in the education and training session (8.1 Behavioural practice/rehearsal). Staff who have 
attended the education and training session will be encouraged to use this tool and apply this knowledge on their 
respective wards, and will be advised that their leadership on the local implementation may be an example to other staff 
who were not in attendance (13.1 Identification of self as a model). 
 Post education and training session, the RAPID tool will be available on the wards (12.5 adding objects to the environment). 
Nursing home staff will be prompted to place the RAPID tool in a prominent location (e.g. resident’s care plan) to remind 
staff to complete it every time a resident exhibits behavioural symptoms (7.1 Prompts/cues, 8.3 Habit formation). Staff will 
be encouraged to compete the RAPID tool in conjunction with each other (i.e. nurses and healthcare assistants) with input 
from GPs, family members and residents, where appropriate (12.2 Restructuring the social environment).  
 
 The three intervention functions directed at GPs will include: Education, Environmental Restructuring and Persuasion. 
 During the academic detailing session, GPs will be provided with written and oral information regarding the risks and 
benefits of antipsychotics (5.1 Information about health consequences) from a trained academic detailer pharmacist (9.1 
Credible source). After presenting the evidence, GPs will be asked to consider antipsychotics as the last resort when dealing 
with the majority of behavioural symptoms, rather than the first-line treatment (13.2 Framing/re-framing), and will be 
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encouraged to recommend non-drug alternatives instead of prescribing antipsychotics in these instances (8.2 Behaviour 
substitution).  
 As part of the academic detailing session, GPs will be introduced to the RAPID assessment tool. However responsibility for 
its completion will lie with the nursing home staff. GPs will be prompted by staff to review completed RAPID assessment 
tools when they come to do their ward round, by having them placed in a prominent place (e.g. care plans) (7.1 
Prompts/cues, 12.5 Adding objects to the environment). As above, The RAPID tool will focus GPs attention on identifying 
and exploring patterns of events and triggers that occur in residents (e.g. repetitive actions, sun-downing, pain) (4.2 
Information about antecedents) that may ultimately lead to an inappropriate prescription of an antipsychotic, and to 
develop non-drug strategies to use in these situations to address these factors (1.2 Problem solving). Nursing home Staff 
will be encouraged to outline a detailed plan of how and when non-drug and/or drug interventions will be utilised in such 




5. For each category of 
intervention provider (e.g. 
psychologist, nursing 
assistant), describe their 
expertise, background and 
any specific training given. 
1. The education and training sessions: Facilitator will consist of a combination of professions (nursing and pharmacy).  
Pharmacist facilitators will have at least 3 years post-registration experience as a pharmacist with a postgraduate 
degree/specialisation in the area of psychotropic medicine use in people with dementia.  
Nursing facilitators will meet the following criteria: 
a. At least two year’s work experience in supporting people with dementia 
b. Highly regarded and/or experienced senior care staff, team leader or manager 
c. Some training or facilitation experience and/or related qualifications 
d. A degree or postgraduate diploma in dementia or in the relevant area 
e. Knowledge experience and an understanding of Person-Centred care 
2. Academic detailing: Academic detailer will have received 2-day training (by an approved training provider) in conducting academic 
detailing and will be a pharmacist with at least 3 years post-registration experience with a postgraduate degree/specialisation in 
the area of psychotropic medicine use in people with dementia 
3. Introduction of an assessment tool: The RAPID assessment tool will be introduced by a pharmacist with least 3 years post-
registration experience, with a postgraduate degree/specialisation in the area of psychotropic medicine use in people with 
dementia. 
The facilitators will be briefed by the research team (if not already part of the research team) and will be provided with the facilitator’s 
manual, slides for presentation to staff and the RAPID assessment tool. 
HOW 
6. Describe the modes of 
delivery (e.g. face-to-face 
or by some other 
mechanism, such as 
1. Education and training sessions with nursing home staff (face-to-face, group setting) 
2. Academic detailing with GPs (face-to-face, one-to-one) 




internet or telephone) of 
the intervention and 
whether it was provided 
individually or in a group. 
 
WHERE 
7. Describe the type(s) of 
location(s) where the 
intervention occurred, 
including any necessary 
infrastructure or relevant 
features. 
1. Education and training sessions with nursing home staff (off-site, in a local university meeting room) 
2. Academic detailing with GPs (in the GP’s surgery) 
3. Introduction of an assessment tool (the RAPID assessment tool) to the nursing home environment (2 locations; off-site, in a local 
university meeting room and also on the ward within the nursing home) 
 
WHEN and HOW MUCH 
8. Describe the number of 
times the intervention was 
delivered and over what 
period of time including 
the number of sessions, 
their schedule, and their 
duration, intensity or dose. 
1. Education and training sessions with nursing home staff (Once off, Delivered over 14 hours, split over 2 days, two weeks apart) 
2. Academic detailing with GPs (Once off, 20 minute session) 
3. Introduction of an assessment tool (the RAPID assessment tool) to the nursing home environment (Initially once off (2 hour 
session) to those in attendance at education and training session. Repeated 1-2 times on each ward to catch different staff, small 
scale sessions (15 mins each)) 
 
TAILORING 
9. If the intervention was 
planned to be 
personalised, titrated or 
adapted, then describe 




10. If the intervention was 
modified during the course 
of the study, describe the 




11. Planned: If intervention 
adherence or fidelity was 
All facilitators will adhere to a single facilitators guide. All facilitators will meet initially to run through the educational and training sessions 
at least once beforehand. 
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assessed, describe how 
and by whom, and if any 
strategies were used to 
maintain or improve 
fidelity, describe them. 
Utilisation of the RAPID assessment tool will be monitored monthly by the research team to assess adherence of nursing home staff to the 
intervention. Attendance at education and training sessions will also be monitored. 
12. 
 
Actual: If intervention 
adherence or fidelity was 
assessed, describe the 
extent to which the 
intervention was delivered 
as planned. 
Sixteen nursing home staff members attended the two education and training days (seven nurse managers, two staff nurses, five HCAs, one 
physiotherapist and one occupational therapist). Of approximately 75 staff members working in this nursing home, this represents a 21% 
attendance rate. All four GPs attending this nursing home participated in the academic detailing sessions (100% attendance rate). 
 
Utilisation of the RAPID tool was quite low, and full completion of the tool in adherence with the accompanying instructions was rare. Over 
the 3 month period, only 19 RAPID tools were utilised – two in full. Of the 12 staff included in the qualitative evaluation that self-reported to 
have used the RAPID tool, eight acknowledged to have rarely used it (i.e. less than once per week). 
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Appendix 8. Intervention Materials 
See Attached CD-ROM for Intervention Materials for Chapters 6/7. 
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Appendix 9. RAPID assessment tool 
Resident Name (PRINT NAME): ____________  Date of Birth: __________   
Completed by (PRINT NAME): _____________ Date: _________ 
COMPLETE THIS PAGE ONLY ONCE FOR EVERY RESIDENT WITH A DIAGNOSIS OF 
DEMENTIA AND KEEP IN RESIDENT’S FILE/FOLDER. THIS PAGE DOES NOT NEED TO BE 
REPEATED EVERY TIME A RESIDENTS PRESENTS WITH A BEHAVIOUR, UNLESS THE 
INFORMATION CHANGES OR IF PREVIOUS MEDICAL HISTORY BECOMES AVAILABLE 
 
1. Does the resident have a confirmed underlying mental health condition (e.g. 
schizophrenia, bipolar disorder, depression, anxiety disorder?) 
YES    NO   DON’T KNOW 
If YES, Resident may need psychotropic medication long-term. 
If YES, please specify underlying mental health condition: 
___________________________________ 
2. Describe briefly what this resident likes and doesn’t like to do.  
    
 
3. Have antipsychotic medications ever been prescribed for this resident? 
YES    NO   DON’T KNOW 
 
If YES and information is available, please list all known antipsychotics that have 
been prescribed and any additional comments that may be useful (e.g. when it 
was used, did it work, were there any side effects etc.?) 
 
Full medication history not available for this resident 
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Resident Name (PRINT NAME): ____________  Date of Birth: __________   
Completed by (PRINT NAME): _____________  Date: _________ 
COMPLETE PAGES 2-3 EVERYTIME A RESIDENT WITH DEMENTIA PRESENTS WITH A 
BEHAVIOUR(S). COMPLETE EACH SECTION AS MUCH AS POSSIBLE. NOTE THAT SOME 
QUESTIONS MAY NOT BE RELEVANT FOR THIS RESIDENT AT THIS TIME. 
1. Describe the behaviour(s) (ABC Charts) 
Date and 
time 




















or as a result 
of the 
behaviour 





times per week) 









difficult to redirect) 
 
 
     
      
      
 
2. Circle the resident’s behaviour(s). Note that the shaded behaviours are those 
that are most likely to respond to antipsychotic therapy. Unshaded behaviours 




Psychosis Aggression Agitation Depressio
n 






urs                                         
  
Delusions Defensive Restless/ 
anxious 



























   
   Sad, 
tearful 
   
   Suicidal    
 
3. Do any of the behaviours present an immediate risk of harm to self and/or 
others? 
  YES    NO 






4. Identify and treat any potential cause(s) of behaviour, or delirium, with input 
from the resident, healthcare assistants and family (PINCH-ME) 
PINCH-ME Please tick 
once 
assessed 




Infection (e.g. urinary tract) 
 
  
Nutrition (e.g. hunger) 
 
  
Constipation or retention 
 
  
Hydration (e.g. thirsty) 
 
  






If the answer to either screening questions is YES, you should consider a formal delirium 
assessment or medical review 
 
5. Outline the plan for this resident, with involvement from family (where 
possible). Non-pharmacological options (e.g. distraction, engagement, adapting 
the environment) should be attempted first line.  
Drug therapy may be necessary if the resident poses a risk to self and/or others, 
multiple non-pharmacological approaches have not worked and reversible 
causes have been ruled out. 
 
 
6. Mutually agree with the GP on a review date for the planned intervention (non-
pharmacological and/or drug therapy).  Recommend 1-2 weeks when changing 
dose, 3 months for maintenance. Make a note of the planned review date in 
resident’s drug chart as another reminder. 
 
Review Date: ___/____/____ 
Additional screening questions for delirium: Yes or No 
Is the resident drowsy? 
 
 







Appendix 10. Data Collection Tools for Chapter 7 




Date of data 
extraction 
 
Year of Birth  
Does this resident 
have dementia? (Y/N) 
 









pharmacy in past 28 
days (drug, dose, 
form, frequency) 
Drug Dose Form Frequency 
    
PRN administration of 
psychotropic within 
last 28 days as 
indicated on drug 
chart (drug, dose, 
form, date and 
timings of admin) 






   
Any changes in 
psychotropic 
medicine in last 28 
days (drug, dose, 
frequency, form) 
Drug Dose Form Frequency 
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Number of dose 
reductions of 
antipsychotics in past 
28 days 
 






FOR RESIDENTS WITH CONFIRMED DEMENTIA DIAGNOSIS ONLY: 
QUM-D 
Appropriateness 
score of antipsychotic  
 
Number of falls in 
past 28 days 
 
Total NPI-NH score 






Pre- and Post-Course Evaluation 
1. On a scale of 1-5, how would you rate your understanding of person-centred 
dementia care? 
 
No Understanding   Average  High understanding 




2. On a scale of 1-5, how would you rate your understanding of the risks and 
benefits of antipsychotic prescribing in people with dementia? 
 
No Understanding  Average  High understanding 




Please indicate your level of agree with the statements listed below 
1. The objectives of the training and education were clearly defined.   




2. Participation and interaction were encouraged.  




3. The topics covered were relevant to me, working in a long term care setting.   




4. The content was organised and easy to follow.    




5. The materials distributed were helpful. 




6. This training and education experience will be useful in my work in a long term 
care setting.  




7. The trainers were knowledgeable about the topics.   




8. The trainers were well prepared.  




9. The training objectives were met.   
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10. The time allotted for the training and education was appropriate.  






11. What did you like most about this training and education? 
 
12. What aspects of the training and education could be improved, if we were to 
scale up and deliver it to multiple long term care settings?       
 
13. Have your attitudes towards people with dementia and/or the use of 
antipsychotics changed since completing this course? If so, please explain. 
 
14. How do you hope to change your practice as a result of this training and 
education?   
 
15. What do you think worked best, internal facilitation, external facilitation, or a 
combination? Why? 
 
16. Please share other comments or expand on previous responses here: Thank 
you for your feedback!   
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Appendix 11. Topic Guides for Chapter 7 
Topic Guide for GPs 
 
So just to start off, what did you think about the project? As I mentioned earlier it 
included the educational outreach session here and also the RAPID assessment tool in 
the nursing home  
What did you like about it? What did you not like about it? 
 [Prompts] Why/Why not? 
 (Ensure discussion covers both content and delivery of education, and the 
assessment tool) 
In your opinion what impact, if any, did this intervention have? 
 [Prompt if not discussed]  
What was the impact on requesting and prescribing of antipsychotics 
What was the impact on Knowledge,   
What was the impact on Attitudes,  
What was the impact on Communication and collaboration with the nursing home staff?  
What was the impact on the residents and family members? 
Were there any unintended consequences? 
From the educational session, were there any key messages that persuaded you to 
change your behaviour? 
[Prompts] What were those key messages? What did they persuade you to change? 
If nursing staff used the assessment tool with you, how did you find the assessment tool? 
[Skip if they say they haven’t used it] 
[Prompts] Are there any parts of the assessment tool that are more useful than others? 
Why do you think there was relatively low uptake of the assessment tool in the nursing 
home?  
[Prompts] How could it be improved? How could it be incorporated into daily clinical 
practice? 
[You already mentioned a few useful suggestions] Is there anything [else] that could be 
done differently to make the intervention more beneficial for you?  
[Prompts] Are there any components of the intervention that should be dropped or 
modified? Is there anything missing from the intervention that should be there? (Ensure 
discussion covers both education, and the assessment tool) 
If this type of intervention is be rolled out to other GP practices, do you have any 
suggestions to make it better?  
(Ensure discussion covers education, and the assessment tool) 
Is there anything else I haven’t asked you today that you would like to mention? 
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Topic Guide for Nursing Home Staff 
 
So just to start off, what did people think about the project? As I mentioned earlier it 
included the education and training days in UCC and also the RAPID assessment tool.  
What did you like about it? What did you not like about it? 
[Prompts] Why/Why not? 
(Ensure discussion covers both content and delivery of education/training, and the 
assessment tool) 
In your opinion what impact, if any, did this intervention have? 
[Prompt if not discussed]  
What was the impact on requesting and prescribing of antipsychotics 
What was the impact on Knowledge,  
What was the impact on Attitudes,  
What was the impact on Communication and collaboration with GPs?  
What was the impact on the residents and family members? 
What was the impact on the ward as a whole (i.e. were there any knock-on effects to 
those who didn’t attend the education and training days?) 
Were there any unintended consequences? 
 
[Skip if no-one attended the training days] For those of you who attended the 
education and training days, were there any key messages that persuaded you to 
change your behaviour? 
How did people find the assessment tool?  
[Prompts] Are there any parts of the assessment tool that are more useful than others? 
Why do you think there was relatively low uptake of the assessment tool?  
[Prompts] How could it be improved? How could it be incorporated into daily clinical 
practice? 
[You already mentioned a few useful suggestions] Is there anything [else] that could be 
done differently to make the intervention more beneficial for you?  
[Prompts] Are there any components of the intervention that should be dropped or 
modified? Is there anything missing from the intervention that should be there? (Ensure 
discussion covers both education/training, and the assessment tool) 
If this type of intervention is be rolled out to other nursing homes, do you have any 
suggestions to make it better?  
(Ensure discussion covers education/training, and the assessment tool) 
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